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ABSTRACT OF THE DISSERTATION 
Anti-Inflammatory Effects of Adipose-Derived Mesenchymal Stem Cells  
for Flexor Tendon Healing 
by 
Cionne N. Manning 
Doctor of Philosophy in Biomedical Engineering 
Washington University in St. Louis, 2013 
Professor Stavros Thomopoulos, Chairperson 
 
Despite advances in surgical techniques over the past three decades, tendon repairs remain prone 
to poor clinical outcomes.  While previous attempts to improve flexor tendon healing have 
focused on the later stages of healing (i.e., proliferation and matrix synthesis), the early 
inflammatory phase of tendon healing remains poorly understood and its modulation during 
healing has not yet been studied.  The overall goal of this work is therefore to determine whether 
flexor tendon healing can be enhanced through modulation of the inflammatory environment 
after surgical repair.   
 
To meet this objective, the inflammatory response after flexor tendon injury and repair was first 
characterized to help identify inflammation-related targets for future treatments.  Temporal 
changes in immune cell population and gene expression of inflammation-, matrix degradation-, 
and extracellular matrix-related factors were examined.  Of the observed changes, the most 
dramatic effect was the greater than 4000-fold up-regulation in the expression of the pro-
xii 
 
inflammatory factor IL-1β.  While some inflammation is essential for healing to occur, such high 
levels of pro-inflammatory cytokines may result in collateral tissue damage and impair tendon 
healing.   
 
To examine the effect of inflammatory cytokines on tendon fibroblasts, the native cell type that 
must eventually re-build the injured tendon, we established two in vitro models of inflammation: 
one induced by exogenous IL-1β and one induced by macrophages (the primary cellular source 
of IL-1β).  We found that IL-1β and other pro-inflammatory cytokines secreted by macrophages 
induce further up-regulation of pro-inflammatory factors by tendon fibroblasts.  Furthermore, 
exposure of tendon fibroblasts to an inflammatory environment led to up-regulation of factors 
related to matrix degradation and down-regulation of factors related to extracellular matrix 
formation. These changes in expression are likely detrimental to tendon healing in vivo.  
 
In an effort to reduce the negative effects of inflammatory cytokines on tendon fibroblasts, 
adipose-derived mesenchymal stem cells (ASCs) were incorporated into the two in vitro models 
and their ability to modulate inflammation was investigated.  While ASCs were unable to 
counteract the effects of IL-1β directly, ASC co-culture with macrophages successfully 
suppressed the negative effects of macrophages on tendon fibroblasts.  FACS analysis revealed 
that ASCs induced a phenotypic switch from a pro-inflammatory macrophage phenotype to an 
anti-inflammatory macrophage phenotype, thus resulting in exposure of tendon fibroblasts to 
fewer pro-inflammatory cytokines.   
 
xiii 
 
In order to translate these in vitro findings in vivo, a surgically manageable scaffold capable of 
delivering and retaining ASCs at the repair site was developed.  The fibrin/nanofiber scaffolds 
were well-tolerated in the in vivo flexor tendon repair setting and successful delivery of ASCs 
was achieved. Pilot data demonstrated promise with this approach, as demonstrated by down-
regulation of IL-1β and MMP1 in the ASC treated animals. However, the pilot study was 
underpowered, and additional animals and assays are required to fully evaluate the effect of 
ASCs in vivo.   
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Chapter 1 - Introduction 
1.1 Intrasynovial flexor tendon healing 
Extensive surgical repair is commonly required to treat flexor tendon injuries.  These repairs are 
frequently associated with poor clinical outcomes1–4.  One of the major causes leading to loss of 
hand function after injury and repair is the development of repair-site elongation and rupture5,6.  
Failure of the repair site to accrue strength within the first three weeks after surgery is the major 
factor leading to rupture4,6–11.  It has been reported that 13% of flexor tendon repairs rupture 
completely and another 48% of repairs develop repair-site elongation or gapping5.  Gaps greater 
than 3 mm are directly correlated with decreased structural properties of the repair site5.  
Moreover, adhesion formation within the digital sheath is another major factor leading to loss of 
hand function5,6,10,12–15.  Thus, efforts to improve flexor tendon healing aim to address two 
contrasting goals: 1) reduction of adhesions, and 2) increased ECM synthesis at the repair site. 
 
Despite advances in surgical techniques over the past three decades, tendon repairs remain prone 
to poor clinical outcomes16.  Previous attempts to improve tendon repair have focused on 
inhibiting adhesion formation within the digital sheath and accelerating cell proliferation and 
matrix production at the repair.  While rehabilitation protocols1–4,17–30 and surface 
modifications9,31–57 have successfully reduced adhesion formation and improved tendon gliding 
within the sheath, tendon repairs remain prone to rupture due to failure of the tendons to accrue 
strength within the first 3 weeks post-operatively.  In an attempt to accelerate cellular activity 
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and matrix synthesis, growth factors have also been utilized7,8,15,23,27,28,58–89.  This approach, 
however, has only had limited success.   
 
These prior attempts at improving tendon healing have focused on the later stages of healing.  
The early inflammatory phase of tendon healing (i.e., the first week after repair) is poorly 
understood and its modulation during healing has not yet been studied.  While it is clear that 
some inflammation is essential for proper healing90,91, excessive levels of pro-inflammatory 
cytokines may result in collateral tissue damage and, thus, may be detrimental to tendon 
healing92–96.  Studies of tendon-to-bone healing suggest that altering the inflammatory response 
either through direct blockade of specific pro-inflammatory factors94 or by fine modulation of the 
immune cell population92,93,97 may be advantageous to tendon healing. 
 
1.2 Natural course of tendon healing 
Wound healing is classically characterized as four overlapping, yet distinct, phases: haemostasis, 
inflammation, proliferation, and remodeling.  Immediately upon repair, fibrin and inflammatory 
cells fill the repair site98–111.  Within the first 2-3 days, the epitenon cells (i.e., fibroblastic cells 
on the tendon surface) begin to proliferate, resulting in a thickening of the epitenon layer.  
Erythrocytes, macrophages, and other inflammation-related cells remain at the repair site 3 days 
post-operatively6 and granulation tissue begins to form as early as day 4 post-operatively98–111 
(Figure 1.1).   
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Figure 1.1:  Pictorial of the haemostasis/inflammatory phase of cutaneous wound healing.  
Tendon repair during this phase of healing is similar.  Reproduced with permission by Reinke et 
al.112 
 
Between days 7 and 9, extrinsic fibroblasts from the surface of the tendon begin to migrate into 
the repair site and deposit small diameter collagen fibers, forming a callus between the tendon 
stumps98–111.  The collagen fibers are initially oriented perpendicular to the longitudinal axis of 
the tendon, implying an origin from the surface of the tendon98–111.  At this point (days 7-14) 
early indications of vascularization are evident103.  Tendon fibroblasts (TFs) from within the 
tendon proper begin to proliferate between days 14-21 and extend into the callus by the fourth 
post-operative week (Figure 1.2).   
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Figure 1.2:  Pictorial of the proliferative phase of cutaneous wound healing.  Tendon repair 
during this phase of healing is similar.  Reproduced with permission by Reinke et al.112 
 
Fibroblasts within the gap re-align by days 21-28 and become oriented in the longitudinal axis of 
the tendon and newly synthesized collagen is laid down longitudinally98–111.  Newly formed 
collagen continues to mature, cross-links form and mature, and the repair begins to accrue 
strength by 9 weeks113 (Figure 1.3).  By 12 weeks, repaired tendons regain approximately one 
third of their original ultimate tensile load113.   
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Figure 1.3:  Pictorial of the remodeling phase of cutaneous wound healing.  Tendon repair 
during this phase of healing is similar.  Reproduced with permission by Reinke et al.112 
 
1.3 Previous efforts to improve flexor tendon healing 
1.3.1 Rehabilitation protocols for improved range of motion 
Extensive research supports the concept that manipulation of the mechanical environment (i.e. 
rehabilitation) post flexor tendon repair can enhance the healing process.  Mechanical load may 
enhance tendon healing through two mechanisms: (1) direct stimulation of TFs and (2) motion of 
the tendon, preventing accrual of adhesions between the tendon and its sheath. It is well 
established, both in vitro and in vivo, that TFs are responsive to mechanical load.  Both static and 
cyclic load have been shown to promote cellular activity. Additionally, Hannafin et al. used 
stress-deprived tendon explants to illustrate the necessity of load for normal tendon mechanics 
and morphology.  A gradual decline in tensile modulus was observed in stress deprived tendons 
compared to loaded controls.  Cellularity, cell morphology, and collagen alignment were also 
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significantly affected by stress deprivation17.  Furthermore, Slack et al. demonstrated increased 
protein and DNA synthesis in loaded tendon explants compared to unloaded18.  Thus, 
manipulation of the mechanical loading environment during healing may improve tendon healing 
by stimulating cellular activity during the early post-operative period.  Several groups have 
applied this concept in experimental and clinical studies1–3,19–24 by employing one of two distinct 
rehabilitation protocols – active and passive motion rehabilitation.  In both regimes, cyclic 
excursion of the tendon through the sheath inhibited the formation of adhesions between the 
tendon and its sheath, leading to improved gliding of the tendon and enhanced range of motion 
of the repaired digit.  The key difference between these two types of rehabilitation regimens, 
however, is the amount of load exerted across the repair during the exercises.    During active 
motion rehabilitation, the patient performs the exercises unassisted, which requires muscle 
activation and, thus, produces high loads across the repair.  During passive motion rehabilitation 
(Figure 1.4), on the other hand, a physical therapist manipulates the digit through flexion and 
extension.  Since this does not require muscle activation, the loads applied across the repair are 
much lower. 
 
Figure 1.4:  Schematic of post-operative rehabilitation in the canine animal model.  A) The 
operated-on forelimb is immobilized in a spica cast.  B) The wrist of the forelimb is accessed by 
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a removable portion of the cast.  C) Rehabilitation consisted of repetitive digital flexion-
extension with the wrist flexed.  Reproduced with permission by Silva et al.24 
 
While both passive and active motion rehabilitation protocols have been successful in 
stimulating adhesion-free healing3,19,20211,2,22,23, there appears to be an increased risk of repair site 
gapping or rupture during active motion rehabilitation.  One study showed improved clinical 
outcomes with active motion rehabilitation.  However, due to the variability that is introduced 
with active motion, high rupture rates have been reported. 
 
Gelberman and Woo showed that timing of rehabilitation is critical.  They found that early 
passive mobilization led to enhanced tensile properties and range of motion compared to delayed 
mobilization or immobilized digits22,23.  Takai et al. found that frequency of mobilization also 
plays a key role.  Tendons that received the high-frequency protocol (i.e. 12 cycles/min of 
controlled passive motion for 5 min/day) showed significantly higher tensile properties than 
those that received the low-frequency protocol (i.e. 1 cycle/min for 60 min/day)21. 
 
Based on these studies, early mobilization regimens that emphasize high frequency, cyclic 
excursion of at least 1.7mm within the sheath at low-loads (i.e. passive motion) are 
recommended1,21–24.  Although recent modifications in rehabilitation protocols have proven 
highly effective in reducing adhesion formation, due to a lack of strength at the repair site, the 
tendons remain susceptible to ruptures1–4,22,24,25.  As mechanical (rehabilitation) approaches for 
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improving the repair have been exhausted, clinical and experimental studies suggest that future 
strategies be aimed at accelerating the repair process by altering the biological environment26–30. 
 
1.3.2 Surface modifications for enhanced tendon gliding  
Digital function relies heavily on the ability of the tendon to glide within its sheath.  Adhesion 
formation between the repaired tendon and its sheath effectively limits tendon excursion within 
the sheath and, thus, greatly hinders the range of motion of the repaired digit.  Although proper 
rehabilitation can significantly reduce adhesion formation, increased gliding resistance remains a 
major concern after tendon repair. 
 
Uchiyama and Sun both showed that uninjured tendons are able to glide smoothly within the 
digital sheath due to a low-friction contact that is created in part by hyaluronic acid (HA).  They 
found that hyaluronidase treatment, which effectively strips away all HA from the tendon 
surface, led to increased gliding resistance of the tendon within the sheath41,42.  Based on this and 
other studies, treatment of injured tendons with HA has been extensively investigated9,31–45,47–49.  
Nishida et al. soaked tendon grafts in hyaluronic acid prior to in vivo implantation and 
demonstrated enhanced gliding properties compared to untreated controls34.  Similarly, Amiel et 
al. demonstrated positive effects of HA treatment49.   
 
While most initial studies showed some beneficial effect of HA on tendon gliding, some studies 
were difficult to interpret49,51–55.  These inconsistent results may be attributed to the insufficient 
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coating method.  Simply soaking the tendons in HA may lead to rapid clearance of the lubricant 
from the tendon surface.  Thus, several groups have used carbodiimide derivatization to modify 
hyaluronic acid (cd-HA) so that the HA can be chemically bound to the tendon surface35,38,43–47 
and provide a more long-term gliding surface38,56.  Yang et al. found that ex vivo tendons treated 
with cd-HA-gelatin displayed enhanced gliding ability after the 50th loading cycle compared to a 
simple-HA treatment (i.e. unmodified hyaluronic acid) and compared to control.  Zhao et al. 
found similar results in vivo using autologous tendon grafts38.  Lubricin, another key component 
of flexor tendon lubrication has also been shown to play an important role in minimizing 
adhesion formation36,37,39,40 (Figure 1.5).  
 
Figure 1.5:  Gliding resistance for the peroneus longus tendons after 1000 cycles was decreased 
with various surface modifications: cd-gelatin, cd-HA-gelatin, and cd-gelatin+lubricin 
treatments.  Reproduced with permission by Taguchi et al.39 
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Through the implementation of both natural and synthetic surface modifications31–49, significant 
improvements in gliding function of the tendon within its sheath has been achieved.  However, 
due to failure of the tendons to accrue strength during the first 3 weeks post-operatively, repaired 
tendons remain at risk for gap formation and rupture.  
 
1.3.3 Growth factor-based therapies for enhanced tendon healing 
Rehabilitation and tendon surface coating methods have led to significant improvements in post-
repair range of motion. However, they have not let to improvements in repair site strength. 
Recent attempts to improve tendon healing have therefore focused on biological manipulation of 
the wound environment via the use of growth factors.  Growth factors are powerful regulators of 
biological activity that are naturally synthesized and released into the wound environment 
following injury and repair58–62.  However, the naturally synthesized growth factors appear to be 
insufficient to restore the tendon to its pre-injury status in terms of strength and stiffness.  
Therefore, in an effort to promote cellular activity and matrix synthesis and, thus, enhance the 
strength of the healing tendon, researchers have attempted to deliver exogenous growth factors, 
namely, platelet derived growth factor BB (PDGF-BB), basic fibroblast growth factor (bFGF), 
and transforming growth factor beta (TGF-β) to the repair site in order.   
 
Due to the ability of PDGF-BB to promote cell proliferation in vitro23,62, PDGF-BB has been a 
popular growth factor for tendon and ligament healing therapies.    Several investigators report 
increased fibroblast proliferation in vivo when stimulated with PDGF-BB63,64.  In addition, 
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PDGF-BB delivery to injured tissues in both ligament and skin wounding models led to 
substantial improvements in enhanced tensile properties60,63–65.  
 
Similarly, bFGF has also been effective in promoting cell proliferation27,28,62 and collagen 
production27,28.  In one study, canine anterior cruciate ligaments (ACLs) were injured using a 
biopsy punch and bFGF-impregnated pellets were sutured into the defects.  After 6-24 weeks of 
healing, the ACLs that were treated with bFGF exhibited enhanced healing potential.  bFGF 
treatment led to neovascularization and improved collagen fiber orientation at the repair site66.   
 
Investigators have also extensively researched TGF-β for enhanced tendon healing.  TGF-β1 has 
been shown to effectively promote cell proliferation and ECM synthesis as well as increase the 
strength and stiffness of the repair site in medial lateral ligament and skin wounding models60–65.  
However, TGF-β1 has also been implicated in adhesion formation67.     
 
Taken together, these studies suggest that the use of specific growth factors may be beneficial for 
tendon and ligament healing.  However, the use of growth factors is complicated.  Woo et al.60 
and Chan et al.27,28 highlight the importance of dosage, while others indicate that the residence 
time of the growth factors is also a mitigating factor68–70.  Bolus application of growth factors 
typically leads to clearance of the growth factor from the wound site within 48 hours68.  Since 
tendons are pauci-cellular, they rely on the migration of fibroblasts from surrounding tissue, 
which typically takes 2-3 days.  Thus, growth factors delivered by a bolus injection at the time of 
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surgical repair may be cleared before they are able to stimulate the cells of interest and, thus, 
may have limited effectiveness.   
 
To prolong the residence time of the growth factors, a variety of different biomaterials that bind 
the cytokines of interest to a biocompatible matrix have been utilized66,69–83.  For example,  a 
novel growth factor delivery system developed by Sakiyama-Elbert and colleagues has been 
shown to significantly prolong the release of heparin-binding growth factors86,87,114,115.  Using 
this delivery system, both PDGF and bFGF were successful in stimulating  TFs to proliferate and 
produce collagen in vitro86–89.  In vivo, sustained delivery of PDGF-BB via a heparin/fibrin based 
delivery system (HBDS) led to enhanced biological activity (as demonstrated by increases in 
total DNA, collagen crosslinks, and gene expression related to tendon regeneration and 
remodeling) and improved range of motion and excursion of the treated tendons compared to 
controls (i.e., tendons that received the HBDS alone)7,8,86 (Figure 1.6).  However, sustained 
delivery of PDGF-BB was unsuccessful in increasing the structural properties of the tendon (e.g., 
strength and stiffness).  On the other hand, bFGF was actually detrimental to tendon healing15.  
Sustained delivery of bFGF to healing tendons led to increased scar formation and, thus, led to 
inferior range of motion compared to controls.  Furthermore, while TGF-β3 improved healing in 
a rotator cuff model (Appendix)116, it has been shown to be detrimental in the context of flexor 
tendon healing.  Specifically, suppression or deletion of TGF-β led to increased range of motion 
in the flexor tendon repair model29,117.   Thus, despite some promising results, it is clear that 
these growth factors are not sufficient to enhance the strength of flexor tendon repair.   
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Figure 1.6:  Delivery of PDGF-BB via a heparin-binding delivery system at the time of flexor 
tendon injury and repair significantly enhanced range of motion and tendon excursion of the 
repaired tendon.  CTL: Control/Repair-only; DS: Delivery System; PDGF: DS + PDGF; NORM: 
normal/uninjured.  Reproduced with permission by Thomopoulos et al.118  
 
1.4 The role of inflammation in chronic and acute tendon injuries 
Previous attempts to improve tendon healing have focused on the later stages of tendon 
healing98–111,113,119–121.  The early inflammatory phase (i.e., the first week after repair) of tendon 
healing is poorly understood and its modulation during healing has not yet been studied.  Classic 
flexor tendon repair studies by Potenza and Gelberman in the 1960s and the 1980s, respectively, 
described inflammatory cells at the site of repair as early as 1 day post-operatively.  However, 
the details of the cell types present and the temporal changes in those cell populations were not 
described98,102.   
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1.4.1 The role of inflammation in chronic tendinopathies 
Recent results in a variety of tendon models indicate that the predominant cell types that 
infiltrate injured tendons within the first 24 hours are macrophages, monocytes, and 
neutrophils97,122–129.  Millar et al. collected biopsy samples of pathologic subscapularis and 
supraspinatus tendons from human patients undergoing arthroscopic shoulder surgery and 
evaluated the samples immunohistochemically to identify the cell populations present.  
Macrophages (positive for the cell markers CD68 and CD206), T cells (positive for the cell 
marker CD3), mast cells (positive for mast cell tryptase), and endothelial cells (positive for the 
cell marker CD34) were quantified.  The authors found significantly greater macrophage, mast 
cell, and T-cell expression in both torn supraspinatus tendons and matched subscapularis tendons 
compared to normal controls.  The authors also found that the extent of inflammatory cell 
infiltration was inversely correlated to the size of the rotator cuff tear (i.e., smaller tears had 
more cell infiltration than larger tears), indicating that the infiltration of inflammatory cells 
occurs early in human tendinopathies130.  Studies by Schubert et al.131 and Scott et al.132 provide 
additional evidence for early inflammatory cell infiltration in tendinopathies.  Schubert et al. 
found increased numbers of macrophages and lymphocytes in samples collected from patients 
presenting with Achilles tendinosis for several months131.  Scott et al., however, examined 
tissues from patients presenting with Achilles pain and tenderness for an average of 22 months 
and did not identify many macrophages or lymphocytes.  Instead, the authors reported mast cells 
as the predominant cell type132.   
 
Taken together, these studies provide further evidence that macrophages and lymphocytes 
predominate in early human tendinopathies.  Furthermore, Millar et al. identified a significant 
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up-regulation of pro-inflammatory cytokines and apoptotic genes associated human rotator cuff 
tendinopathies126.  Tendon biopsies were collected from patients at the time of surgery and were 
analyzed for gene expression using semi-quantitative reverse transcription polymerase chain-
reaction.  The authors observed increased expression of tumor necrosis factor alpha (TNFα), 
macrophage inhibitory factor, and interleukins 18, 15, and 6 in tendinopathic samples compared 
to controls.  The subsequent secretion of these cytokines was confirmed using 
immunohistochemistry.  Significant up-regulation of the apoptotic mediators caspase 3 and 8 
also was observed.  This increased expression of pro-inflammatory cytokines and apoptotic 
genes is associated with the large influx of inflammatory cells reported in early human 
tendinopathies.   
 
Pro-inflammatory cytokines have also been reported in inflamed equine tendons.  Hosaka et al. 
found significant up-regulation of interleukin-1 alpha, interleukin-1 beta (IL-1β), TNFα and 
interferon gamma (IFNγ) in equine tendinosis133.  Unlike human models, animal models allow 
for a time course of cell infiltration to be determined.  Using a rodent Achilles tendon model of 
tendinopathy, Marsolais et al. report a 46- and 18-fold increase in neutrophils and pro-
inflammatory macrophages, respectively, 24 hours after collagenase-induced tendinopathy.  By 
day 3, the number of neutrophils decreased by 70%, whereas the number of macrophages 
remained constant.  Neutrophils returned to control levels by day 7, while macrophages did not 
return to normal levels until day 14124. 
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1.4.2 The role of inflammation in acute tendon repairs 
Neutrophils and macrophages have also been identified as the predominant inflammatory cells 
types after tendon-to-bone repair97,125.  Macrophages in particular have been implicated in the 
early healing process.  Classical macrophages, also called M1 or type 1 macrophages are 
recruited from circulating blood monocytes and are activated by IFNγ and/or lipopolysaccharides 
(LPS) (Figure 1.7).  Upon activation, they secrete other pro-inflammatory cytokines such as IL-
1β, TNFα, interleukin-12 (IL-12), and nitric oxide (NO).    A second type of macrophage, called 
M2 or type 2, is activated by interleukin-4 (IL-4) and/or interleukin-13 (IL-13) and, as such, is 
also termed “alternatively activated macrophage” (Figure 1.8).  M2 macrophages play a 
distinctly different role than M1 macrophages.  M2 macrophages secrete the anti-inflammatory 
factor IL-10 and are involved in the regeneration of damaged tissues124,134–151.  Macrophages can 
be identified by the expression of certain surface markers (e.g., CD11b, CD14, F4/80 (in mice), 
EMR1 (in humans)) using flow cytometry or immunohistochemical staining.  CD206 and 
CD301, however, are specific to M2 macrophages and, thus, are generally used to differentiate 
between M1 and M2 macrophages.  The ED1 and ED2 antigens are also widely used to 
differentiate between the two phenotypes.  Type 1 macrophages are ED1+ and type 2 
macrophages are ED2+92,93,97,124,152–155. 
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Figure 1.7: Classically- vs. alternatively-activated macrophages.  Classically activated 
macrophages or M1 macrophages are generated by activating circulating blood monocytes with 
IFNγ and/or LPS.  They secrete IL-1β, TNFα, IL-6, and NO and are ED1+ and are generally 
considered pro-inflammatory.  Alternatively activated macrophages or M2 macrophages are 
activated by IL-4 and/or IL-13 and secrete IL-10.  They can be identified as CD206+, CD301+, 
or ED2+ and are considered to be anti-inflammatory and pro-regenerative. 
 
Additional studies in an ACL tendon-to-bone repair model suggest that excessive inflammation 
may be a key factor leading to poor clinical outcomes and that inhibition of the naturally 
occurring inflammatory response may be beneficial for healing92,93,97.  Based on the observations 
that a large influx of M1 macrophages occurs in the bone tunnel during the early stages of ACL 
healing97,128, Hayes et al. hypothesized that the macrophages may contribute to the formation of 
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scar tissue following ACL reconstruction.  To test this hypothesis, the authors treated rats with 
clodronate (a bisphosphonate that selectively induces macrophage apoptosis) after ACL 
reconstruction.  The animals were sacrificed 7, 14, 28, and 42 days post-operatively and tissues 
were analyzed histologically and biomechanically.  The authors reported a significant reduction 
in the number of macrophages and the amount of TFG-β at the repair site in the samples that 
received the clodronate treatment.  Macrophage-depleted samples also exhibited reduced scar 
tissue formation and increased collagen fiber organization, osteoid formation, and mineral 
apposition rate compared to controls at all timepoints.  Furthermore, the specimens treated with 
clodronate displayed significant improvements in biomechanical properties.  The authors 
concluded that macrophages can inhibit the healing potential of ACL repairs and that modulating 
inflammation may prove beneficial for tendon-to-bone healing92. 
 
Other studies found that immobilization of the knee after ACL reconstruction led to improved 
mechanical properties via a shift in macrophage phenotype.  Dagher et al. hypothesized that 
immobilization of the ACL after repair would accelerate resolution of acute inflammation and 
enhance the healing process.  An external fixation device was used to immobilize the knees of 
rats after ACL reconstruction.  A mobilized group was used as control.  The animals were 
allowed 2-4 weeks of healing before sacrifice.  Analysis of the ACL tendon-to-bone insertion 
sites showed a switch in macrophage phenotype due to immobilization.  Whereas the 
macrophages found at the repair site of mobilized rats were of the pro-inflammatory M1 
phenotype, immobilization led to a decrease in M1 macrophages and an increase in anti-
inflammatory, pro-regenerative M2 macrophages (Figure 1.8).  The phenotype switch led to 
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improved tendon-to-bone integration, as evidenced by reduced scar tissue formation, increased 
collagen fiber organization, and enhanced biomechanical properties93. 
 
Figure 1.8:  Immobilization of knees after ACL repair led to decreased levels of ED1+ cells (i.e., 
M1 macrophages) and an increase in ED2+ cells (i.e., M2 macrophages) compared to controls.  
Reproduced with permission by Dagher et al.93 
 
Lastly, Gulotta et al. found that suppression of the pro-inflammatory cytokine TNFα in a rat 
rotator cuff model led to improved tendon-to-bone healing at the early post-operative 
timepoints94.  Upon surgical repair of the supraspinatus tendon, experimental groups received 3.0 
mg/kg of pegylated soluble tumor necrosis factor receptor type I every other day for a total of 3 
doses. The control group received saline solution using the same dosing schedule.  Animals were 
sacrificed 2, 4, and 8 weeks post-operatively and histologic and biomechanical assessments were 
performed.  Immunohistochemical staining verified the efficacy of the TNFα blockade.  The 
authors reported decreased TNFα staining in the experimental group at 4 and 8 weeks.  Fewer 
M1 macrophages were evident at 4 weeks compared to controls and enhanced biomechanical 
properties were observed at both 2 and 4 weeks post-operatively.  No differences were noted in 
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biomechanical or histologic properties by 8 weeks.  This study suggests that TNF-α blockade 
may enhance tendon-to-bone healing at the early post-operative timepoints, potentially through 
the suppression of M1 macrophages94. 
 
Taken together, these results suggest that classically activated macrophages (M1 macrophages) 
may impede tendon healing.  While some inflammation is critical for clearance of dead cells and 
tissues from the wound and for chemotaxis of fibroblasts to the repair site,112,156–162 excessive 
levels of macrophage-secreted pro-inflammatory cytokines, such as IL-1β and TNFα, may be 
detrimental to tendon healing, as they induce matrix metalloproteinase (MMP)-mediated 
catabolism of healthy tendon ECM surrounding the wound144,163–165. Thus, modulating the 
inflammatory environment (e.g., by reducing the number of M1 macrophages and increasing the 
number of M2 macrophages) may be advantageous for tendon healing.      
 
1.5 Mesenchymal stem cell-based therapies to enhance tendon healing 
1.5.1 Mesenchymal stem cells for promoting ECM synthesis 
Previous growth factor-based efforts were insufficient to significantly improve flexor tendon 
healing due to the paucity of cells in intrasynovial flexor tendons.  Thus, recent focus has shifted 
toward cell-based therapies for tendon repair166–174.  For such therapies, mesenchymal stem cells 
(MSCs) are a particularly attractive cell type for a variety of reasons.  MSCs are multipotent 
stromal cells and, thus, have the capability to differentiate along multiple different cell lineages, 
including tenogenic, osteogenic, chondrogenic, and adipogenic lineages166,167,169,175–180 (Figure 
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1.9).  MSCs transplanted at the time of tendon repair could theoretically differentiate into TFs 
and produce the ECM needed to enhance repair-site strength and stiffness.   
 
Figure 1.9:  Schematic demonstrating the pluripotency of mesenchymal stems cells (MSCs).  
MSCs can differentiate along multiple different cell lineages, including tenogenic (tendon), 
chondrogenic (cartilage), adipogenic (fat), osteogenic (bone), and myogenic (muscle) lineages.  
Reproduced with permission by Uccelli et al.171 
 
Indeed, several recent studies have shown that administration of undifferentiated or pre-
differentiated MSCs improved histological and biomechanical outcomes in a variety of soft-
tissue repair models84,85,181–199.  Young et al. incorporated bone marrow derived MSCs in a type 1 
collagen gel that was then contracted onto a biodegradable suture that was used to repair gap 
defects in rabbit Achilles tendons. After four weeks of healing, tendons treated with the MSC-
treated sutures were two times as strong and stiff as contralateral controls that were repaired with 
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unmodified sutures.  Increases in cross sectional area and collagen fiber alignment were also 
observed84.  Similar results were observed by Awad et al. in a rabbit patellar tendon model85,200.  
In one study, autologous MSCs delivered in a collagen composite led to an 18-26% increase in 
modulus and maximum stress 4 weeks after surgery200.  Similar results were observed in a 
second study by the same group in which larger patellar tendon defects were created.  Although 
improved biomechanics were observed, after 26 weeks of healing, the MSC-treated repairs were 
still 75% weaker than normal/uninjured tendons.  Similarly, Gulotta et al. labeled bone marrow-
derived MSCs by transducing the cells with adenovirus-mediated LacZ (Ad-LacZ) and delivered 
the transduced cells via a fibrin carrier to injured rat rotator cuffs.  Although tendons treated with 
Ad-LacZ-transduced MSCs exhibited greater β-galactosidase activity at the repair site 
(indicating that the MSCs were present and metabolically active), no histological or 
biomechanical differences were observed compared to carrier-alone and repair-only controls181.  
Based on these disappointing results, subsequent approaches by Gulotta et al. involved 
genetically modifying the MSCs to over-express factors believed to be important in the 
development of the tendon-to-bone insertion site183,201.  In separate studies, MSCs were 
transduced with adenovirus-mediated membrane type 1 metalloprotease (Ad-MT1-MMP)182 and 
scleraxis (Ad-Scx)183. In both studies, the authors reported enhanced biomechanical and 
histological properties after 4 weeks of healing182,183. 
 
1.5.2 Mesenchymal stem cells for modulating inflammatory environment 
Studies have demonstrated that MSCs exhibit potent anti-inflammatory and immunosuppressive 
properties.  In vivo, MSC delivery has been shown to enhance skin graft survival202–206 and 
prevent graft versus host disease (GVHD) after bone marrow transplantation207–209 in various 
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animal models.  Clinical studies indicate that MSCs may play a role in preventing and treating 
chronic GVHD in human patients, but these results have not yet been confirmed by large clinical 
trials207,210.   
 
Numerous in vitro studies have helped elucidate the mechanisms behind MSC-derived 
immunomodulation170,203,208,211–242.  These studies indicated that MSCs are capable of 
suppressing the adaptive immune response via direct suppression of T and B lymphocyte 
proliferation (i.e., T and B cells)170,203,208,211–242 (Figure 1.10).  Direct co-culture of MSCs with T 
cells or B cells has been shown to significantly inhibit the proliferation of the lymphocytes (and 
subsequent secretion of pro-inflammatory cytokines) by arresting them in the G1 phase of the 
cell cycle222.  Indirect co-culture, using transwell plates (i.e., plates that separate the two cell 
types with a porous membrane, inhibiting cell-cell contact, but allowing for the diffusion of 
soluble factors) revealed similar findings173,203,213,215–219,222,225,226,228,233,234,236,237,239,243–247.  MSC-
conditioned supernatants were also able to inhibit the proliferation of mixed lymphocyte 
reactions172,173,217,219,220,227,236,248.  These results indicate that soluble factors secreted by the 
MSCs are responsible for the inhibition of lymphocyte proliferation.   
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Figure 1.10:  Schematic demonstrating the ability of MSCs to inhibit T and B lymphocytes (i.e., 
T and B cells) via the secretion of various soluble factors (e.g., PGE2, IDO, TGFβ1).  
Reproduced with permission by Uccelli et al.171 
 
While it is widely accepted that soluble factors secreted by MSCs are responsible for the 
inhibition of T and B cell proliferation, the precise mechanism remains unclear.  The factors 
most commonly cited include indoleamine 2,3-dioxygenase (IDO)217,220,224,225,248, NO225,226,234,237, 
and prostaglandin E2 (PGE2)216,244.  DelaRosa et al. suggested that secretion of IDO (an 
intracellular enzyme that catalyzes tryptophan into kynurenine249) by stem cells is required for 
the inhibition of immune cells.  Using human adipose-derived MSCs (hASCs), the authors 
showed inhibition of mixed lymphocyte reactions when in direct or indirect contact with MSCs 
and observed a significant decrease in the production of IFNγ, TNFα, and interleukins 2 and 5.  
To determine whether IDO was essential, the authors applied 1-methyl-DL-tryptophan (1-MT), a 
pharmacological inhibitor of IDO.  They found that hASCs failed to inhibit lymphocyte 
proliferation in the absence of IDO.  Similarly, the authors used genetically modified hASCs 
with silenced IDO enzymes to demonstrate the need for IDO in the suppression of 
lymphocytes217.  Maby-El Hajjami et al. found similar results using MSCs electroporated with 
MSC
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IDO-small interfering RNA248.   Further investigations by Meisel et al. showed that the depletion 
of tryptophan by IDO was the underlying cause of IDO-mediated immunosuppression.  The 
authors found that T-cell proliferation was restored when tryptophan was added to the mixed 
lymphocyte/MSC co-culture224.  Ren et al. also verified the need for IDO in human and monkey 
MSC-mediated immunosuppression. However, the authors found that IDO was not necessary for 
MSC-mediated immunosuppression in cells derived from mice.  Rather, the authors reported 
nitric oxide (NO) to be the key mediator of MSC-mediated immunosuppression in mice.  The 
authors used pharmacological inhibitors and neutralizing antibodies against a variety of possible 
factors and found that NG-monomethyl-L-arginine (an inhibitor of nitric oxide) restored 
lymphocyte proliferation, suggesting that NO was essential for suppression225.  Moreover, MSCs 
from mice lacking the gene for inducible nitric oxide synthase (iNOS-/- mice), had a reduced 
ability to suppress T-cell proliferation234,237.  Prostaglandin E2 (PGE2) has also been cited as key 
to the immunosuppressive activity of human MSCs211,250–253.  Aggarwal et al. found that the 
secretion of PGE2 was significantly up-regulated when immune cells were co-cultured with 
MSCs.  To determine if PGE2 had a significant role in immunosuppression, the authors 
employed two different PGE2 inhibitors (NS-398 and indomethacin).  They found that PGE2 
inhibition led to a 70% restoration of immune cell proliferation, as well as a significant increase 
in the production of pro-inflammatory cytokines TNFα and IFNγ211.  Other studies reported 
heme oxygenase, hepatic growth factor, and TGF-β as key mediators of MSC-mediated 
immunosuppression218,221,232.  These results suggest that multiple factors are likely involved in 
the immunosuppressive activity of MSCs. 
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Recent evidence suggests that MSCs can also modulate the innate immune response.  MSCs 
appear capable of reprogramming inflammatory macrophages into an anti-inflammatory 
macrophage phenotype136,140,141,244,254–256.  In vivo, MSC delivery has been shown to enhance 
healing in a variety of injury and disease models where inflammation plays a critical 
role140,244,254.  These improvements have been attributed to a shift in the local cellular 
environment.  Transplanted MSCs appear to reprogram inflammatory M1 macrophages into anti-
inflammatory pro-regenerative M2 macrophages, leading to a decrease in pro-inflammatory 
cytokines (e.g. TNFα, IL-12) and an increase in anti-inflammatory cytokines (e.g. IL-4, IL-
13)140,244,254.  Significant increases in the survival rate of septic mice treated with the MSCs have 
been reported216.  MSCs have also been shown to enhance healing of spinal cord injuries225 and 
dermal wounds226.  The beneficial effects of MSCs in these models, however, were eliminated in 
the absence of monocytes and macrophages (i.e., macrophage depletion by clondronate).  
 
In vitro, Kim et al. have recently shown that M2 macrophages can be generated by co-culturing 
immature (non-polarized) macrophages with MSCs in vitro255,257.  Monocytes were isolated from 
human blood and bone marrow and cultured with 10% human serum blood for 7 days (without 
addition of any cytokines) to generate macrophages.  2x105 MSCs were then added either 
directly on top of the monocyte-derived macrophages or in a transwell insert that prevented 
direct cell-cell contact, but allowed soluble factors to diffuse through the porous membrane.  The 
cells were then incubated for an additional 3 to 4 days.  Using flow cytometry, the authors 
demonstrated a shift toward a M2 phenotype when the monocyte-derived macrophages were co-
cultured (either directly or indirectly) with MSCs.  Macrophages co-cultured with MSCs 
exhibited high-levels of CD206 expression, a marker of alternatively activated macrophages.  
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Co-cultured macrophages also expressed high levels of the anti-inflammatory cytokine 
interleukin-10 (IL-10) and low levels of the pro-inflammatory cytokine TNF-α compared to 
controls.   
While several recent studies indicate that the beneficial effects of MSCs on a variety of healing 
models can be attributed to the ability of MSCs to reduce inflammation through the recruitment 
of M2 macrophages140,244,254,255,257–260, the mechanisms of action remain unclear.  Francois et al. 
suggested that MSC-secreted IDO is responsible for this phenomenon220 (Figure 1.11).    The 
authors found that co-culture of naïve or IFNγ pre-stimulated MSCs with monocyte-derived 
macrophages led to a significant increases in the production of IL-10138 (a feature of 
M2macrophages).  Further analysis showed that the macrophage population became CD206+ 
after co-culture with MSCs.  These results support the notion that MSCs can reprogram 
inflammatory, M1 macrophages into anti-inflammatory, IL-10 producing, M2 macrophages.  
Addition of 1-MT (a pharmacological inhibitor of IDO) to the MSC/macrophage co-culture 
significantly reduced the amount of IL-10 produced, indicating a possible involvement of IDO in 
the differentiation of monocytes into M2, immunosuppressive macrophages220,261. 
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Figure 1.11: Proposed mechanism for MSC-mediated monocyte differentiation into M2 
macrophages. MSCs, when activated by IFNγ, secrete IDO, which catalyzes the degradation of 
tryptophan (TRP) into kynurenine (KYN). Tryptophan depletion and/or metabolites of the 
kynurenine pathway mediate the differentiation of monocytes into IL-10 secreting, CD206+ 
immunosuppressive M2 macrophages.  Reproduced with permission by Francois et al.220 
 
Nemeth et al., on the other hand, suggested that PGE2 secretion by MSCs is responsible for 
monocyte differentiation into M2 macrophages244.  The authors reported increased levels of 
cyclooxygenase 2 (COX2, also known as PGE2 synthase) after MSC/macrophage co-culture.  To 
determine if COX2 played a key role in the shift of macrophages from the M1 to the M2 
phenotype, MSCs from Ptgs2−/− mice (i.e., mice lacking PGE2 synthase/COX2) were tested.  Co-
culture of macrophages with MSCs from these mice was unable to produce IL-10.  The authors 
concluded that activated MSCs produced PGE, which acted to reprogram M1 macrophages into 
M2, IL-10 secreting, immunosuppressive macrophages.  Nemeth et al. suggest a possible role for 
NO in this phenomenon.  They showed that when the MSCs and macrophages isolated from 
mice lacking the gene for nitric oxide (Nos2-/- mice) were co-cultured, IL-10 production was not 
induced.  However, the addition of S-nitroso-N-acetylpenicillamine, a  nitrosothiol derivative 
that releases nitric oxide, was able to restore the ability of Nos2−/− cells to produce IL-10244.  
While no clear consensus exists as to the mechanism of action, it is well reported that MSCs are 
capable of reprogramming inflammatory M1 macrophages into anti-inflammatory, IL-10 
secreting, M2 macrophages. 
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1.6 Scope and Procedure of the Dissertation 
Studies in tendon-to-bone models suggest that altering the early inflammatory response either 
through direct blockade of specific pro-inflammatory factors94 or by fine modulation of the 
immune cell population92,93,97 may be advantageous to tendon healing.  Based on these studies 
and the potential for MSCs to regulate those processes140,244,254,255,257, the overall goal of this 
dissertation was to investigate the role of inflammation on flexor tendon healing and the ability 
of mesenchymal stem cells to modulate this process.  The inflammatory phase of flexor tendon 
healing was first characterized using an animal model in order to establish the cytokine profile 
time course and to help identify targets for future treatments.  Next, a series of in vitro 
experiments were performed to determine whether the high levels of pro-inflammatory cytokines 
seen in vivo are detrimental to the native TFs.    Two models of inflammation were developed for 
this purpose: one induced by exogenous delivery of the pro-inflammatory factor, IL-1β, and one 
induced by M1 macrophages (the primary cellular source of IL-1β in vivo).  ASCs were then 
incorporated into the two models to explore the ability of ASCs to modulate the inflammatory 
environments.  The central hypothesis of this dissertation is that ASCs will protect TFs via the 
modulation of macrophage phenotypes.  It is hypothesized that ASCs co-cultured with pro-
inflammatory macrophages (i.e., M1 macrophages) will prompt the macrophages toward an anti-
inflammatory phenotype (i.e., M2 macrophages), resulting in fewer pro-inflammatory cytokines, 
thus lessening their negative effects on TFs.  Finally, a tendon-specific scaffold was developed 
for the delivery of ASCs in vivo.   The scaffold was used in a pilot study to investigate the ability 
of ASCs to enhance flexor tendon healing via modulation of the early inflammatory phase of 
flexor tendon healing. 
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1.6.1 Specific Aims 
Aim 1:  Characterize the early inflammatory response after flexor tendon injury and repair and 
identify targets for future treatments. 
Hypothesis:  Gene expression levels will coincide with the temporal changes in the cell 
populations (i.e., TFs vs. inflammatory cells). 
Anticipated results:  The early post-operative healing response after tendon repair will mirror 
that of dermal wound healing in terms of hemostasis and immune cell recruitment.  Pro-
inflammatory factors will be up-regulated during the early stages when immune cells 
predominate at the repair site, while ECM genes will be up-regulated at the later timepoints when 
fibroblasts infiltrate the wound.  MMPs will be up-regulated throughout the course of healing, 
but will increase over time as the remodeling phase approaches.   
Study Design: Flexor tendon injuries will be created and immediately repaired using repair 
techniques identical to those used clinically.  Animals will be sacrificed at 1, 3 and 9 days for 
gene expression and histologic assessments. 
 
Aim 2:  Examine the effects of inflammation on native TFs using in vitro models: (1) induced by 
exogenous IL-1β and (2) induced by co-culture with pro-inflammatory macrophages. 
Hypothesis:  Pro-inflammatory factors, either delivered directly or secreted by macrophages, will 
negatively impact TF behavior. 
Anticipated results:  IL-1β will induce up-regulation of pro-inflammatory and matrix 
metalloproteinase genes and a down-regulation of tendon-specific and ECM genes by TFs.  
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Since M1 macrophages are the primary cellular source of IL-1β, co-culture with macrophages 
will induce similar changes. 
Study Design:  TFs will be exposed to exogenous IL-1β and various macrophage phenotypes and 
the effect will be examined via gene and protein expression.  
 
Aim 3:  Investigate the ability of ASCs to modulate inflammation and its effects on TFs either by 
acting directly on the inflammatory cytokine, IL-1β, or indirectly by eliciting phenotypic changes 
in macrophage populations. 
Hypothesis:  ASCs will suppress the negative effects of pro-inflammatory factors (exogenous or 
macrophage-mediated) on TFs. 
Anticipated results:  ASCs co-cultured with TFs in an inflammatory environment induced by IL-
1β, will either take up IL-1β, effectively reducing the amount of IL-1β in the media, or secrete 
anti-inflammatory factors that counteract the effects of IL-1β.  ASCs in co-culture with 
inflammation-inducing macrophages will promote a phenotypic switch towards an anti-
inflammatory, M2 macrophage phenotype, resulting in decreased levels of pro-inflammatory 
factors and suppression of the negative effects of M1 macrophages on TFs. 
Study Design  ASCs will be incorporated into the two in vitro models of inflammation and their 
effect on TF gene expression and protein expression will be assessed. 
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Aim 4:  Develop a tendon-specific scaffold to deliver ASCs in vivo at the time of tendon repair 
and investigate the ability of ASCs to enhance flexor tendon healing via the modulation of the 
early inflammatory phase of flexor tendon healing. 
Hypotheses:  ASCs will improve flexor tendon repair by modulating the early inflammatory 
phase of healing.  
Anticipated results:  ASCs delivered at the time of flexor tendon injury and repair will suppress 
the early inflammatory response via the recruitment of anti-inflammatory, M2 macrophages as 
opposed to pro-inflammatory, M1 macrophages.  As a result, genes related to inflammation and 
matrix degradation will be decreased in the ASC-treated groups compared to untreated controls. 
Study Design: Fibrin/nanofiber scaffolds, either acellular or cellular (i.e., containing 1 million 
ASCs) will be implanted at the site of flexor tendon injury and repair in a clinically relevant 
canine model.  Animals will be sacrificed at 3 and 9 days for gene expression and histologic 
assessments.  
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Chapter 2 - The Early Inflammatory Response after Flexor 
Tendon Healing 
 
2.1 Introduction 
Despite improved surgical techniques and rehabilitation protocols over the past few decades, 
flexor tendon repairs remain prone to poor clinical outcomes1–4,16, including development of 
repair-site elongation and rupture4–11 and adhesion formation within the digital sheath5,6,10,12–15.  
Wound healing is classically divided into four overlapping phases: haemostasis (day 0), 
inflammation (day 1-7), proliferation (day 3-14), and remodeling (day 7-several weeks)112,156–160.  
The first stage, haemostasis, occurs immediately following injury.  Vasoconstriction and clotting 
factors released by injured cells initiate the formation of a fibrin clot, which serves as a 
temporary seal over the injury site.  Chemoattractants secreted by injured cells, and activated 
platelets within the fibrin clot, initiate the beginning of the inflammation phase112,156–160.  
Polymorphonuclear cells (PMNs) are recruited to the wound site within hours of injury to clear 
the wound of debris and bacteria.  After 48-72 hours, monocytes infiltrate the wound, 
differentiate into macrophages, and control the clearance of dead cells and tissues through 
phagocytosis and the production of metalloproteinase proteolytic enzymes (i.e., MMPs), such as 
collagenase112,156–160.  The third stage, proliferation, is characterized by fibroblast migration, 
proliferation, and deposition of extracellular matrix to form granulation tissue112,156–160.  During 
the fourth and final stage, remodeling, a careful balance between MMP-mediated collagen 
degradation and continued synthesis of collagen by fibroblasts, results in reorganization of the 
extracellular matrix. The maturation and alignment of collagen fibers during this phase leads to 
increased tensile strength of the healing tissue112,156–160. 
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Previous attempts to improve tendon repair have focused on the later stages of healing.  
Rehabilitation protocols have successfully reduced adhesion formation within the digital sheath 
during the proliferative/matrix synthesis phase1–4,17–30 (see Chapter 1, section 1.3.1).  Natural and 
synthetic surface modifications also have been utilized to enhance tendon gliding and to inhibit 
adhesion formation during the proliferative/matrix synthesis phase9,31–57 (see Chapter 1, section 
1.3.2).  However, due to failure of the healing tendons to accrue strength during the first 3 weeks 
post-operatively, the repair remains at risk for gap formation and rupture.  Thus, focus has 
recently shifted to biological manipulation of the proliferative/matrix synthesis stage to promote 
cellular activity and matrix synthesis7,8,15,23,27,28,58–89.  Stimulation of cells using growth factors, 
however, has had limited success.  While platelet-derived growth factor BB (PDGF-BB) and 
basic fibroblast growth factor (bFGF) were successful in stimulating tendon fibroblasts (TFs) to 
proliferate and to produce collagen in vitro86–89, neither were able to enhance the structural 
properties of the tendon when delivered in vivo7,8,15,86.  Furthermore, the enhanced cellular 
activity stimulated by bFGF led to increased scar formation that was detrimental to tendon 
healing15 (see Chapter 1, section 1.3.34).  While the later stages of flexor tendon healing have 
been previously targeted, the early inflammatory phase (i.e., first week) of tendon healing is 
poorly understood and its modulation during healing has not yet been attempted.    
 
The purpose of this study was to characterize the early inflammatory response after flexor tendon 
injury and repair in order to help identify targets for future treatments.  Using a clinically 
relevant large animal model of flexor tendon injury and repair, temporal changes in immune cell 
population and gene expression of inflammation-, matrix remodeling-, extracellular matrix- 
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(ECM), and differentiation-related factors were examined during the early post-operative period 
up to 9 days.   
 
We expect that the early post-operative healing response after tendon repair will mirror that of 
dermal wound healing in terms of hemostasis, cell recruitment, matrix deposition and 
remodeling112,156–160.  Specifically, we predict that inflammatory cells (i.e., PMNs and 
monocytes/macrophages) will dominate the repair in the first few days after repair, with a 
corresponding increase in the gene expression of pro-inflammatory factors161,262.  As the 
inflammatory cells diminish and fibroblasts begin to infiltrate the wound, we expect that the 
expression of pro-inflammatory genes will decrease towards baseline, while the extracellular 
matrix- and matrix degradation-related genes will increase.   
 
2.2 Methods 
 
Flexor tendon animal model: All procedures were approved by the Washington University 
Animal Studies Committee. Flexor tendon injury and repair was performed in the clinically 
relevant canine animal model (N=11)7,8,15,86,99,263. The sheaths of the second and fifth digits of the 
right forelimb in the region between the annular pulleys proximal and distal to the proximal 
interphalangeal joint were exposed through midlateral incisions. The sheaths were entered and 
the flexor digitorum profundus tendons were transected sharply.  The tendons were repaired 
using surgical techniques identical to those used in humans (4-0 Supramid core suture, 6-0 
Proline running epitenon suture).  Both the second and fifth digits of the right forelimb were 
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repaired. After surgery, the operative limb was immobilized using a fiberglass shoulder spica 
cast with the elbow flexed to 90° and the wrist flexed to 70° and a controlled passive motion 
rehabilitation protocol, similar to that used clinically, was applied.  The protocol consists of two 
five-minute rehabilitation sessions performed five days a week starting on the first postoperative 
day3,25 The dogs were euthanized on days 1, 3 or 9 post-operatively and the operated tendons 
were removed by dissection and prepped for either gene expression analysis (N=3) or histologic 
analysis (N=5).  Tendons from the contralateral paw were also dissected to serve as 
normal/uninjured controls.  
 
Histology: Upon dissection, tendons allocated for histology were fixed in 4% paraformaldehyde 
overnight, embedded in paraffin, and cut into 5 µm sections.  To examine the immune response, 
sections were stained with hematoxylin and eosin (H&E) and assessed for various immune cells 
(i.e., PMNs, monocytes, macrophages) by an independent certified pathologist (Necat 
Havlioglu), blinded to group.  Fibroblasts were characterized as spindle-shaped cells with an 
elliptic nucleus and thin cytoplasm. PMNs were identified as cells containing nuclei with two to 
four lobules and a granulated cytoplasm, while cells with a single-lobed or kidney-shaped 
nucleus were classified as monocytes/macrophages. A standard scoring system was used to 
determine the levels of each outcome (- no prevalence, + mild prevalence, ++ moderate 
prevalence, +++ marked prevalence). For overall cellularity and the prevalence of certain cell 
types, the number of cells per high powered field (HPF, 20x) was counted and assigned a score 
as follows: + <50 per HPF, ++ 51-100 per HPF, +++ 101-150 per HPF, ++++ >150 per HPF. 
Vascularity was measured on the following scale: + <5 per HPF, ++ 6-10 per HPF, +++ > 10 per 
HPF. All assessments were done using a 20x objective and 12-21 fields of view were averaged. 
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The percentage of fibroblasts compared to overall cellularity was also assessed and scored as 
follows: + = less than 5%, ++ = 5-50%, +++ > 50%.  Sections were also viewed under polarized 
light for the assessment of collagen alignment.  Proliferating cell nuclear antigen (PCNA) 
staining (Invitrogen, NY) was performed according to the manufacturers’ protocols to access cell 
proliferation and apoptosis, respectively. 
 
Gene expression: Tendons allocated for gene expression were dissected and 10 mm sections (5 
mm on each side of the repair) were isolated and immediately flash frozen in liquid nitrogen. 
RNA was extracted from the tendons using the RNeasy mini kit (Qiagen, CA) following the 
manufacturer’s protocol. RNA yield was quantified using a NanoDrop spectrophotometer 
(Thermo Scientific, DE) and 500 ng of RNA was reverse transcribed to cDNA using the 
Superscript VILO cDNA synthesis kit (Invitrogen Corporation, CA) following manufacturer’s 
instructions. Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) 
was performed using SYBR Green chemistry on a StepOnePlus Real-Time PCR System 
(Applied Biosystems, CA). All primers for real-time PCR were purchased (Qiagen, CA). Gene 
expression changes were measured for genes related to inflammation (IL-1β, TNFα, COX2), 
matrix degradation (MMP1a, 1b, 3, 13), extracellular matrix (collagen type 1 (COL1), collagen 
type 3 (COL3), lysol oxidase (LOX), decorin (DCN)), and differentiation (scleraxis (SCX), 
tenomodulin (TNMD), lubricin (LUB), and vascular endothelial growth factor (VEGF)).  Data 
was analyzed using the delta delta Ct method.  The results were first normalized to a 
housekeeping gene (glyceraldehyde 3-phosphate dehydrogenase (GAPDH)) and then again to 
normal/uninjured group.  The delta Ct values were compared using a 2-way ANOVA (for 
treatment and time), followed by a Fisher’s post-hoc test.  Significance was set to p < 0.05.   
38 
 
2.3 Results 
Inflammation: Overall cellularity at the repair site was significantly increased 1 day post-
operatively (Table 2.1).  The dominant cell type contributing to this increase in cellularity was 
the PMN (Figures 2.1, 2.2, Table 2.1).  The majority of the PMNs were within the fibrin clot at 
the entrance to the repair.  PMNs were also present in the tendon tissue near the surface of the 
repair (Figures 2.1, 2.2).   
 
Table 2.1:  Histological analysis of the early inflammatory response 1, 3, and 9 days post-
operatively.  The prevalence and type of immune cells at the repair site was assessed over time.  
A standard scoring system was used to determine the levels of each outcome.  
Cellularity/PMN/Mono: + <50 per HPF, ++ 51-100 per HPF, +++ 101-150 per HPF, ++++ >150 
per HPF. Vascularity: + <5 per HPF, ++ 6-10 per HPF, +++ > 10 per HPF.  Fibroblast 
percentage: + = less than 5%, ++ = 5-50%, +++ > 50%.  PMN = Polymorphonuclear cells, Mono 
= monocytes/macrophages, Fibro% = fibroblast percent compared to overall cellularity, HPF = 
High powered field (20x), (N=3-5). 
 
 
 
Cellularity PMN Mono Fibro % Vascularity 
Day 1 ++ ++ - + -/+ 
Day 3 + + + + -/+ 
Day 9 + + + ++/+++ ++ 
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Figure 2.1:  Representative histologic sections of normal and repaired tendons 1, 3, and 9 days 
post-operatively.   The sections were stained with H&E and viewed under brightfield for cell 
identification. An overview of a representative section from each timepoint is shown to the left 
(4x objective, 2 mm scale bar).  Colored squares indicate the regions of interest (repair surface, 
tendon surface, repair center, tendon substance) on the overview images and corresponding high 
magnification images (20x objective, 200 µm scale bar) are shown to the right with 
corresponding border colors.    Inflammatory cells are seen infiltrating the repair site via the 
tendon surface on day 1.  The Inflammatory response decreases over time and fibroblasts 
invaginate and fill the repair by day 9.  New blood vessel formation on the tendon surface is 
evident on day 9. 
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Figure 2.2:  Representative histologic sections of repaired tendons 1, 3, and 9 days post-
operatively. The sections were stained with either H&E or PCNA and viewed under brightfield 
for identification of immune cells (PMN), vascularity, and cell proliferation (PCNA). Changes in 
cell proliferation were most evident near the surface of the tendon.  PMNs (black arrows) 
infiltrated the repair site on day 1, but decreased over time.  New blood vessel formation was 
evident on the surface of the tendon away from the repair site by day 9.  Images for PMNs and 
vascularity are the same regions as those presented in Figure 2.1 (see border color for region of 
image). 40x objective, 200 µm scale bar, (N=3-5). 
 
A corresponding spike in pro-inflammatory genes (TNFα, IL-1β, COX2) was evident.  TNFα 
was up-regulated 10.6-fold compared to normal, while IL-1β and COX2 were up-regulated a 
remarkable 4403- and 837-fold (Figure 2.3).   
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Figure 2.3:  Fold changes in gene expression of pro-inflammation- and matrix degradation-
related factors relative to normal 1, 3, and 9 days post-operatively.  * p < 0.05, † p <0.10, 2-way 
ANOVA, significant effect of time (except for TNFα), bars signify Fisher’s post-hoc 
comparisons, * by x-axis signifies a significant difference compared to normal tendons, (N=3). 
 
On day 3, overall cellularity remained higher than in normal/uninjured tendon, but was decreased 
compared to day 1.  A shift in the immune cell population was noted at this timepoint, with fewer 
PMNs evident at the repair site compared to day 1 (Figures 2.1, 2.2, Table 2.1). Presumably, this 
is why the expression of pro-inflammatory factors, IL-1β and COX2, were down-regulated 2.5- 
0
5
10
15
20
1d 3d 9d
Fo
ld
 
di
ffe
re
n
ce
 
re
la
tiv
e
 
to
 
n
o
rm
a
l
TNFα
0
2000
4000
6000
8000
10000
12000
1d 3d 9d
Fo
ld
 
di
ffe
re
n
ce
 
re
la
tiv
e
 
to
 
n
o
rm
a
l
IL-1β
0
300
600
900
1200
1500
1d 3d 9d
Fo
ld
 
di
ffe
re
n
ce
 
re
la
tiv
e
 
to
 
n
o
rm
a
l
COX2
0
5000
10000
15000
20000
25000
30000
1d 3d 9dF
o
ld
 
di
ffe
re
n
ce
 
re
la
tiv
e
 
to
 
n
o
rm
a
l 
MMP1
0
5
10
15
20
1d 3d 9d
Fo
ld
 
di
ffe
re
n
ce
 
re
la
tiv
e
 
to
 
n
o
rm
a
l
MMP3
0
200
400
600
800
1000
1d 3d 9d
Fo
ld
 
di
ffe
re
n
ce
 
re
la
tiv
e
 
to
 
n
o
rm
a
l
MMP13
* *
*
*
*
* * * *
†
*
*
* * *
* * * * * *
*
*
*
*
*
*
*
*
42 
 
and 4.9-fold, respectively, compared to day 1.  TNFα remained up-regulated 6.78-fold.  The 
most prominent immune cell type by day 3 was from the monocyte/macrophage lineage (Figures 
2.1, 2.2, Table 2.1).  Macrophages are known to be a major source of IL-1β during wound 
healing156,161. Consistent with this, expression levels of pro-inflammatory genes remained 
significantly elevated at day 3 compared to normal/uninjured control tendon (IL-1β, COX2, and 
TNFα were up-regulated 1743-, 170.52-, and 6.78-fold, respectively, compared to 
normal/uninjured tendons) (Figure 2.3).  The number of monocytes/macrophages at the repair 
site remained stable through day 9 (Figures 2.1, 2.2, Table 2.1); however, IL-1β and COX2 
expression continued to decrease, but remained significantly up-regulated compared to 
normal/uninjured tendons (924.5- and 26.3-fold for IL-1β and COX2, respectively).  TNFα 
levels remained relatively constant at this timepoint (8.57-fold greater than normal) (Figure 2.3).  
While the expression of inflammatory factors decreased over time, expression levels remained 
significantly higher than normal, even 9 days post-repair.   
 
 
Proliferation: PCNA staining showed proliferation of epitenon cells (i.e., tendon surface cells) as 
early as day 1 (Figure 2.2).  By day 3, the epitenon was thickened and the tendon surface cells 
continued to proliferate.  Proliferation of cells deeper in the tendon substance (i.e., endotenon 
cells) was also observed on day 3 and continued through day 9 (Figure 2.2).  By day 9, 
fibroblasts infiltrated the repair site and filled the gap between the tendon stumps (Figure 2.1, 
Table 2.1).  Expression of tendon-specific and extracellular matrix genes was significantly down-
regulated 1 day post-operatively (27.0-, 14.9-, 35.6-, and 24.5-fold for COL1, COL3, SCX, and 
TNMD, respectively).  As the cellular environment shifted from immune cell-dominant on day 1 
43 
 
to fibroblast-dominant on day 9 (Table 2.1), the expression of tendon-specific and tendon 
extracellular matrix genes returned to baseline, with the exception of TNMD (Figure 2.5).  
  
 
Remodeling:  Matrix degradation, as evidenced by MMP expression and polarized light 
microscopy, was seen as early as day 1.  MMPs 1, 3, and 13 were up-regulated 1634-, 14.7-, and 
102.1-fold, respectively, compared to normal/uninjured tendons (Figure 2.3).  Polarized light 
microscopy revealed rapid loss of collagen fiber organization that was likely related to the up-
regulation in MMP expression (Figure 2.4).  
 
 
 
Figure 2.4:  Representative histologic sections of normal and repaired tendons 1, 3, and 9 days 
post-operatively.  The sections were stained with H&E and viewed with polarized light to assess 
collagen fiber alignment.  White regions indicate fiber alignment along the long axis of the 
tendon.  Dark regions indicate a loss of fiber alignment.  Some collagen fiber alignment was lost 
as early as 1 day post-operatively.  Alignment was further disrupted by day 3 and remained 
steady through day 9.  4x objective, 2 mm scale bar, (N=3-5). 
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MMPs involved in the degradation of collagen types 1 and 3 (MMP1, MMP13) were further up-
regulated on day 3 (Figure 2.3) and collagen fiber alignment was further disrupted (Figure 2.4).  
By day 9, the expression of MMPs 1 and 13 continued to rise, reaching 24,158- and 493.5-fold 
increases compared to normal/uninjured tendon (Figure 2.3).  Collagen fiber alignment remained 
similar to that of day 3 (Figure 2.4).  On day 9, newly formed blood vessels were observed 
(Figures 2.1-2.2, Table 2.1).  Few (if any) vessels were evident on days 1 and 3 (Figures 2.1-2.2, 
Table 2.1). Therefore, the new vessels seen at day 9 were likely a result of the up-regulation of 
vascular endothelial growth factor (VEGF, 17.9-fold) observed on day 1 (Figure 2.5).     
 
 
Figure 2.5:  Fold changes in gene expression of tendon ECM and tendon-specific factors relative 
to normal 1, 3, and 9 days post-operatively.  * p < 0.05, † p <0.10, 2-way ANOVA, significant 
effect of time (except for LOX and TNMD), bars signify Fisher’s post-hoc comparisons, * by x-
axis signifies a significant difference compared to normal tendons, (N=3). 
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2.4 Discussion 
While the proliferation and remodeling stages of flexor tendon healing have been studied in 
detail98–111,113,119–121 and subsequently targeted to enhance flexor tendon healing1–4,7,8,15,17–30,58–89, 
the early inflammatory phase of tendon healing is poorly understood and its modulation during 
healing has not yet been investigated.  This study characterized the early inflammatory response 
following flexor tendon injury and repair.  We examined temporal changes in the cell population 
and gene expression of inflammation-, matrix remodeling-, extracellular matrix-, and 
differentiation-related factors and found that flexor tendon healing mimics that of dermal wound 
healing in terms of haemostasis and the sequential recruitment of PMNs and 
monocytes/macrophages112,156–160.  PMNs infiltrated the repaired tendon as early as one day post-
operatively, but were replaced by monocytes/macrophages as the dominant immune cell type by 
day 3.  By day 9, tendon fibroblasts appeared at the repair site in large numbers.  As noted by 
others98–101,104–110,120,121, the source of the fibroblasts appeared to be the epitenon cells.  The 
epitenon cells began to proliferate as early as 1 day post-operatively.  By day 3, the epitenon 
thickened and the cell proliferation continued. By day 9, fibroblasts invaginated the repair via the 
surface of the tendon and filled the gap between the tendon stumps.  During this process, 
expression of pro-inflammatory and matrix remodeling genes were significantly up-regulated.  
TNFα, IL-1β, and COX2 levels spiked as early as day 1, but decreased over time as the cell 
population changed from immune cell dominant to tendon fibroblast dominant.  In contrast, 
extracellular matrix- and differentiation-related genes were significantly down-regulated on day 
1, when immune cells dominated the repair, but increased towards baseline values as PMNs 
underwent apoptosis and fibroblasts were recruited to the repair site.  Finally, MMPs were 
significantly up-regulated upon injury and steadily rose over time as macrophages cleared the 
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wound of debris and dead tissue and as fibroblasts filled the repair and initiated the remodeling 
phase of healing.  As expected, the temporal increase in MMP expression coincided with a 
decrease in collagen fiber alignment.   
 
Previous characterizations of flexor tendon healing focused on: (1) describing the morphological 
changes at the repair site98–111, (2) identifying the cellular source that contributes to tendon 
healing98–101,104–110,120,121, and (3) examining the effect of rehabilitation on adhesion 
formation113,119.  While these studies have been instrumental in informing surgical techniques 
and rehabilitation protocols, the early inflammatory process was not carefully characterized.  
Potenza merely described the inflammatory response as “red and white blood cells” filling the 
repair, but did not provide a detailed description of the exact types of immune cells present or 
any temporal changes in the immune cell population98.  Gelberman et al. described fibrinous 
bridges overlying a “mesh of erythrocytes, macrophages, and other inflammatory-type cells” on 
day 3, but earlier timepoints were not investigated102.  The expression of inflammatory and 
catabolic factors was not described until the past decade.  Berglund et al. revealed a significant 
spike in the expression of pro-inflammatory factors (IL-1β and COX2) 3 days post-operatively, 
but no earlier timepoints were examined264.  IL-1β and COX2 levels remained elevated through 
day 6, but returned to baseline by day 12.  Similarly, the matrix degradation factor, MMP13, was 
significantly up-regulated on day 3 and remained elevated through day 24 (with no temporal 
changes)264.  These results are generally in agreement with the current study; however, they were 
obtained in a rabbit flexor tendon-healing model, which is less clinically relevant than the canine 
model due to the smaller size of the tendons and the inability to perform passive motion 
rehabilitation.  In contrast, canine flexor tendons are similar in size to those of humans and a 
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passive motion rehabilitation protocol, similar to that used clinically, was applied in the current 
study.  Furthermore, the current study combined the use of histology and gene expression to 
elucidate the cellular source of the gene expression changes.   
 
Regardless, there were a number of limitations to the current study. First, additional timepoints 
could be used to better determine when some of these temporal changes occurred, as there 
appeared to be a dramatic transition sometime between days 3 and 9.  Second, the cellular source 
contributing to the gene expression results was a combination of inflammatory cells and 
fibroblasts. Therefore, the specific expression patterns for individual cell types remain unknown.  
However, histological assessment of the various cell types partly addresses this limitation.  The 
percentage of fibroblasts (compared to overall cellularity) was estimated based on a 
morphological assessment and quantification.  Given the high cellularity and the low fibroblast 
percentage on day 1, we can postulate that the up-regulation of pro-inflammatory factors at this 
early timepoint was primarily due to infiltration of immune cells (i.e., PMNs and 
moncoytes/macrophages).  Similarly, the initial down-regulation of tendon-specific and tendon 
ECM genes is likely due to a diluted fibroblast population.  RNA extracted from 
normal/uninjured tendons was mainly from fibroblasts. These cells express SCX, TNMD, COL1, 
and COL3.  On the other hand, RNA extracted from the repaired tendons on day 1 was mainly 
derived from inflammatory cells, which do not express those genes.  As the cell population 
shifted from immune cell-dominant to fibroblast-dominant, the expression of tendon-specific and 
tendon ECM-related factors returned to baseline levels.  While the histological assessment of 
fibroblast percentage helped to interpret the gene expression data, immunohistochemical 
analyses would further elucidate the cellular source of the differential gene expression seen over 
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time.  Immunohistochemistry also would help verify the translation of these genes into protein.  
However, the appropriate canine antibodies are not yet commercially available.  A third 
limitation is the lack of protein-level assessment, which does not always parallel transcription. 
Protein expression could be assessed by Western immunoblot analysis; however, this approach 
also requires canine-specific antibodies and additional animals.  Finally, the animal model used 
was an acute injury model, in which the injury is created and surgically repaired immediately.  
Clinically, a delay of days to weeks often occurs between injury and repair.  This has important 
implications for the inflammatory process, which only dominates in the first 3 days after surgical 
repair. 
 
While some inflammation is critical for tissue healing90,91,162, excessive levels of pro-
inflammatory cytokines (e.g. IL-1β, TNFα, and NO) that are secreted by macrophages may, in 
fact, be detrimental to tissue healing by causing MMP-mediated catabolism of healthy tendon 
ECM surrounding the wound144,163–165.  In vitro studies have shown that pro-inflammatory 
factors, such as IL-1β and TNFα, induce TFs to up-regulate their own expression of 
inflammatory and catabolic mediators (i.e., MMPs),163,164,265,266 while down-regulating their 
expression of type 1 collagen164,267.  Similarly, at the tissue level, IL-1β exposure leads to up-
regulation of MMPs and down-regulation of type 1 collagen expression, resulting in reduction of  
the ultimate tensile strength and elastic modulus of the tendons and an increase in maximum 
strain268.  In a tendon-to-bone model, TNFα-blockade led to fewer pro-inflammatory 
macrophages and improved structural properties at the early post-operative timepoints94.  Other 
studies suggest that modulating the immune cell population itself may improve tendon healing92–
96
.  Hayes et al. found that selectively inducing macrophage apoptosis via the use of a 
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bisphosphonate (i.e., clodronate), led to reduced scar tissue formation, increased collagen fiber 
organization, and improved structural properties (i.e., load to failure and stiffness) in a tendon-to-
bone healing model92.  Similarly, Dagher et al. found that immobilization of the knee after ACL 
reconstruction led to improved mechanical properties via a shift in macrophage phenotype.  
Whereas the macrophages found at the repair site of mobilized rats were of the pro-inflammatory 
phenotype (i.e., M1 macrophages), immobilization led to a decrease in M1 macrophages and an 
increase in anti-inflammatory, pro-regenerative macrophages (i.e., M2 macrophages).  Improved 
tendon-to-bone integration was noted, as evidenced by reduced scar tissue formation, increased 
collagen fiber organization, and enhanced biomechanical properties (e.g. failure load and 
stiffness)93.  Taken together, these results suggest that M1 macrophages (which secrete IL-1β) 
may impede tendon healing and, thus, modulation of the early inflammatory phase of tendon 
healing may prove beneficial.   
 
While the pro-inflammatory factors (such as IL-1β) and cytotoxic mediators secreted by 
macrophages may result in excessive matrix degradation269, macrophages also play a pivotal role 
in fibroblast chemo-attraction.  Synthesis of numerous potent growth factors, such as TGF-β, 
bFGF, and PDGF, by macrophages promote cell proliferation and synthesis of extracellular 
matrix112,156–162.  Macrophages also play an important role in angiogenesis through the secretion 
of VEGF112,156–161112,156–162.  Indeed, several studies have shown that global depletion of 
macrophages during wound healing leads to retarded wound repair90,91,162,270.  One such study 
showed that ablation of macrophages in the wound resulted in decreased expression of TGF-β, 
reduced fibroblast proliferation, and a reduction in extracellular matrix synthesis162. 
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Based on these studies, fine modulation of the inflammatory environment might enhance tendon 
healing. This approach may be more effective than a global IL-1β blockade or macrophage 
depletion. Future studies could aim to reduce IL-1β production during the early post-operative 
period via control of macrophage phenotype, promoting a switch from pro-inflammatory M1 
macrophages to anti-inflammatory M2 macrophages.  Upon recruitment to the wound, 
monocytes differentiate into macrophages.  The functional phenotype of the macrophages is 
dependent on the wound environment.  Bacterial products (such as lipopolysaccharide, LPS) and 
inflammatory cytokines (such as interferon gamma, IFNγ), which are typically present during the 
early stages of wound healing, promote differentiation of monocytes into pro-inflammatory M1 
macrophages (also known as classically activated macrophages or CAMs)136,138,139,141,156,271.  
Recent studies suggest that mesenchymal stem cells (MSCs) can induce a phenotype switch from 
pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages139,140,245,255,272.  Thus, 
we hypothesize that MSC-mediated modulation of the macrophage population during the early 
inflammatory phase of tendon healing may prove beneficial to the healing process by reducing 
the levels of pro-inflammatory factors (such as IL-1β), which in turn will enhance tendon 
fibroblast viability and reduce collateral damage of healthy tendon tissue.   
 
The next two chapters (Chapters 3-4) will investigate 1) the effects of IL-1β on native tendon 
fibroblasts to determine whether the high levels of IL-1β observed in vivo may be detrimental to 
the native TFs and whether this might be a future target for enhanced healing; and 2) the effects 
of various macrophage phenotypes on native tendon fibroblasts to determine whether a shift 
from a M1 macrophage phenotype to an M2 macrophage phenotype would be beneficial to 
tendon healing. 
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Chapter 3 - The Effects of the Pro-Inflammatory Cytokine, 
Interleukin 1β, on Tendon Fibroblasts: An In Vitro Model of 
Inflammation 
 
3.1 Introduction 
 
In the previous chapter, we demonstrated that intrasynovial flexor tendon injuries induce a rapid 
local inflammatory response characterized by early infiltration of inflammatory cells (e.g., 
macrophages, polymorphonuclear cells) and a significant up-regulation of pro-inflammatory 
(e.g., IL-1β, TNFα, and COX2 and matrix degradation genes (e.g., MMP-1, -3, -13) within the 
first 9 days post injury and repair. In addition, we observed significant down-regulation of genes 
related to flexor tendon ECM (collagen type I (COL1), collagen type III (COL3), lubricin 
(LUB)) and tendon fibroblast differentiation (e.g., SCX, TNMD).  Remarkably, IL-1β gene 
expression increased 4000-fold within 3 days post-operatively.  Similar results have been 
reported in a rabbit flexor tendon model of acute injury and repair. Berglund et al. observed 
significant up-regulation of IL-1β, COX2, and MMP-13 gene expression 3 days after flexor 
tendon injury and repair.  As with our study, the most striking outcome was the increase in IL-1β 
expression (1600-fold increase)273.  IL-1β has also been implicated in a variety of tendinopathy 
models both in animals and in human patients126,133.  
 
In vitro studies by other investigators have shown that human tendon fibroblasts (TFs) exposed 
to pro-inflammatory cytokines (i.e., IL-1β, TNFα, IL-6) further up-regulate their expression of 
inflammatory cytokines and matrix metalloproteinases123,155,163,164,265–268,273–278.  Moreover, 
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exposure of bioartificial tendons to IL-1β ex vivo has been shown to cause down-regulation of 
type 1 collagen expression and an up-regulation of MMPs, resulting in a reduction in the ultimate 
tensile strength and elastic modulus of the tendon analogues and an increase in maximum 
strain268.   
 
Based on these studies, our objective in the current study was to examine the effect of IL-1β on 
TFs to determine whether the high levels of IL-1β observed in vivo might be detrimental to the 
native TFs.  Based on previous studies6–13, we hypothesize that IL-1β will induce up-regulation 
of pro-inflammatory and matrix metalloproteinase genes by canine TFs.  In addition to up-
regulation of inflammation and matrix degradation genes, however, we also expect a down-
regulation of genes related to tendon extracellular matrix and fibroblast differentiation.  To test 
these hypotheses, an in vitro model of inflammation was used in which exogenous IL-1β was 
delivered to TFs in culture.  The response of TFs to IL-1β was determined by monitoring the 
expression of genes and proteins related to inflammation and matrix remodeling.  Understanding 
these cellular responses will allow for subsequent experiments targeting the inflammatory 
process during tendon healing. 
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3.2 Methods 
 
Tendon Fibroblast Cell Isolation and Culture:  TFs were isolated from the tail of adult Sprague 
Dawley rats (N=4).  The tissue was minced and digested in 0.2% Collagenase Type IA in 
Phosphate Buffered Saline for 1-2 hours.  The digested tissue was collected by centrifugation 
and incubated in alpha-modified eagles medium (Alpha-MEM) with 10% Fetal Bovine Serum 
(FBS) and 1% Penicillin/Streptomycin (P/S) (37°C, 5% CO2, 95% humidity).  The cells were 
used on passage 4.   
 
Dose-response study:  Prior to IL-1β treatment, the amount of FBS in the tendon fibroblast 
culture media was gradually reduced over time until only 1% FBS remained in order to reduce 
the potential competing effects of the various factors in the FBS. All experiments were 
performed using media containing minimal amounts of FBS (i.e., 1% FBS).  To determine the 
effect of IL-1β on TFs, TFs (N=4 cell isolations) were plated at 5.2x104 cells/cm2 in 6 well plates 
and treated with varying amounts of IL-1β (0 ng/ml, 0.01 ng/ml, 0.1 ng/ml, 1 ng/ml, 10 ng/ml, 
100 ng/ml; rat-derived, R&D Systems, Minneapolis, MN).  The cells were cultured for 1, 2, and 
3 days before RNA was isolated and qRT-PCR was performed.   
 
Gene Expression: Total RNA was isolated (RNEasy Minikit; Qiagen, Valencia, CA) from the 
TFs on days 1, 2, and 3 after treatment with IL-1β.  500 ng RNA was reverse transcribed to 
cDNA using the Superscript VILO cDNA synthesis kit (Invitrogen Corporation, CA).  qRT-PCR 
was performed to measure the gene expression levels of pro-inflammatory factors (IL-1β, TNFα, 
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COX2) and matrix degradation factors (MMP1, 3, 13) for all dosages.  Additional factors related 
to ECM (collagen type 1 (COL1), collagen type 3 (COL3)) and TF differentiation (SCX, 
TNMD) were only assessed for the 10 ng/ml group.  All primers for qRT-PCR were purchased 
(Qiagen, CA).  The data was analyzed using the delta delta Ct method, in which the results were 
normalized to a housekeeping gene (GAPDH) and then to the control group (i.e., untreated TFs).  
The delta Ct values were compared using a multi-factor ANOVA (for the effects of IL-1β, 
dosage, and time) followed by a Fisher’s post-hoc test.  The delta Ct values for the additional 
genes assessed only in the 10 ng/ml group were compared using a 2-way ANOVA (for the 
effects of IL-1β and time).  Significance was set to p < 0.05.   
 
Protein Expression: Cell supernatants were collected on days 1, 2, and 3 from the 10 ng/ml 
group. Samples were stored at -80°C until analysis.  The levels of IL-1β, TNFα, and MMP3 were 
assessed using commercially available kits (ELISAs, R&D Systems, Minneapolis, MN).  Data 
was normalized to control (TFs cultured alone).  Group means were compared using a 2-way 
ANOVA (for the effects of IL-1β and time). Significance was set to p < 0.05. 
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Live/Dead Assay: A separate set of experiments was performed to assess the viability of the TFs 
after IL-1β exposure.  TFs were treated with 10 ng/ml of IL-1β or left untreated (control).  1, 2, 
and 3 days after IL-1β treatment, the supernatant was removed and the cells were stained with a 
commercially available Live/Dead Viability/Cytotoxicity kit according to the manufacturers 
protocols (Invitrogen, NY).  Cells were imaged using a fluorescent microscope and the 
percentage of live cells was calculated using ImageJ. 
 
 
3.3 Results 
 
IL-1β induced up-regulation of genes related to inflammation and matrix degradation by TFs: 
Significant up-regulation of various inflammatory and matrix degradation genes (compared to 
control, 0 ng/ml) were observed on days 1 and 3 when TFs were treated with IL-1β (Figures 3.1-
3.2).  On day 1, the lowest dose, 0.01 ng/ml, was sufficient to significantly up-regulate 
expression of COX2 and MMP3, while 0.10 ng/ml was sufficient to up-regulate MMP13. 1 
ng/ml up-regulated IL-1β and MMP1, while 10 ng/ml was required to up-regulate TNFα.  To 
maintain these effects through day 3, higher dosages of IL-1β were often necessary. However,  
10 ng/ml was sufficient to maintain up-regulation of all tested genes till day 3, with the exception 
of TNFα, which required a dose of 100 ng/ml. 
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Figure 3.1:  IL-1β induced up-regulation of inflammation-related genes by TFs occurs in a dose-
dependent manner. Gene expression for each dosage is normalized to control (0 ng/ml).              
* p < 0.05, multi-factor ANOVA. There was a significant effect of dosage and time for all genes.  
There was a significant effect of IL-1β treatment for IL-1β and COX2 (TNFα, p= 0.08), (N=4,  
except for IL-1β on day 1, N=3). 
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Figure 3.2:  IL-1β induced up-regulation of matrix degradation-related genes by TFs occurs in a 
dose-dependent manner. Gene expression for each dosage is normalized to control (0 ng/ml).      
* p < 0.05, multi-factor ANOVA. There were significant effects of IL-1β treatment, dosage, and 
time for all genes. (N=4). 
 
In contrast, 10 ng/ml of IL-1β significantly inhibited genes related to tendon extracellular matrix 
(COL1, COL3) and differentiation (SCX, TNMD) (Figure 3.3). 
Day 1
Day 3
1.00
10.00
100.00
1000.00
10000.00
100000.00
day 1 day 3
Fo
ld
 
di
ffe
re
n
ce
 
re
la
tiv
e 
to
 
co
n
tro
l
MMP1
1.00
10.00
100.00
1000.00
10000.00
100000.00
1000000.00
day 1 day 3Fo
ld
 
ch
an
ge
 
re
la
tiv
e 
to
 
co
n
tro
l
MMP3
0.01 100 0.01 100
Dosage of IL-1β (ng/ml)
0.01 100 0.01 100
Dosage of IL-1β (ng/ml)
*
* *
*
*
*
*
* *
* *
*
*
*
*
1.00
10.00
100.00
1000.00
10000.00
100000.00
day 1 day 3
Fo
ld
 
di
ffe
re
n
ce
 
re
la
tiv
e 
to
 
co
n
tro
l
MMP13
0.01 100 0.01 100
Dosage of IL-1β (ng/ml)
*
*
*
*
*
*
 Figure 3.3: IL-1β induced down
Gene expression of tendon ECM
TFs and in TFs treated with 10 ng/ml of IL
significant effect of IL-1β treatment
 
59 
-regulation of tendon ECM- and differentiation
 (COL1, COL3) and differentiation (SCX, TNMD) in 
-1β for 1 or 3 days. * p < 0.05, two
 (N=4). 
 
-related by TFs. 
control 
-way ANOVA, 
60 
 
IL-1β induced secretion of matrix degradation enzymes by TFs: At the protein level, TFs 
cultured alone did not secrete detectable levels of IL-1β, TNFα, or MMP3 (data not shown). 
Treatment with 10 ng/ml IL-1β, however, significantly increased the amount of MMP-3 in the 
cell supernatant in a time-dependent manner (Figure 3.4).  As expected, IL-1β levels also 
significantly increased.  As there were no time-dependent increases in the IL-1β levels, the spike 
in IL-1β can be attributed to the exogenous addition of IL-1β to the media and not to the TFs 
themselves (Figure 3.4).  TNFα remained undetectable even after IL-1β treatment (data not 
shown).    
 
 
Figure 3.4: IL-1β induced MMP3 protein expression by TFs. Expression of MMP3 (left) and IL-
1β (right) from control TFs (white bars) and TFs treated with 10 ng/ml of IL-1β (grey bars) for 1, 
2, and 3 days. UND = undetected.  * p < 0.05, ANOVA, significant effect of IL-1β treatment and 
time.  There was a significant decrease in IL-1β protein between day 1 and 3 for the TF+IL-1β 
group, (N=4). 
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IL-1β reduced TF cell viability: TF cultures exposed to 10 ng/ml of IL-1β exhibited decreased 
numbers of viable cells (Figure 3.5). Whereas 96% and 99% percent of TFs remained viable in 
the control group on days 1 and 3, respectively, only 14% and 22% were viable in the IL-1β-
treated group. 
 
 
Figure 3.5: IL-1β treatment led to decreased TF viability.  TFs were either left untreated (white 
bars in A and inset B1) or treated with 10 ng/ml of IL-1β (grey bars in A and inset B2).  In panel 
B, live cells appear green and dead cells appear red. Scale bar = 1 mm, * p < 0.05, 2-way 
ANOVA, significant effect of IL-1β treatment, (N=3). 
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3.4 Discussion 
 
In the previous chapter, we demonstrated that tendon injuries induce a local inflammatory 
response characterized by high levels of pro-inflammatory cytokines, such as IL-1β, TNFα, and 
COX2, and simultaneous increases in the matrix-degradation factors MMP-1, -3, and -13.  The 
most dramatic change observed in vivo was the greater than 4,000-fold up-regulation of the gene 
encoding for the pro-inflammatory cytokine, IL-1β.  Using an in vitro model of inflammation via 
exogenous delivery of IL-1β, we found that exposure of tendon fibroblasts to IL-1β caused 
significant up-regulation of various genes related to inflammation (i.e., TNFα, IL-1β, COX2) and 
matrix degradation (i.e., MMP 1, 3, 13) in a dose-dependent manner.  To reproducibly induce 
significant up-regulation of genes related to both inflammation and matrix degradation at days 1 
and 3, and therefore replicate the gene expression profile we observed in the in vivo model,       
10 ng/ml of IL-1β was required.  At this established dose, exposure of tendon fibroblasts to IL-
1β led to significant down-regulation of factors related to tendon ECM (COL1, COL3) and 
differentiation (SCX, TNMD).    
 
These results are in agreement with those of other investigators.  In previous in vitro reports, 
exposure of human TFs to pro-inflammatory cytokines (i.e., IL-1β, TNFα, IL-6) led to further 
up-regulation of inflammatory and matrix degradation genes by the TFs163,164,265,266,273–277.  
Specifically, IL-1β induced up-regulation of IL-1β and other inflammatory and catabolic 
mediators, including TNFα, COX2, IL-6, PGE2, and the MMPs 1, 3, and 13123,155,163,164,265–268,273–
279
.  Furthermore, the MMP-mediated degradation of tendon ECM subsequently led to the loss of 
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type 1 collagen164,267.  These studies, however, only investigated a single dosage (i.e., 10 ng/ml) 
and it is unclear how this dosage relates to the in vivo environment after tendon injury. 
 
In the current study, the expression of IL-1β, TNFα, and MMP3 proteins released into the media 
also were analyzed.  As expected, IL-1β was significantly increased in the groups that received 
IL-1β.  However, the levels of IL-1β decreased over time, indicating that the detected IL-1β is 
mainly from the exogenous delivery of the protein and not from synthesis by the TFs themselves.  
The up-regulation of MMP3 observed at the gene expression level was translated into increased 
levels of MMP3 protein, which increased over time.  In contrast, the increase in TNFα at the 
gene expression level was not observed at the protein level.  In fact, at the protein level, TNFα 
was undetectable in all groups.   
 
While relative amounts of IL-1β protein can be assessed between the treated and non-treated 
groups and over time, the absolute values may not be accurate as 10 ng/ml of IL-1β was added to 
the treated groups, yet only 27 pg/ml was detected on average.  In future studies, it would be 
advisable to make a standard curve from the same IL-1β stock as used in the experiment instead 
of using the IL-1β provided in the ELISA kit.  This would allow for a better understanding of 
how the levels of IL-1β observed compare to the amount of IL-1β delivered.  Furthermore, the 
assessment in this study of MMPs was limited.  First, only MMP3 was assessed, as ELISA kits 
were not available for the other MMPs.  The MMP3 enzyme is involved in the degradation of 
various collagen types; however, it is unable to degrade collagen type 1, which makes up more 
than 90% of the collagen component of tendons.  MMP1, the primary metalloproteinase that 
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degrades collagen type 1, would be more relevant.  Second, the activity of the MMP3 enzyme 
was not assessed; to assess the activity of the enzyme, zymography could be performed.  
 
The in vitro model suggests that the IL-1β produced in vivo after tendon injury and repair may, in 
turn, increase expression of genes related to inflammation and matrix degradation, decrease 
expression of genes involved in extracellular matrix production and tendon fibroblast 
differentiation, and decrease cell viability. However, the amount of IL-1β produced in vivo after 
tendon injury is unknown.  Therefore, it is unclear whether the dosages examined in this study 
are biologically relevant.  Another limitation of this model is the use of only one exogenous 
factor to simulate inflammation, whereas the in vivo environment includes a milieu of different 
cytokines at the repair site.  Due to these limitations, in the next chapter, we describe the 
development of a more biologically relevant in vitro model of inflammation using macrophages, 
a cell type found in a variety of different tendon injury and repair models, which secretes high 
levels of pro-inflammatory factors, including IL-1β and TNFα92,93,97,122–124,130,280,281. 
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Chapter 4 - The Effects of Macrophages on Tendon 
Fibroblasts: A Co-culture Model of Inflammation 
 
4.1 Introduction 
 
In the previous chapter, we established an in vitro model of inflammation via exogenous delivery 
of IL-1β. Addition of this cytokine reproduced the high levels of IL-1β seen in vivo after flexor 
tendon injury and repair (see Chapter 2).  Although this model demonstrated that exposure to IL-
1β may be detrimental to tendon healing, promoting increased expression of inflammatory and 
matrix degradation genes and decreased expression of tendon ECM and TF-specific genes, it did 
not recreate the complex in vivo inflammatory environment.   
 
The primary source of IL-1β during the early period of in vivo tendon healing is produced by 
cells of the monocyte/macrophage lineage280–292.  Following tissue damage, monocytes are 
recruited to the site from circulating blood. These cells rapidly differentiate into macrophages in 
response to extracellular molecular signals. Macrophages will adopt distinct activation states that 
can be broadly classified into two subtypes: classically activated (M1) and alternatively activated 
(M2) macrophages. M1 (or type 1) macrophages are activated by a combination of IFNγ and a 
microbial stimulus, such as bacterial lipopolysaccharide96,124,134–151,293–297.  Upon activation, M1 
macrophages secrete IL-1β as well as other pro-inflammatory factors (e.g., TNFα, IL-12, and 
NO) that aid in the removal of debris and pathogens from the wound96,124,134–151,293–297.  M2, or 
type 2, macrophages are activated by interleukin-4 and/or interleukin-13 and play a distinctly 
different role than M1 macrophages96,124,134–151,293–297.  M2 macrophages secrete the anti-
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inflammatory factor IL-10 and are involved in the regeneration of damaged tissues96,124,134–151,293–
297
. 
 
Cells of the monocyte/macrophage lineage were identified in vivo as early as 3 days after tendon 
injury and repair (see Chapter 2).  Moreover, macrophages have been identified in a variety of 
tendinopathies and tendon repair models in both humans and in animals92,93,97,124,126,128,130.  
Therefore, we sought to investigate the effect of macrophages on tendon fibroblasts.  Since IL-1β 
was shown in the previous chapter to induce the expression of inflammation- and matrix 
degradation-related genes and since M1 macrophages are primary sources of IL-1β in vivo, it is 
hypothesized that co-culture of TFs with M1 macrophages will yield similar results to those seen 
with direct IL-1β application.  Specifically, we expect TFs to up-regulate their expression of 
inflammation- and matrix degradation-related genes and down-regulate their expression of 
tendon ECM- and TF-specific genes.  To test this hypothesis, we established an in vitro model of 
inflammation via co-culture of TFs with macrophages of varying phenotypes (M0 (non-
polarized/immature), M1 (classically activated), or M2 (alternatively activated)).  The effect of 
soluble factors produced by macrophages on TFs was determined by monitoring the TF gene 
expression and overall protein expression of factors related to inflammation, matrix production 
and degradation, and TF differentiation.   
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4.2 Methods 
 
Tendon fibroblast cell isolation and culture: TFs were isolated from the tail of male 6 week old 
C57BL/6J mice (Jackson Laboratories, N=5).  The tissue was minced and digested in 0.2% 
Collagenase Type IA in Phosphate Buffered Saline for 1-2 hours.  The digested tissue was 
collected by centrifugation and incubated in alpha-modified eagles medium (Alpha-MEM) with 
10% Fetal Bovine Serum (FBS) and 1% Penicillin/Streptomycin (P/S) (37°C, 5% CO2, 95% 
humidity). Cells were used on passage 2-3.   
 
Macrophage cell isolation and culture:  6 week old male C57BL/6J mice were purchased 
from Jackson Laboratories (N=5).  To generate macrophages, the femurs and tibiae of the mice 
were flushed with RPMI-1640 to obtained total bone marrow.  L929-conditioned medium was 
used to generate bone marrow-derived macrophages over a 6-day culture period.  L929 cells 
secrete macrophage colony-stimulating factor (M-CSF), which is required to differentiate bone 
marrow cells into macrophages.  Thus, to obtain M-CSF, L929 cells were cultured and the 
supernatant (containing M-CSF) was collected and added as a supplement to RPMI Complete 
media.  1x106 L929 cells were plated in a 75-cm2 flask containing 25 mL RPMI Complete 
Media (RPMI media + 10% FBS + 1% P/S) and cultured for 1 week without passage.  The 
supernatant was collected, sterile filtered, stored at -20⁰C, and replaced with fresh RPMI 
Complete media.  The cells were cultured for an additional week without passage and the 
supernatant was again collected, sterile filtered, and pooled with the supernatant from the 
previous week.  The pooled supernatants were stored at -20⁰C until use.  The supernatant was 
used to make the L929-supplemented media (30% L929 Supernatant + 10% FBS + 1% P/S in 
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RPMI media).  The bone marrow cells were cultured in the L929-supplemented media 
(0.5x106/well, 6 well plates) to generate macrophages.  After 1 week of culture, the macrophages 
were then primed to become either M1 or M2 macrophages or left untreated (M0).  To generate 
M1 macrophages, cells were treated with 50 ng/ml IFNγ (R&D systems, Minneapolis, MN) and 
100 ng/ml Escherichia coli LPS (Invivogen, San Diego, CA) in RPMI Complete media for 24 
h.  M2 macrophages were generated by treated the cells with 10 ng/ml IL-4 (R&D systems, 
Minneapolis, MN) in RPMI Complete media for 24 h.  Untreated macrophages (M0) received 
RPMI Complete media only.  All experiments were performed in duplicate.   
 
Macrophage/tendon fibroblast co-culture: To determine the effects of macrophages on TFs, M0, 
M1, or M2 macrophages were co-cultured with TFs using transwell plates.  After 24 h of 
priming, the media was replaced with fresh RPMI complete media and TFs were seeded in the 
inserts of the transwell plates (2.6x104 cells/cm2).  Macrophages and TFs were co-cultured for 
24h before supernatant collection and RNA isolation was performed.  Control groups consisted 
of TFs alone, M0 macrophages alone, M1 macrophages alone, and M2 macrophages alone 
(Figure 4.1). 
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Figure 4.1: Schematic of experimental design. M0, M1, and M2 macrophages were cultured 
alone (A-C) or in co-culture with TFs (D-F).  TFs were also cultured alone as a control (G). 
 
Flow cytometry: Cells were prepared for flow cytometry by staining with anti-F480 antibody 
(eBiosciences clone BM8, San Diego, CA), CD11b (eBiosciences clone M1/70, San Diego, CA), 
CD301 Alexa Fluor® 488 (AbD Serotec, Oxford, UK) and CD206 APC (AbD Serotec, Oxford, 
UK).  Data were acquired on a BD FACS Canto Flow Cytometer (BD Biosciences, San Jose, 
CA) and analyzed with FlowJo software (Treestar, Ashland, OR).  The gating strategy was 
devised to select only live, singlet cells that stained positive for both F480 and CD11b (general 
macrophage markers).  The expression of M2 macrophage-specific markers (CD206 and CD301) 
in the selected macrophage population was then assessed (Figure 4.2).  Data are expressed as 
geometric mean fluorescent intensity ± standard deviation. Statistical differences were assessed 
D
M0
TF
E
M1
TF
F
M2
TF
A
M0
TF
B
M1
TF
C
M2
TF
G
TF
70 
 
using a two-way ANOVA (for the effects of macrophage type and the presence of TFs) followed 
by a Fisher’s post-hoc test.  Significance was set to p < 0.05. 
 
Figure 4.2: Representative figure describing the flow cytometry gating strategy.  (A) Side scatter 
area (SSC-A) and forward scatter area (FSC-A) were used to eliminate any dead cells from the 
cell population examined. (B) Side scatter width (SSC-W) and forward scatter width (FSC-W) 
were used to ensure that only singlets were analyzed. (C) Macrophage cell populations were 
identified by F480 and CD11b staining. (D) Expression of CD206 (a marker specific to M2 
macrophages) was assessed. 
 
Gene expression: Total RNA was isolated (RNEasy Minikit; Qiagen, Valencia, CA) from the 
TFs on day 1.  500 ng RNA was reverse transcribed to cDNA, using the Superscript VILO 
cDNA synthesis kit (Invitrogen Corporation, CA).  qRT-PCR was performed to measure the 
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gene expression levels of pro-inflammatory factors (IL-1β, TNFα, COX2), matrix 
metalloproteinases (MMP1a, 1b, 3, 13), and ECM-related factors (COL1, COL3, BGN, DCN), 
and TF-specific factors (SCX and TNMD). All primers for qRT-PCR were predesigned (Qiagen, 
CA).  The data was analyzed using the delta delta Ct method, in which the results were 
normalized to the housekeeping gene (GAPDH) and then to the control group (i.e., untreated 
TFs).  The delta Ct values were compared using an ANOVA (for the effect of macrophage type), 
followed by a Fisher’s post-hoc test.  Significance was set to p < 0.05.   
 
Protein expression: Cell supernatants were collected on day 1 and samples were stored at -80°C 
until analysis.  The levels of IL-1β, TNFα, NO and Prostaglandin E2 (PGE2) were assessed 
using commercially available kits (IL-1β ELISA, R&D Systems, Minneapolis, MN; TNFα 
ELISA, R&D Systems, Minneapolis, MN; Nitric Oxide Colorimetric Assay, EMD Millipore 
Chemicals, Darmstadt, Germany; Prostaglandin E2 Parameter Assay Kit, R&D Systems, 
Minneapolis, MN).  Data was normalized to control; specifically, protein levels from the TFs 
cultured alone were subtracted from their paired groups (i.e., groups containing TFs from the 
same animal).  Group means were compared using a 2-way ANOVA (for effect of macrophage 
type and presence of TFs), followed by a Fisher’s post-hoc test. Significance was set to p < 0.05. 
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4.3 Results 
 
Verification of macrophage induction:  Verification of the different macrophage phenotypes was 
obtained by assessing surface marker and protein expression.  Flow cytometry revealed that all 
macrophages expressed high levels of CD11b and F480, and that macrophages treated with M2-
priming media also expressed high levels of CD206 and CD301 (Figure 4.3).    Geometric mean 
fluorescent intensities (MFI) of CD206 and CD301 were 2.6- and 1.5-fold greater, respectively, 
in the M2 macrophages compared to the M0 macrophages.  Similarly, the MFIs of CD206 and 
CD301 were 5.1- and 1.5-fold greater, respectively, in the M2 macrophages compared to the M1 
macrophages.  The presence of TFs did not have a significant effect on surface marker 
expression.  To further evaluate macrophage phenotypes, protein expression was examined.  M1 
macrophages consistently secreted significantly greater amounts of inflammation-related proteins 
(Figure 4.4).  For example, M1 macrophages secreted approximately 3-, 8.8-, 17-, and 5.5- fold 
more IL-1β, TNFα, PGE2, and NO, respectively, than did M0 and M2 macrophages.  Secretion 
of these proteins by M0 and M2 macrophages was not statistically different from each other 
(Figure 4.4). 
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Figure 4.3: Verification of macrophage phenotype using FACS analysis.  Expression of surface 
markers for mono-culture macrophages 1 day after addition of M1-priming media, M2-priming 
media, or untreated (M0).  Geometric mean fluorescent intensity of the M2 markers CD206 and 
CD301 were significantly increased in the M2 group compared to the M0 and M1 groups.           
* p < 0.05, ANOVA, significant effect of macrophage type for all protein assays, bars signify 
Fisher’s post-hoc comparisons (N=5). 
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Figure 4.4: M1 macrophages express high levels of pro-inflammatory factors.  Protein 
expression of mono-culture macrophages 1 day after M1-priming media, M2-priming media, or 
untreated (M0). UND = undetectable.  * p < 0.05, ANOVA, significant effect of macrophage 
type for all protein assays, bars signify Fisher’s post-hoc comparisons (N=5). 
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M1 macrophages induce up-regulation of pro-inflammatory and matrix degradation factors by 
TFs:  The effect of macrophages on TFs was determined by co-culturing TFs with the various 
macrophage types.  Gene expression analysis of the TFs revealed significant up-regulation of 
factors related to inflammation in all macrophage co-culture cases compared to TFs cultured 
alone (Figure 4.5).  M1 macrophages induced a significant up-regulation of TNFα, IL-1β, and 
COX2 in co-cultured TFs compared to control (i.e., TFs cultured alone).  Co-culture with M0 
and M2 macrophages also led to a significant up-regulation of IL-1β in the TFs, but to a much 
lesser extent than M1 macrophages.  Co-culture with M0 and M2 macrophages led to 2.1- and 
8.6-fold increases in IL-1β, respectively, whereas co-culture with M1 macrophages led to a 
2800-fold increase in IL-1β.  Co-culture with M1 macrophages also led to significant up-
regulation of matrix-metalloproteinases (Figure 4.6).  M1 macrophages caused significant 
increases in MMP-1a, -1b, -3, and -13 in TFs.  M0 macrophages did not have any significant 
effect on the expression of MMPs in the TFs, while M2 macrophages caused a significant up-
regulation of MMP-1a and -1b.  However, as with IL-1β, the up-regulation caused by M2 
macrophages compared to control was significantly less than that caused by M1 macrophages.  
M1 macrophages led to 150- and 100-fold increases in MMP-1a and -1b, respectively, while M2 
macrophages only led to 5.5- and 8.7-fold increases. Co-culture with M0, M1, or M2 
macrophages led to a significant decrease in ECM production by TFs, as evidenced by down-
regulation of collagens (COL1, COL3) and biglycan (BGN) and up-regulation of decorin (DCN).  
The main role of DCN is to regulate fibril diameter, so COL1 and DCN typically trend in 
opposite directions298.  As with inflammation-related genes, M1 macrophages had the largest 
effect (Figure 4.7).  M1 macrophages caused a 3.3- and 2.9-fold decrease in COL1 and COL3 by 
 TFs, respectively.  In addition, M1 macrophag
fold).   
Lastly, macrophages had little effect on the 
The only significant effect was a 3.2
macrophages. 
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Figure 4.5:  M1 macrophages induce up-regulation of inflammation-related genes by TFs.  Fold 
changes in TF gene expression of inflammation-related factors relative to control after 1 day of 
co-culture with M0, M1, or M2 macrophages.  * p < 0.05, † p < 0.10, ANOVA, significant effect 
of macrophage type for all genes, bars signify Fisher’s post-hoc comparisons, * by x-axis 
signifies a significant difference compared to control TFs (N=5). 
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Figure 4.6:  M1 macrophages induce up-regulation of matrix degradation-related genes by TFs.  
Fold changes in TF gene expression of matrix degradation-related factors relative to control after 
1 day of co-culture with M0, M1, or M2 macrophages.  * p < 0.05, ANOVA, significant effect of 
macrophage type for all genes, bars signify Fisher’s post-hoc comparisons, * by the x-axis labels 
signifies a significant difference compared to control TFs (N=5). 
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Figure 4.7:  M1 macrophages induce down-regulation of tendon ECM as evidenced by 
decreased expression of COL1, COL3, and BGN and increased expression of DCN.  Fold 
changes in TF gene expression of extracellular matrix-related factors relative to control after 1 
day of co-culture with M0, M1, or M2 macrophages.  * p < 0.05, ANOVA, significant effect of 
macrophage type for all genes, bars signify Fisher’s post-hoc comparisons, * by x-axis signifies a 
significant difference compared to control TFs (N=5). 
 
 
Figure 4.8:  M1 macrophages induce down-regulation of the TF-specific gene, TNMD, by TFs. 
Fold changes in TF gene expression of TF-specific factors relative to control after 1 day of co-
culture with M0, M1, or M2 macrophages.  * p < 0.05, ANOVA, significant effect of 
macrophage type for all genes, bars signify Fisher’s post-hoc comparisons, * by x-axis signifies a 
significant difference compared to control TFs, (N=5). 
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Furthermore, co-cultures of M1 macrophages with TFs led to higher levels of IL-1β and PGE2 
protein secretion compared to M1 macrophages alone (2.9- and 1.8-fold, respectively).  NO was 
down-regulated 1.6-fold in the M1 group when co-cultured with TFs, but this difference was not 
statistically significant (Figure 4.9). 
 
 
 
Figure 4.9:  M1 macrophages induce the secretion of inflammatory factors by TFs.  Protein 
expression of IL-1β, TNFα, PGE2, and NO after 1 day of co-culture with M0, M1, or M2 
macrophages in the presence and absence of TFs.  Data are normalized to TF controls (i.e., levels 
measured for TF controls were subtracted from paired groups).  * p < 0.05, † p < 0.10, 2-way 
ANOVA, significant effect of macrophage type for all proteins, significant effect of time for IL-
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1β and PGE2, bars signify Fisher’s post-hoc comparisons, (N=5).  Note: Data for the groups 
lacking TFs were previously presented in Figure 4.4, but are presented again here to highlight the 
effect of TFs. 
 
4.4 Discussion 
 
The in vitro co-culture model of inflammation described here improved on the simple IL-1β-
induced model presented in the previous chapter. As cells of the monocyte/macrophage lineage 
have been identified in various tendinopathy and tendon healing models 92,93,97,124,126,128,130, we 
sought to create a biologically relevant model of in vitro inflammation using macrophage-TF co-
culture. Three macrophage phenotypes were generated and their effects on TFs were 
investigated.  Gene expression analyses revealed that macrophages promoted up-regulation of 
the pro-inflammatory factors (such as IL-1β), up-regulation of matrix degradation factors (such 
as MMP1), and down-regulation of tendon ECM factors (such as collagen type I).  Among the 
three macrophage phenotypes examined, co-culture with M1 macrophages had the most dramatic 
effect on the expression by TFs of inflammatory, matrix degradation, and tendon ECM genes.   
At the protein level, increases in IL-1β and PGE2 were observed in the medium of the M1 co-
culture group compared to M1 macrophages in mono-culture.  This suggests that exposure of 
TFs to M1 macrophages leads to up-regulation of IL-1β and PGE2 synthesis and secretion by 
TFs.  However, it is unclear whether the increases in IL-1β and PGE2 in the M1 co-culture group 
are due to increased synthesis and secretion of those factors by the TFs or whether the presence 
of the TFs caused increased synthesis and secretion of those factors by the M1 macrophages.  
Based on the fact that the expression levels for the corresponding genes (IL-1β and COX2) were 
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similarly up-regulated by TFs, it is likely that those genes were translated into proteins and, thus, 
the source of the additional IL-1β and PGE2 proteins is at least in part the TFs.   No assay for 
MMP protein activity (i.e., zymography) was performed, however.  Thus, it remains unknown 
whether the up-regulation of matrix metalloproteinase genes translates into increased MMP 
activity. 
 
Taken together, these data suggest that the presence of IL-1β and other pro-inflammatory 
cytokines may be deleterious to tendon healing in vivo.  Specifically, M1 macrophages, which 
produce these inflammatory factors, may induce further up-regulation of inflammatory and 
matrix degradation factors by the local TFs.  In vivo, up-regulation of pro-inflammatory genes 
and matrix metalloproteinase factors may result in excessive matrix degradation and collateral 
damage to healthy tendon tissue adjacent to the injury site, and, thus, may be detrimental to 
tendon healing. 
 
While M0 and M2 macrophages also appear to cause some up-regulation of inflammatory and 
matrix-degradation genes, the effect is much less than that of M1 macrophages.  Moreover, 
studies by other investigators have shown that macrophage depletion or modulation may be 
beneficial in a tendon-to-bone healing model.  Hayes et al. report a significant improvement in 
collagen fiber organization and biomechanical properties in macrophage-depleted samples (via 
clodronate treatment)92.  Dagher et al. found that immobilization of the knee after ACL 
reconstruction led to improved mechanical properties via a shift in macrophage phenotype.  
Whereas the macrophages found in mobilized animals were of the pro-inflammatory M1 
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phenotype, immobilization led to a decrease in M1 macrophages and an increase in anti-
inflammatory, pro-regenerative M2 macrophages.  In addition, improved tendon-to-bone 
integration was achieved, as evidenced by reduced scar tissue formation, increased collagen fiber 
organization, and enhanced biomechanical properties93. 
 
Taken together, these results suggest that classically activated macrophages (M1 macrophages) 
may, in fact, impede tendon healing and that modulation of the macrophage population toward a 
M2 phenotype may be advantageous.  Thus, treatments that aim to reduce the number of M1 
macrophages at the repair site may prove beneficial for tendon healing92,93,97.    
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Chapter 5 - Mesenchymal Stem Cell-Mediated Modulation 
of In Vitro Inflammation. 
 
5.1 Introduction 
 
The early inflammatory response after transection and repair of intrasynovial flexor tendons is 
characterized by an early influx of PMNs followed by infiltration of cells from the 
monocyte/macrophage lineage (see Chapter 2).  Gene expression analysis from in vivo repairs 
revealed significant up-regulation of pro-inflammatory genes, presumably as a result of this 
immune cell population.  In vitro investigations described in Chapters 3 and 4 indicated that IL-
1β and other pro-inflammatory cytokines secreted by M1 macrophages may induce further up-
regulation of inflammatory factors by native TFs and may deter new ECM formation.   
 
Studies by other investigators suggest that M1 macrophages may be detrimental to tendon 
healing due to their secretion of pro-inflammatory cytokines and that modulation of this 
inflammatory response may be advantageous to healing92–94. While a certain level of 
inflammation is necessary for healing to occur90 (e.g., to provide chemotactic factors for the 
recruitment of fibroblasts to the repair site), high levels of pro-inflammatory cytokines may be 
detrimental to tendon healing92–94. Completely suppressing inflammation, however, is also likely 
to be detrimental to healing. Traditional non-steroidal anti-inflammatory drugs (NSAIDS) and 
selective COX2 inhibitors (Coxibs) inhibit cyclooxygenase (COX) activity, effectively reducing 
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pro-inflammatory prostaglandin production and hyperalgesia299–303.  While NSAIDS and Coxibs 
are successful in reducing pain and swelling, numerous studies have cautioned against their use 
following tendon-to-bone repair, citing impaired healing responses304–311.  The effects of 
NSAIDS and Coxibs on tendon mid-substance healing are not as well documented.  Due to the 
paucicellular nature of flexor tendons, accrual of repair site strength is delayed until cells migrate 
to the repair site, proliferate, and synthesize extracellular matrix.  In vitro studies have reported 
inhibition of tendon fibroblast proliferation and matrix glycosaminoglycan production when 
treated with NSAIDS312,313.   Thus, broadly shutting down inflammation with the use of agents 
such as NSAIDS may impair flexor tendon healing.  A balance must therefore be achieved 
between too much inflammation, which would incite a catabolic tendon fibroblast response, and 
too little inflammation, which would impair fibroblast recruitment, proliferation, and matrix 
synthesis.  
 
Fine control of the inflammatory environment may be achieved using MSCs. Previous reports 
suggest that MSCs possess anti-inflammatory and immunosuppressive 
capabilities170,173,203,208,211–241,243–247,314.  In vitro, MSCs have been shown to significantly 
suppress the proliferation of immune cells, such as T and B lymphocytes173,203,213,215–
219,222,225,226,228,229,231,233,234,236,237,239,243–247,314
, resulting in reduced secretion of inflammatory 
factors (e.g., IFNγ, TNFα) and interleukins 2 and 5.  Recent evidence suggests that MSCs can 
also modulate the innate immune response by promoting differentiation into anti-inflammatory 
macrophages (i.e., M2 macrophages)136,140,141,244,254–257.   
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MSCs can be derived from a number of tissue sources. Historically, MSCs have been derived 
from bone marrow aspirates.  However, recent studies have shown that MSCs derived from 
adipose tissue exhibit very similar characteristics.  Like bone marrow-derived MSCs (BMSCs), 
adipose-derived MSCs (ASCs) have been shown to differentiate along multiple cell-lineages, 
while also demonstrating immunomodulatory capabilities comparable to those of 
BMSCs169,216,223,229,231.  Given that adipose tissue is generally more abundant and accessible, thus 
increasing the ease of isolation and the overall yield, adipose tissue is an excellent and clinically 
relevant source of adult stem cells169. 
 
The purpose of the current study was to investigate the ability of ASCs to modulate 
inflammation and its effects on tendon fibroblasts either by acting directly on the inflammatory 
cytokine, IL-1β, or indirectly by eliciting phenotypic changes in macrophage populations (Figure 
5.1).   
 
 
Figure 5.1: Schematic of hypotheses.  ASCs co-cultured with TFs in an IL-1β-induced 
inflammatory environment may protect TFs from the effects of IL-1β through the uptake of IL-
ASC
TFIL-1β
?
?
M1
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1β or through the secretion of anti-inflammatory factors to counteract the effects of IL-1β 
(central blocking line).  ASCs co-cultured with inflammation-inducing macrophages (M1) may 
prompt a phenotypic switch toward an anti-inflammatory, M2 macrophage phenotype, resulting 
in decreased levels of pro-inflammatory factors, increased levels of anti-inflammatory factors, 
and reduced inflammatory effects on TFs (leftmost blocking line). 
 
 
ASCs were incorporated into the two in vitro inflammatory models that were established in 
previous chapters (see Chapters 3, 4).  We hypothesized that ASCs co-cultured with TFs in an 
inflammatory environment induced by IL-1β, would either take up IL-1β, effectively reducing 
the amount of IL-1β in the media, or secrete anti-inflammatory factors that would counteract the 
effects of IL-1β.  We hypothesized that ASCs in co-culture with inflammation-inducing 
macrophages would promote a phenotypic switch towards an anti-inflammatory, M2 
macrophage phenotype, resulting in decreased levels of pro-inflammatory factors (e.g., IL-1β, 
TNFα, NO), increased levels of anti-inflammatory factors (e.g. IL-10), and reduced 
inflammatory effects on TFs (as evidenced by the suppression of inflammatory and matrix 
degradation-related genes by TFs). 
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5.2 Methods 
 
5.2.1 IL-1β-Induced Inflammation Model 
 
Cell Isolation and Culture: ASCs and TFs were isolated from adult Sprague Dawley rats (N=4).  
ASCs were isolated from abdominal adipose tissue and TFs were isolated from tail tendons.  The 
tissue was digested and the cells were cultured as previously described (see Chapter 3).  Rat TFs 
and ASCs were used at passage 4.   
 
Co-culture Model:  To determine whether ASCs can modulate the effects of exogenous IL-1β 
delivery on TFs, ASCs were co-cultured with TFs using transwell plates. Based on studies 
indicating that pre-treatment of the MSCs with IFNγ is required for 
immunosuppression209,217,237,239,248,315, ASCs were either left untreated (naïve) or pre-treated for 
48 hr with 50 ng/ml IFNγ (R&D Systems, Minneapolis, MN) (activated).  ASCs and TFs were 
co-cultured at a 1:1 cell density ratio (2.6x104 cells/cm2) using 6 well transwell plates (Costar, 
0.4 µm pore size, Fisher Scientific, Pittsburgh, PA).  In general, TFs were plated in the wells and 
ASCs were plated in the inserts.  The cells were allowed 24 hr to attach before treatment with 10 
ng/ml IL-1β (R&D Systems, Minneapolis, MN) on day 0.  Experiments were run using 1% FBS 
as described previously in Chapter 3.  The experimental and control groups examined were:  
A) TFs cultured alone (TT) 
B) TFs treated with IL-1β (TT+) 
C) TFs co-cultured with naïve ASCs (TA)  
D) TFs co-cultured with naïve ASCs and treated with IL-1β (TA+) 
E) TFs co-cultured with activated ASCs (TAa) 
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F) TFs co-cultured with activated ASCs and treated with IL-1β (TAa+) 
Additional TFs were added to the inserts of groups 1 and 2 to maintain equal cell numbers in all 
groups (Figure 5.2). 
   
Figure 5.2: Schematic of experimental design for the IL-1β-induced inflammation model. TFs 
were cultured alone or co-cultured with either naïve ASCs (nASCs) or activated ASCs (aASCs) 
in the presence of IL-1β (A-C).  Controls consisted of the same experimental groups, but in the 
absence of IL-1β (D-F).  Note: TFs were cultured in the inserts of the transwell plates for groups 
A and D to keep the total number of cells uniform between all groups. 
 
Gene Expression: Total RNA was isolated from the tendon fibroblasts on days 1, 2, and 3 and 
was reverse transcribed to cDNA, as described in Chapter 3.  Quantitative real-time reverse 
A
TFs
TFs
B
TFs
TFs
D
TFs
nASCs
F
TFs
aASCs
C
TFs
nASCs
E
TFs
aASCs
Media
Media
Media Media
Media
Media
+ IL-1β
+ IL-1β
+ IL-1β
90 
 
transcription-polymerase chain reaction (qRT-PCR) was performed to measure the gene 
expression levels of pro-inflammatory factors (IL-1β, TNFα, COX2), MMPs (-1, -3, -13), ECM-
related factors (COL1, COL3), and differentiation factors (SCX, TNMD).  The data were 
analyzed using the delta Ct method, in which the results were normalized to the housekeeping 
gene GAPDH.  For statistical analysis, the delta Ct values were compared using a multi-factor 
ANOVA for the effects of IL-1β, ASCs, and time, followed by a Fisher’s post-hoc test.  
Significance was set to p < 0.05. 
 
Protein Expression: Cell supernatants were collected on days 1, 2, and 3. Samples were stored at 
-80°C until analysis.  The levels of IL-1β and TNFα were assessed using commercially available 
kits (ELISAs, R&D Systems, Minneapolis, MN).  Data were normalized to control; specifically, 
protein levels from the TFs cultured alone were subtracted from their paired groups (i.e., groups 
containing TFs from the same animal).  For statistical analysis, the data were compared using a 
multi-factor ANOVA (for the effects of IL-1β, ASCs, and time) followed by a Fisher’s post-hoc 
test.  Significance was set to p < 0.05. 
 
5.2.2 Macrophage-Induced Inflammation Model 
Cell Isolation and Culture: ASCs, tendon fibroblasts, and monocytes were isolated from 6 week 
old C57BL/6J mice (N=9).  ASCs were isolated from adipose tissue and TFs were isolated from 
tail tendons.  The tissue was digested and the cells were cultured as described in Chapter 4.  TFs 
and ASCs were used on passage 2-3 and 2-4, respectively.  Note that the ASCs were not 
activated as in the IL-1β-induced model.  Macrophages were generated from bone marrow 
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monocytes using L929-supplemented media.  Macrophages were primed to become either M1 or 
M2 macrophages, as described in Chapter 4, or left untreated (M0).   
 
Tri-culture Model:  To determine whether ASCs can modulate the effects of M0 or M1 
macrophages on TFs, tri-cultures of ASCs, TFs, and either M0 or M1 macrophages were 
generated using transwell plates.  After 24 h of macrophage priming, the priming media was 
replaced with fresh RPMI Complete media.  ASCs were seeded directly on top of the pre-
existing macrophages at a density of 1.2x104 cells/cm2 and TFs were seeded in the inserts of the 
transwell plates at a density of 2.6x104 cells/cm2.  Macrophages, ASCs, and TFs were tri-
cultured for 1 day before supernatant collection and RNA isolation was performed.  To allow 
more time for the ASCs to produce a phenotypic switch, a separate group was analyzed, in which 
ASCs and macrophages were co-culture for 4 days before TFs were added to the culture for the 
remaining day.  Additional control groups consisted of tendon fibroblasts alone, M0 
macrophages alone, M1 macrophages alone, and M2 macrophages alone (Figure 5.3).  
Experimental and control groups examined were: 
A) M0s in mono-culture 
B) M1s in mono-culture 
C) M2s in mono-culture 
D) M0s in co-culture with TFs 
E) M1s in co-culture with TFs 
F) M2s in co-culture with TFs 
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G) M0s in tri-culture with TFs and ASCs 
H) M1s in tri-culture with TFs and ASCs 
I) TFs cultured alone 
 
Figure 5.3: Schematic of experimental design for the macrophage-induced inflammation model. 
M0, M1, and M2 macrophages were cultured alone (A-C) to verify macrophage phenotype.  TFs 
were co-cultured with M0, M1, or M2 macrophages (D-F) or tri-cultured with naïve ASCs and 
either M0 or M1 macrophages (G-H).  TFs cultured alone served as controls (I).  
 
Flow Cytometry: To determine whether co-culture with ASCs leads to a phenotypic switch in the 
macrophage population, the macrophage/ASC cell populations were collected and cell surface 
markers for macrophages (CD11b, F4/80) and specifically for M2 macrophages (CD206, 
CD301) were analyzed via FACS analysis, as previously described (see Chapter 4).  
Macrophages alone were analyzed as controls.   Data were expressed as geometric mean 
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fluorescent intensity ± standard deviation.  Statistical differences were assessed using a two-way 
ANOVA (for the effect of macrophage type and TF presence) followed by a Fisher’s post-hoc 
test.  Significance was set to p < 0.05. 
  
Gene Expression: Total RNA was isolated from the tendon fibroblasts 1 day after TFs were 
seeded and was reverse transcribed to cDNA, as described in Chapter 4.  qRT-PCR was 
performed to measure the gene expression levels of pro-inflammatory factors (IL-1β, TNFα, 
COX2), MMPs (-1a, -1b, -3, -13), ECM-related factors (COL1, COL3, BGN, DCN), and 
differentiation factors (SCX, TNMD).  The data were analyzed using the delta delta Ct method, 
in which the results were normalized to the housekeeping gene GAPDH and then to the paired 
control (i.e., TF control).  For statistical analysis, the delta Ct values were compared using a 
multi-factor ANOVA (for the effects of macrophage type, ASCs, and TFs) followed by a 
Fisher’s post-hoc test and a paired t-test.  Significance was set to p < 0.05. 
 
Protein Expression: Cell supernatants were collected 1 day after TFs were seeded.  Samples 
were stored at -80°C until analysis.  The levels of IL-1β, TNFα, IL-10, Nitric Oxide and PGE2 
levels using commercially available kits (IL-1β ELISA, R&D Systems, Minneapolis, MN; TNFα 
ELISA, R&D Systems, Minneapolis, MN; IL-10 ELISA, R&D Systems, Minneapolis, MN; 
Nitric Oxide Colorimetric Assay, EMD Millipore Chemicals, Darmstadt, Germany; 
Prostaglandin E2 Parameter Assay Kit, R&D Systems, Minneapolis, MN).  Data were 
normalized to control; specifically, protein levels from the TFs cultured alone were subtracted 
from their paired groups (i.e., groups containing TFs from the same animal).  For statistical 
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analysis, the data were compared using a multi-factor ANOVA (for the effects of macrophage 
type, ASCs, and TFs) followed by a Fisher’s post-hoc test and a paired t-test.  Significance was 
set to p < 0.05. 
 
5.3 Results 
 
5.3.1 IL-1β-Induced Inflammation Model 
 
ASCs Mildly Suppress IL-1β-induced Effects on TFs:  As described in Chapter 3, significant 
increases in the expression of genes related to inflammation (TNFα, IL-1β, COX2) and matrix 
degradation (MMP1, 3, 13) were observed 1 day after TFs were exposed to IL-1β (Figure 5.4).  
Conversely, tendon-related genes (i.e., COL1, COL3, SCX) were down-regulated 1 day after 
IL1-β exposure when compared to control (i.e., untreated TFs) (Figure 5.4).  However, only the 
decrease in COL1 was statistically significant.  
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Figure 5.4: ASCs failed to suppress the IL-1β-induced effects on TF gene expression.   TFs co-
cultured with naïve ASCs (TA), activated ASCs (TAa), or cultured alone (TT) in the presence 
(+) and absence of IL-1β for 1 day.  Data was normalized to a housekeeping gene (GAPDH) and 
is presented as group means ± SD.  * p < 0.05, † p < 0.10, multi-factor ANOVA with a Fisher’s 
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post-hoc test.  Significant effects of IL-1β are indicated by bars over the groups with and without 
IL-1β.  No significant effect of ASCs was observed. 
 
Co-culture with naïve ASCs did not have a significant effect at the gene expression level or at 
the protein level (Figure 5.5).  Co-culture with activated ASCs led to a 3.1-, 1.8-, and 1.4-fold 
down-regulation of TNFα, IL-1β, and MMP1 mRNA, respectively, on day 1; however, these 
reductions failed to reach statistical significance (Figure 5.5).  The effects of IL1β were generally 
diminished with time (i.e., 2 and 3 days after IL-1β exposure) (Figure 5.6). 
 
 
Figure 5.5: ASCs failed to reduce IL-1β levels.  The effect of ASCs on IL-1β-induced 
inflammation is shown in terms of expression of matrix degradation-related genes 1 day after IL-
1β treatment. Cumulative IL-1β produced by TFs co-cultured with naïve ASCs (TA), activated 
ASCs (TAa), or cultured alone (TT) in the presence (+) and absence of IL-1β on days 1, 2, and 3.  
Data are presented as group means ± SD.  * p < 0.05 compared to paired groups on day 1.     
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Multi-factor ANOVA with a Fisher’s post-hoc test.  There was a significant effect of time.  
There was no effect of ASC treatment (N=4).   
 
Figure 5.6: Effect of IL-1β on TFs is greatest 1 day after treatment.  Gene expression of TFs 
treated with 10 ng/ml IL-1β normalized to control (untreated TFs).  Data are presented as group 
means ± SD.  * p < 0.05, † p < 0.10, 2-way ANOVA with a Fisher’s post-hoc test.  Significant 
effects of IL-1β are indicated by stars on the x-axis.  Significant effect of time was observed for 
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IL-1β, MMP13, COL3, and SCX.  Results of the post-hoc test are indicated by bars across the 
timepoints that differ significantly. 
 
5.3.2 Macrophage-Induced Inflammation Model 
 
ASCs Suppress the Negative Effects of M1 Macrophages on TFs:  ASCs had a significant effect 
on M1 macrophages.  As described in Chapter 4, M1 macrophages induced significant up-
regulation of pro-inflammatory and matrix degradation-related genes by TFs, while concurrently 
down-regulating TF expression of ECM-related and TF-specific genes.  ASC co-culture with M1 
macrophages significantly altered the expression by TFs of many of those factors towards 
baseline values (Figure 5.7).  TNFα gene expression by TFs was down-regulated 2.4- and 2.1-
fold after 1 and 5 day of ASC co-culture, respectively (Figures 5.7, 5.8).  While changes failed to 
reach statistical significance at the gene expression level for the 5 day timepoint, significant 
reductions were observed at the protein level (Figure 5.10).  IL-1β gene and protein expression 
were not affected after a single day of co-culture (Figures 5.7, 5.9).  5 days of ASC co-culture 
with M1 macrophages, however, led to a 7.1-fold down-regulation of IL-1β by TFs (Figure 5.8).  
While this change was not statistically significant, a corresponding reduction in IL-1β was seen 
at the protein level (Figure 5.10).  COX2 was also unaffected after only 1 day of co-culture 
(Figures 5.7, 5.9), but a significant down-regulation (11.3-fold) was observed after 5 days of co-
culture.  No significant effects were seen at the protein level, however (Figure 5.10).   
 
 Figure 5.7:  ASCs suppress the effects of 
culture.  TF gene expression after 1 day of co
culture with macrophages and ASCs (M0+ASC, M1+ASC).  Data 
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untreated TFs) and presented as group means ± SD.  * p < 0.05, multi-factor ANOVA with 
Fisher’s post-hoc test.  Significant effects of ASCs were observed for TNFα, MMP1a, MMP3, 
COL1, SCX, TNMD, bars signify Fisher’s post-hoc comparisons, * by the x-axis labels signifies 
a significant difference compared to control, (N=5).  Note: Control group data (M0, M1, M2) are 
the same data as presented in Figures 4.6-4.8.   
 
MMP gene expression was also suppressed by ASC co-culture with M1 macrophages.  MMP1a 
expression by TFs was down-regulated 2.3- and 11.3-fold after 1 and 5 days of ASC co-culture, 
respectively (Figures 5.7, 5.8).  MMP1b was unaffected by a single day of ASC co-culture, but 
after 5 days of ASC co-culture, a 2.1-fold decrease in MMP1b gene expression by TFs was 
observed.  Similarly, a small, but statistically significant reduction in MMP3 was observed after 
1 day of ASC co-culture (Figure 5.7), and increased to a 7-fold down-regulation after 5 days of 
ASC co-culture (Figure 5.8).  No effects on MMP13 expression were observed at either 
timepoint (Figures 5.7, 5.8).  ECM-related gene expression (COL1 and COL3) by TFs was 
unaffected after 1 day of ASC co-culture, but was up-regulated 1.8-fold towards baseline after 5 
days of co-culture.  However, this change failed to reach statistical significance (Figure 5.8).  No 
significant effects on tendon fibroblast-specific genes were observed at either timepoint (Figures 
5.7, 5.8). 
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type for all genes, significant effect of ASCs for IL-1β and PGE2, bars signify Fisher’s post-hoc 
comparisons, * by the x-axis labels signifies a significant difference compared to control TFs.  
UND = Undetected, (N=5).  Note: Control group data (M0, M1, M2) is the same data as 
presented in Figure 4.9.   
 
 
Figure 5.10:  ASCs suppress the effects of M1 macrophages on the secretion of pro-
inflammatory factors after 5 days of co-culture.  Protein expression of inflammatory factors after 
1 day of co-culture with TFs and macrophages (M0, M1, M2) or 5 days of tri-culture with TFs, 
macrophages and ASCs (M0+ASC, M1+ASC).  Data were normalized to control (i.e., protein 
levels from the TFs cultured alone were subtracted from their paired groups) and presented as 
group means ± SD.  * p < 0.05, multi-factor ANOVA with Fisher’s post-hoc test.  Significant 
effect of macrophage type for both factors, significant effect of ASCs for both factors, bars 
signify Fisher’s post-hoc comparisons, * by the x-axis labels signifies a significant difference 
compared to control TFs.  UND = Undetected, (N=4). 
 
ASCs Demonstrate Limited Ability to Suppress the Effects of M0 Macrophages on TFs:  As 
described in Chapter 4, M0 macrophages induced up-regulation of various inflammation- and 
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matrix degradation-related genes (TNFα, IL-1β, MMP1b, MMP13) and down-regulation of 
tendon ECM-related genes (COL1, COL3) by TFs, but not to the extent of M1 macrophage 
induction (Figure 5.7).  ASC co-culture with M0 macrophages for 1 or 5 days did not 
significantly affect the expression of inflammation-related genes by TFs (Figures 5.7, 5.8).  
Similarly, the secretion of pro-inflammatory factors by TFs was also unaffected (Figures 5.9, 
5.10).  ASC co-culture with M0 macrophages for 1 day significantly down-regulated the 
expression of certain metalloproteinase genes (i.e., MMP1a and MMP3, 2.1-fold each) by TFs 
(Figure 5.7), but no effect was observed after 5 days of co-culture (Figure 5.8).  However, we 
note that MMP1a and MMP3 were not among the genes that were significantly up-regulated by 
TF exposure to M0 macrophages (see Chapter 4). When examining ECM- and tendon fibroblast-
specific factors, ASC co-culture with M0 macrophages for 1 day led to significant up-regulation 
of COL1 and down-regulation of SCX and TNMD (Figure 5.7), but no effect was observed after 
5 days of co-culture (Figure 5.8).  
 
ASCs Shift Macrophages Toward an M2 Phenotype:  To examine a potential mechanism by 
which ASCs co-culture suppressed the negative effects of M0 and M1 macrophages on TFs, the 
phenotype of the co-cultured macrophages was determined using flow cytometry.  CD11b and 
F480 are expressed by all macrophages. In contrast, CD206 and CD301 are cell surface markers 
specific to M2 macrophages. ASCs co-cultured with M0 macrophages for a single day led to a 2-
fold increase in CD301 expression, surpassing the levels of M2 macrophage controls; however, 
no shift in CD206 expression was observed (Figure 5.11).  The addition of TFs to the co-culture 
systems did not alter these trends (Figure 5.11).  No apparent phenotypic changes were evident 
with ASC co-culture of M1 macrophages (Figure 5.11) after a single day.  Increasing the ASC 
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co-culture period to 5 days, however, led to significant phenotypic changes in both M0 and M1 
macrophages.  M0 macrophages co-cultured with ASCs for 5 days expressed significantly 
greater levels of both CD206 and CD301 compared to M0 macrophage controls (1.3- and 4.1-
fold, respectively).  Similarly, M1 macrophages co-cultured with ASCs for 5 days led to a 
significant 2-fold increase in the expression of CD206 compared to M1 macrophage controls 
(Figure 5.11).   
 
 
Figure 5.11:  ASC co-culture shifts M0 macrophages toward a M2 phenotype.  Mean fluorescent 
intensity of M2 macrophage-specific surface markers, CD206 and CD301, after 1 or 5 days of 
co-culture.  Macrophages (M0, M1, M2 groups) were either co-cultured with TFs for 1 day or 
tri-cultured with TFs and ASCs for 1 or 5 days (TFs were only added for the last 24 h).  Data are 
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presented as group means ± SD.  * p < 0.05, † p < 0.10, 2-way ANOVA with Fisher’s post-hoc 
test.  Significant effects of macrophage type for CD206 and CD301, significant effect of ASCs 
for CD301 on day 1 and day 5, significant effect of ASCs for CD206 on day 5.  Bars signify 
Fisher’s post-hoc comparisons, */† by the x-axis labels signifies a significant difference 
compared to control TFs. 
 
5.4 Discussion 
 
In the previous chapters, we characterized the early inflammatory response in vivo after flexor 
tendon injury and repair and established two in vitro models to mimic the in vivo environment.  
We found that IL-1β and other inflammatory cytokines secreted by macrophages induce up-
regulation of IL-1β and other pro-inflammatory factors by TFs at both the gene and protein level.  
Exposure of TFs to these inflammatory environments also led to up-regulation of factors related 
to matrix remodeling and down-regulation of factors related to tendon extra cellular matrix by 
the TFs.  Based on studies by other investigators that demonstrate MSC-mediated 
immunosuppression170,173,202–247, we sought to investigate the ability of ASCs to modulate 
inflammation and its effects on tendon fibroblasts either by acting directly on the inflammatory 
cytokine IL-1β, or indirectly by influencing macrophage activity.   
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5.4.1 IL-1β-Induced Inflammation Model 
 
To determine whether ASCs could act directly on IL-1β, ASCs and TFs were co-cultured using 
transwell plates in the presence or absence of IL-1β.  Transwell plates separate the two cell types 
with a porous membrane, inhibiting cell-cell contact, but allowing for the diffusion of soluble 
factors.  Naïve ASCs did not appear to significantly alter the gene expression or protein 
expression of TFs exposed to the inflammatory environment.  ASCs that were activated with 
IFNγ were also examined for potential protective effects.  Co-culture with activated ASCs led to 
reductions in the expression of the inflammatory cytokines TNFα and IL-1β and in the matrix 
degradation enzyme MMP1; however, these reductions failed to reach statistical significance.  
No significant effect of the activated ASCs was seen at the protein level either. 
 
It is well established that MSCs exhibit immunomodulatory effects on lymphocytes through the 
secretion of soluble factors173,203,213,215–219,222,225,226,228,229,231,233,234,236,237,239,243–247,314.  Among 
other factors, secretion of the anti-inflammatory factor, IL-10, by MSCs has been 
reported227,242,316,317.  Given that ASCs have been shown to have similar immunomodulatory 
capabilities as MSCs173,216,229,231223, we hypothesized that ASCs may have similar effects on our 
IL-1β-induced inflammation model.  We hypothesized that ASCs would either secrete anti-
inflammatory factors that would counteract the effects of IL-1β or take up the IL-1β themselves, 
effectively reducing the amount of IL-1β in the media.  However, ASCs (both naïve and 
activated) failed to suppress the negative effects of IL-1β on TFs.   
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The lack of significant ASC-mediated effects observed in this model may be attributed to several 
factors.  First, the small sample size used in this study, coupled with large variability, may have 
resulted in an underpowered statistical analysis.  Second, it is possible that the dosage of IL-1β 
used in this study was too high for ASCs to overcome.  The criterion for the dosage selection 
was the lowest dosage that reproducibly elicited significant up-regulation of all of the genes of 
interest.  Based on this criterion, 10 ng/ml was chosen.  However, all genes except TNFα were 
significantly up-regulated with only 1 ng/ml of IL-1β, and COX2 and the MMPs were all 
significantly up-regulated with as little as 0.01 ng/ml.  It remains unclear what dose is the most 
physiologically relevant for flexor tendon healing.  Third, the number of ASCs and/or the ratio of 
ASCs to TFs may influence the outcomes.  A 1:1 ASC to TF ratio was chosen based on the MSC 
immunosuppression literature, which suggests that a 1:1 ratio is the most effective for the 
suppression of lymphocyte proliferation315243202,211,212,214,234,238,315,318,319.  These studies, however, 
tested ratios up to and including 1:1, but not greater than 1:1.  A higher ratio of ASCs to TFs may 
prove beneficial.  Lastly, the proposed hypothesis may have been incorrect.  We sought to 
determine whether ASCs could act directly on inflammatory factors (such as IL-1β) to protect 
TFs from a harmful inflammatory environment (Figure 5.1).  Based on the literature, however, it 
is more likely that the suppression of inflammatory factors observed by other investigators was a 
result of ASC-mediated inhibition of the immune cells that secrete such factors (e.g., 
lymphocytes).   
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5.4.2 Macrophage-Induced Inflammation Model 
 
The ability of MSCs to alter inflammation indirectly through the modulation of immune cells has 
high clinical relevance for tendon repair.  We previously demonstrated that monocytes infiltrate 
the repair by day 3 (see Chapter 2).  Studies by other investigators have indicated that M1 
macrophages (which share the same lineage as monocytes) are present during tendon-to-bone 
healing and that suppression of M1 macrophages may be advantageous for healing92,93,97,320.  
Other studies suggest that MSCs can reprogram inflammatory, M1 macrophages into anti-
inflammatory, M2 macrophages136,138,139,141,143,220,245,255,257,271.  Thus, we established a tri-culture 
model to test the ability of ASCs to modulate the inflammatory environment by altering 
macrophage phenotype.  ASCs were cultured in direct cell-cell contact with M0 or M1 
macrophages and in indirect contact with TFs using a transwell system.   
 
Previously, we found that M1 macrophages significantly increase TF expression of pro-
inflammatory and matrix degradation-related genes, while concurrently down-regulating 
expression of extracellular matrix- and tendon fibroblast differentiation genes (see Chapter 4).  In 
the current study, we found that ASCs significantly suppress these negative effects when co-
cultured with M1 macrophages for 1 day.  ASCs co-cultured with M1 macrophages for 1 day led 
to a significant down-regulation of pro-inflammatory and matrix degradation genes (TNFα, 
MMP1a, MMP3) toward, but not reaching, baseline values.  However, the reduction of TNFα at 
the gene expression level was not observed at the protein level.  Moreover, while no changes 
were observed in the TF gene expression of IL-1β or COX2, a significant increase in the 
associated proteins were observed (1.5- and 1.6-fold, respectively).  Differences in gene 
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expression and protein expression can be explained by several factors.  First, changes in gene 
expression occur prior to changes in protein expression due to the time required for translation of 
the gene into a protein.  Moreover, genes can be differentially expressed, but never translated.  
Second, whereas the source of the gene expression can be isolated to a single cell type in this 
model (i.e., TFs), the source of the protein expression cannot.  Due to the co-culture system, 
protein levels measured in the supernatant are a combination of proteins secreted by all cell types 
(i.e., TFs, macrophages, ASCs). However, this is similar to the source of proteins in the in vivo 
repair setting. Of note, IL-1β was increased only in the presence of TFs, indicating that the TFs 
are involved in producing the additional IL-1β, either directly or indirectly through feedback to 
the macrophages or ASCs.  PGE2, on the other hand, was increased in the absence of TFs, but 
not in the presence of TFs.   
 
Increased durations of ASC exposure led to further down-regulation of pro-inflammatory and 
matrix degradation genes towards baseline.  ASC co-culture of M1 macrophages for 5 days 
resulted in an additional 6.2-fold down-regulation of MMP3 compared to only 1 day of ASC co-
culture.  Moreover, inflammation- and matrix-remodeling genes that were not differentially 
regulated after 1 day of co-culture were differentially regulated after 5 days.  For example, 
COX2 was down-regulated 11.3-fold compared to control after 5 days (i.e., M1 macrophages 
alone).  This large reduction in COX2 gene expression parallels the significant reduction 
observed in PGE2 production (a product of COX2).  Similarly, TNFα and IL-1β gene expression 
were down-regulated 2.4- and 7.1-fold at the gene expression level.  While these changes were 
not statistically significant, parallel, statistically significant reductions of TNFα and IL-1β were 
observed at the protein level.  5 days of ASC co-culture also led to the suppression of the matrix 
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degradation gene, MMP1b (7-fold), and the up-regulation of the ECM-related gene, COL1 (1.8-
fold, not statistically significant).   
 
To determine the mechanism by which ASC co-culture suppressed the negative effects of M1 
macrophages on TFs, the co-cultured macrophages were examined using flow cytometry.  
Analysis of the cell surface markers revealed a shift in phenotype from M1 to M2 with ASC co-
culture.  Whereas the surface markers CD11b and F480 are expressed by all macrophages; 
CD206 and CD301 are specific to M2 macrophages.  No apparent phenotypic changes were 
evident with ASC co-culture of M1 macrophages after a single day; however, 5 days of co-
culture led to a significant 2-fold increase in the expression of CD206 compared to M1 
macrophage controls.  Moreover, flow cytometry revealed an increased ability of ASCs to push 
M0 macrophages toward a M2 phenotype (compared to M1 macrophages).  ASC co-culture with 
M0 macrophages for 1 day led to a 2-fold increase in CD301 expression, surpassing the levels of 
M2 macrophage controls.  By day 5, an additional 2.1-fold increase in CD301 expression was 
observed (for a total 4.1-fold increase compared to control) and a small, but statistically 
significant increase in CD206 was evident (1.3-fold). 
 
These results are in agreement with those of Kim et al. demonstrated a shift in macrophage 
phenotype when co-cultured with bone marrow-derived MSCs in vitro 255,257.  In addition, Kim et 
al. observed increased levels of the anti-inflammatory cytokine IL-10 and decreased levels of the 
pro-inflammatory cytokine TNF-α compared after 5 days of co-culture.  However, the 
mechanisms by which this phenotypic switch occurs remains unclear.  Francois et al. suggest that 
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MSC-secreted IDO (an intracellular enzyme that catalyzes tryptophan into kynurenine249) is 
responsible for this phenomenon220 (Figure 1.11).  When IDO was inhibited using a 
pharmacological inhibitor (1-MT), IL-10 production was suppressed, indicating a possible 
involvement of IDO in the differentiation of monocytes into anti-inflammatory M2 
macrophages220,261. 
 
While ASC appear to have a limited ability to suppress the negative effects of M0 macrophages 
on TF gene expression, their ability to push M0 macrophages toward an M2 phenotype remains 
attractive.  As seen in Chapter 4, the effects of M0 and M2 macrophages on TFs are significantly 
less than those induced by M1 macrophages (see Chapter 4).  Since the vast majority of 
macrophages at the site of wound repair are recruited from the bone-marrow as undifferentiated 
monocytes, this is an attractive target for improved tendon healing.  Thus, early treatment with 
ASCs could potentially promote differentiation of the infiltrating monocytes towards the anti-
inflammatory M2 macrophage lineage as opposed to the pro-inflammatory M1 macrophage 
lineage.  Without such treatment, the monocytes would typically revert to an M1 macrophage 
phenotype due to the abundance of inflammatory factors (including IFNγ) at the repair site.  
However, our results suggest that ASCs may be able to suppress the negative effects of M1 
macrophages even if the treatment is delayed until after monocytes have differentiated into M1 
macrophages.  Since M2 macrophages are unlikely during the early period after surgical repair 
and differentiation of monocytes in M2 macrophages is the ultimate goal, no M2+ASC group 
was examined in this study. 
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These results are in agreement with those of other investigators.  Kim et al. revealed increased 
expression of CD206 by non-polarized macrophages (i.e., M0 macrophages) after 4-5 days of 
direct or indirect co-culture with MSCs255.  However, the authors did not compare these levels to 
those of M2 macrophage controls.  In the current study, we found that CD206 expression was 
increased in both M0 and M1 macrophages after 5 days of ASC co-culture.  However, these 
levels were significantly lower than those of M2 macrophage controls.  Moreover, we also 
examined a second M2-specific surface marker, CD301.  We found that CD301 expression was 
increased in M0 macrophages after 5 days of ASC co-culture to levels that surpassed those of 
M2 macrophage controls.  Kim et al identified altered intracellular cytokine staining after MSC 
co-culture via flow cytometry255.  Co-cultured macrophages exhibited increased expression of 
the anti-inflammatory cytokine, IL-10, and decreased expression of pro-inflammatory cytokines, 
TNFα, IL-12, and IL-6255.  In the current study, we did not examine intracellular cytokine 
expression, but rather the secretion of such products.  Similarly, we found a significant decrease 
in TNFα production after 5 days of MSC co-culture with M0 macrophages.  However, we did 
not observe expression of IL-10 in any of the experimental or control groups.  
  
In our model, ASC co-culture for a longer period led to more pronounced effects. However, the 
data from the ASC co-cultured groups were obtained on day 5, whereas the data from the control 
groups (M0, M1, M2) was obtained on day 1.  Thus, we are unable to say with certainty whether 
the enhanced effects with increased co-culture period were due to increased time for ASCs to 
induce phenotypic changes in the co-cultured macrophages, or whether there were fewer viable 
macrophages at the 5 day timepoint and thus fewer inflammatory factors being secreted into the 
media.  To better control for this possibility, the control groups were repeated at longer 
114 
 
timepoints.  As with the co-culture groups, the macrophages were primed to become M1 or M2 
macrophages or left untreated (M0) for 1 day. The cells were then cultured in standard medium 
for an additional 4 days.  Under these conditions, however, decreased macrophage viability over 
time resulted in fewer macrophages present when TFs were added.  While this timepoint issue is 
a limitation of the gene and protein expression assays of this study, the increased expression of 
CD206 and CD301 over time strongly supports the idea that longer periods of ASC exposure 
will lead to further down-regulation of inflammation- and matrix remodeling-related genes and 
up-regulation of tendon extracellular matrix-related genes towards baseline levels. 
 
5.4.3 Overall Conclusions 
 
Overall, this study supports the premise that ASCs can modulate the inflammatory environment.  
While there is little evidence to support the hypothesis that ASCs can counteract the effects of 
IL-1β directly, there is strong evidence to support the notion that ASCs can reprogram pro-
inflammatory M1 macrophages into anti-inflammatory M2 macrophages, thus reducing the 
amount of pro-inflammatory cytokines produced (Figure 5.12).  Furthermore, if ASC treatment 
is performed prior to monocyte differentiation into M1 macrophages, ASCs may be able to 
further modulate the inflammatory environment by pushing the undifferentiated (M0) 
macrophages towards a M2 phenotype.  Studies by other investigators suggest that modulation of 
the healing environment through the recruitment of anti-inflammatory M2 macrophages, as 
opposed to pro-inflammatory M1 macrophages may be advantageous for tendon healing92–94. 
ASCs delivered at the time of intrasynovial flexor tendon repair may enhance flexor tendon 
healing by modulating the early inflammatory phase via M2 macrophage differentiation.  In 
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order to translate these in vitro findings, a delivery system capable of delivering and retaining 
ASCs at the repair site must be developed. Such a system will be described in Chapter 6. 
 
Figure 5.12:  ASCs can modulate the inflammatory environment by reprograming pro-
inflammatory, IL-1β-producing M1 macrophages into anti-inflammatory M2 macrophages.  
There was little evidence to support the hypothesis that ASCs could directly counteract the 
effects of IL-1β. There was strong evidence to support the hypothesis that ASCs can modulate 
the amount of pro-inflammatory factors (such as IL-1β), by inducing a phenotypic switch from 
pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages and by suppressing 
production of factors my macrophages.  
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Chapter 6 - Controlled Delivery of Adipose-Derived Mesenchymal 
Stem Cells Using a Nanofiber Scaffold for Tendon Repair 
 
6.1 Introduction 
Previously, we demonstrated that the early inflammatory phase of flexor tendon healing is 
characterized by a remarkable 4000-fold up-regulation of IL-1β gene expression (see Chapter 2).  
IL-1β has been reported to induce negative effects on tendon fibroblasts in vitro and on ex vivo 
tendon explants155,163,267,268,274,278,321.  We confirmed that IL-1β exposure induces up-regulation of 
pro-inflammatory factors and catabolic MMPs by TFs (see Chapter 3).  Furthermore, we 
investigated the effects of M1 macrophages (a primary source of IL-1β) on TFs and found 
similar up-regulation of inflammation- and matrix-degradation-related genes as well as down-
regulation of tendon ECM-related and TF-specific genes (see Chapter 4).  Co-culture of M1 
macrophages with ASCs suppressed the negative effects of M1 macrophages on TFs by inducing 
a phenotypic switch from a pro-inflammatory phenotype (M1) to an anti-inflammatory 
phenotype (M2). In this chapter, we aim to develop a scaffold capable of delivering ASCs in vivo 
at the time of flexor tendon repairs to translate the in vitro findings for enhanced flexor tendon 
healing.   
 
Most approaches for delivering cells in vivo have not been designed for dense connective tissues 
such as tendon.  Therefore, a new scaffold is presented herein that combines a fibrin-based 
hydrogel with an aligned electrospun nanofiber poly lactic co-glycolic acid (PLGA) backbone. 
The scaffold consists of eleven alternating layers of PLGA nanofiber mats and fibrin matrices 
(i.e., 6 layers of PLGA and 5 layers of fibrin). The scaffold allows for the delivery of cells in a 
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controlled manner86–88,115, while the PLGA backbone provides a structure that mimics collagen 
fiber diameter and alignment in tendon and enhances the surgical handling properties of the 
scaffold. While natural matrices (e.g., collagen, fibrin) are advantageous in terms of 
biocompatibility, polymers (e.g., PLGA) provide better control of degradation and mechanical 
properties. PLGA was chosen because it is biodegradable, has the appropriate mechanical 
properties, can easily be electrospun, and is FDA approved322,323. PLGA polymer nanofiber mats 
are biodegradable in an aqueous environment but are resistant to enzymatic degradation. The 
ratio of lactic to glycolic monomers can be varied to alter the degradation rate and mechanical 
properties. 
 
In the current study, we present a novel scaffold for use in tendon repair. The ability of the 
scaffold to maintain cell viability is demonstrated in vitro. Scaffold biocompatibility, feasibility 
for use in tendon repair, and post-implantation cell viability are demonstrated in vivo using a 
clinically relevant large animal model of flexor tendon injury and repair. In this study, our aims 
were to show that: (1) controlled delivery of ASCs can be achieved from the scaffold, (2) the 
scaffold can be implanted successfully at a flexor tendon repair site in vivo, (3) the scaffold is 
biocompatible in vivo, and (4) ASCs implanted at the time of flexor tendon repair suppress the 
expression of pro-inflammatory and matrix degradation factors. 
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6.2 Methods 
6.2.1 Fibrin/nanofiber layered scaffold fabrication 
 
The fibrin/nanofiber scaffold consisted of eleven alternating layers of aligned electrospun PLGA 
nanofiber mats and fibrin matrices (i.e., 6 layers of PLGA and 5 layers of fibrin, Figure 6.1). 
PLGA was chosen because of its biodegradability and mechanical properties322–324. The 
electrospinning solution was prepared at a concentration of 0.25 g/mL by dissolving PLGA 
(85:15, MW 50,000-75,000, Sigma Aldrich) in a mixture of dichloromethane and 
dimethylformamide at a ratio of 4:1. The solution was loaded into a plastic syringe equipped 
with a stainless steel needle (23-gauge) connected to a high-voltage supply (ES30P-5W, Gamma 
High Voltage Research). The feed rate was set at 0.5 mL/h, controlled by a syringe pump (KDS-
200, Stoelting). Fibers with diameters of 400-700 nm (similar in size to collagen fibrils in 
tendon) were collected on a custom-made rotating mandrel to create a uniaxial array of 
nanofibers designed to mimic the anisotropic ECM of tendon tissue (Figure 6.1, B inset) 325,326.  
After 2.5 h of electrospinning, the polymer nanofiber mat (~100 micrometers) was released from 
the collector and freeze-dried for 72 hr to remove residual solvents. Scanning electron 
microscope images (SEM, FEI Nova 200 Nanolab, accelerating voltage 5kV, 3500X) of 
representative scaffolds were used to calculate the approximate diameter and orientation of the 
fibers. The nanofiber mats were then sterilized with ultraviolet light for 30 min (Thermo 
Scientific, model 1375, wavelength 253.7nm, power 40W) and cut into 3x7 mm pieces (with the 
fibers aligned in the 7 mm direction).  
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Figure 6.1: A representative fibrin/nanofiber scaffold with eleven alternating layers of aligned 
electrospun PLGA nanofiber mats separated by fibrin containing 1x106 ASCs is shown. (A-D) 
Micrograph showing the fibrin/nanofiber scaffold in vitro; the PLGA was labeled with FITC 
(green), the fibrin was labeled with Alexa Fluor 546 (red), and the ASC nuclei were labeled with 
Hoescht 33258 (blue) (scale bar = 200 µm). (B inset)  SEM image of the scaffold showing 
PLGA nanofiber alignment. (E) Micrograph showing the fibrin/nanofiber scaffold in vivo 9 days 
after implantation in a tendon repair. Eleven alternating layers of PLGA and fibrin can be seen 
(i.e., 6 layers of PLGA and 5 layers of fibrin); the PLGA was labeled with FITC (green) (scale 
bar = 100 µm). (F) A schematic of the layered scaffold is shown. 
 
Fibrin matrices (30 µl total) were made with the following final component concentrations: 10 
mg/mL of human fibrinogen concentration (20 mg/ml stock solution, EMD Bio), 6.9 mM of 
CaCl2 (50mM stock solution), and 12.5 units/mL of thrombin (1000U/ml stock solution) in Tris-
PLGA Nanofibers
Fibrin
Cell Nuceli
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buffered saline (137 mM NaCl, 2.7 mM KCl, 33 mM Tris; pH, 7.4). The fibrin was polymerized 
directly onto the PLGA nanofiber mats (one layer at a time, 6 µL per layer), effectively serving 
as a bond between layers. Once fibrin and thrombin were mixed together, the fibrin layer began 
to polymerize within 30 s and reached a gel-like consistency within 1-2 min.  The nanofiber mat 
was placed on top of the fibrin after the fibrin reached a gel-like consistency. This process was 
repeated to build a scaffold with the appropriate number of layers.  The assembly of each 
scaffold in this study was completed in ~15 minutes.  The assembled scaffold was then left in the 
incubator (37ºC, 5%CO2, 95% humidity) for ~1 hr to allow for complete fibrin polymerization 
and full adherence between the fibrin and the nanofiber mat layers. For cellular scaffolds, 1x106 
ASCs (per scaffold, 3.3x104 cells/µL) were incorporated into the fibrinogen solution prior to 
polymerization.  The final dimensions of the scaffolds were 7x3x1 mm (Figure 6.1, E). 
 
6.2.2 Cell isolation and culture 
ASCs were isolated 1-2 weeks prior to use. Adipose tissue from the abdominal cavity of canines 
(N=8) was removed surgically. To harvest adipose tissue, dogs were sedated and a 2-4 cm skin 
incision was made in the caudal abdomen just below the umbilicus exposing the subcutaneous fat 
lying lateral to the midline. A 10-15 g sample of adipose tissue was isolated and excised 
bilaterally and the skin wound was closed. The adipose tissue was minced and digested in 0.2% 
Collagenase A in PBS for 2 h, collected, and centrifuged for 10 minutes at 12,000 rpm. The 
digested tissue was filtered using a cell strainer and pelleted by centrifugation. The supernatant 
was aspirated and the pelleted cells were resuspended in alpha-MEM with 10% FBS and 1 % P/S 
and cultured for 1-2 weeks (37°C, 5% CO2, 100% humidity). The cells were used between 
passages 2-4. Numerous investigators, using similar isolation methods, have described the 
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resultant cell population as mesenchymal stem cells based on surface markers (via FACS) and 
pluripotency229,327–329.  The cells in the current study demonstrated pluripotency based on 
standard adipogenic, osteogenic, chonodrogenic, and tenogenic protocols (data not shown). 
 
6.2.3 In vitro experiments 
 
Cell culture:  A set of scaffolds was fabricated for in vitro time-zero imaging in order to 
visualize the different components of the constructs (Figure 6.1A-D). These scaffolds contained 
fluorescein isothiocyanate (FITC)-labeled PLGA, Alexa Fluor 546-labeled fibrinogen 
(Invitrogen Corporation, CA), and ASCs labeled with Hoechst 33258 (Invitrogen Corporation, 
CA). A series of in vitro experiments were also performed to assess the viability and 
proliferation of ASCs within the fibrin/nanofiber scaffold.  
 
Cell viability: To assess the viability and proliferation of ASCs within the scaffold, a set of 
fibrin/nanofiber scaffolds containing 1x106 ASCs were fabricated (N=4 cell isolations, 20 
scaffolds total) and cultured in 24 well plates for up to 14 days. The scaffolds were given fresh 
phenol-free alpha-MEM containing 10% FBS and 1% P/S daily. At each sacrificial time point (0, 
3, 7, 11, and 14 days) the scaffolds were delaminated with forceps (i.e., the individual layers of 
the scaffold were separated from each other) and a Vybrant 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) Cell Proliferation Assay (Invitrogen Corporation, CA) was 
performed according to the manufacturer’s instructions. Live cells reduced the MTT solution to a 
purple formazan product, which was solubilized with 200µl of 2-Propanol. The absorbance of the 
solubilized formazan was measured using a microplate reader at 470 nm. The relative number of 
122 
 
live cells within the scaffold was determined by averaging the absorbance values of four 
different cell isolations at each timepoint and normalizing to the day 0 samples (which contained 
1x106 ASCs). 
 
6.2.4 In vivo experiments 
Flexor tendon animal model: All procedures were approved by the Washington University 
Animal Studies Committee. A series of surgeries were performed in order to: (1) ensure that the 
scaffold did not elicit a negative inflammatory response, (2) determine cell viability, and (3) 
determine the early degradation of the scaffold after implantation. Prior to cell seeding and 
assembly of the scaffolds, ASCs were labeled with a fluorescent membrane dye (Di-I, 
Invitrogen) according to the manufacturer’s instructions. Flexor tendon injury and repair was 
performed in the clinically relevant canine animal model (N=26) using surgical techniques 
identical to those used in humans7,8,86,99,263,330. Eleven-layer scaffolds (dimensions: 7x3x1 mm), 
either containing 1x106 autologous ASCs (isolated 7 day prior) or left acellular, were implanted 
into the intrasynovial flexor tendons of adult mongrel dogs (20-30kg, Covance, Denver, 
Pennsylvania) at the time of repair as follows (Figure 6.2). The sheaths of the second and fifth 
digits of the right forelimb in the region between the annular pulleys proximal and distal to the 
proximal interphalangeal joint were exposed through midlateral incisions. The sheaths were 
entered and the flexor digitorum profundus tendons were transected sharply. Longitudinally 
oriented horizontal slits were created in the center of each tendon stump for scaffold 
implantation. The fibrin/nanofiber scaffold was secured within the repair site using a core suture 
(4-0 Supramid) and sealed in that location using a running epitenon suture (6-0 Proline). Each 
canine received one cellular and one acellular scaffold or one acellular and one repair without 
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any additional treatment in either the second or fifth digit. After surgery, the operated-on right 
forelimb was immobilized using a fiberglass shoulder spica cast with the elbow flexed to 90° and 
the wrist flexed to 70°. To mimic the typical clinical post-operative rehabilitation protocol, 
controlled passive motion was applied to the digits during two five-minute rehabilitation sessions 
performed five days a week starting on the first postoperative day3,25. The dogs were euthanized 
at 3 or 9 days post-operatively. The operated tendons were removed by dissection and prepped 
for either gene expression analysis at 3 days (N=3-11), histologic analysis at 9 days (N=6; 3 for 
immunofluorescent imaging and 3 for evaluation of biocompatibility), and total DNA analysis at 
9 days (N=5). Adhesion formation between the tendon and its sheath was qualitatively evaluated 
at the time of dissection. Tendons from the contralateral paw were also dissected to serve as 
normal/uninjured controls. A subset of scaffolds (N=3) was prepared with a small amount of 
fluorescein isothiocyanate (FITC, 1.85 µg per scaffold) incorporated into the PLGA during 
fabrication. These scaffolds were prepared in order to identify the scaffold 9 days post-
operatively using fluorescent imaging of histologic sections. A “time-zero” control was also 
performed on a cadaver animal to assess the scaffold structure and cellularity at the time of 
implantation.  
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Figure 6.2: A depiction of the surgical technique. (A, D) Flexor tendons were transected sharply 
and longitudinally oriented horizontal slits were created in the center of each tendon stump. (B, 
E) A fibrin/nanofiber scaffold was grasped by a core suture. (C, F) The scaffold was secured 
within the repair site. 
 
 Histology: Upon dissection, adhesion formation was assessed qualitatively. It was noted whether 
any adhesions were present, and if so, whether they were mild or severe. Tendons allocated for 
histology were fixed in 4% paraformaldehyde overnight, frozen in Optimal Cutting Temperature 
Compound (Tissue-Tek CRYO-OCT, Fisher Scientific), and cut into 5 µm sections. The 
residence time of the scaffold and the viability of the implanted cells were examined using a 
fluorescent microscope equipped with the appropriate filters. To examine the immune response 
at the periphery of the scaffold, sections were stained with H&E and assessed for various 
immune cells (i.e., PMNs and monocytes) by an independent certified pathologist, blinded to 
group.  However, we note that the scaffold was apparent in some sections. Fibroblasts were 
characterized as spindle-shaped cells with an elliptic nucleus and thin cytoplasm. PMNs were 
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identified as cells containing nuclei with two to four lobules and a granulated cytoplasm while 
cells with a single-lobed or kidney-shaped nucleus were classified as monocytes. Apoptotic cells 
were characterized by nuclear fragmentation and condensation. A standard scoring system was 
used to determine the levels of each outcome (- no prevalence, + mild prevalence, ++ moderate 
prevalence, +++ marked prevalence). For overall cellularity and the prevalence of certain cell 
types, the number of cells per high powered field (HPF, 20x) was counted and assigned a score 
as follows: + <50 per HPF, ++ 51-100 per HPF, +++ 101-150 per HPF, ++++ >150 per HPF. 
Apoptosis and vascularity were measured on the following scale: + <5 per HPF, ++ 6-10 per 
HPF, +++ > 10 per HPF. All assessments were done using a 20x objective and 5-8 fields of view 
were averaged. Sections were also stained with Picrosirius Red for collagen alignment and 
viewed under polarized light. The analysis focused on the tissue adjacent to the scaffold. 
 
Quantitative Real-time PCR: Tendons allocated for gene expression were dissected and 10 mm 
sections (5 mm on each side of the repair) were isolated and immediately flash frozen in liquid 
nitrogen. RNA was extracted from the tendons using the RNeasy mini kit (Qiagen, CA) 
following the manufacturer’s protocol. RNA yield was quantified using a NanoDrop 
spectrophotometer (Thermo Scientific, DE) and 500 ng of RNA was reverse transcribed to 
cDNA using the Superscript VILO cDNA synthesis kit (Invitrogen Corporation, CA) following 
manufacturer’s instructions. Real time PCR reactions were performed using SYBR Green 
chemistry on a StepOnePlus Real-Time PCR System (Applied Biosystems, CA). All primers for 
real-time PCR were purchased (Qiagen, CA). Gene expression changes were measured for the 
inflammation-related genes (TNFα, IL-1β, and COX-2) and matrix degradation-related genes 
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(MMPs -1, -3, -13). Results were expressed as fold change relative to the housekeeping gene 
(GAPDH). 
 
Total DNA Content: Tendons allocated for Total DNA Content (N=5) were dissected and 10 mm 
sections (5 mm on each side of the repair) were isolated.  The tendon samples were digested with 
papain and DNA content was determined fluorometrically with use of a PicoGreen assay kit 
(Invitrogen, CA).  The results were normalized to the dry weight of the tendon sample. 
 
6.2.4 Statistics 
Cell viability within the scaffolds over time was assessed using paired t-tests to compare 
absorbance values at each timepoint and the values obtained on day 0.  To determine the effect of 
the fibrin/nanofiber scaffold on inflammation- and matrix remodeling-related gene expression, 
mean Ct values were compared using an ANOVA (groups: cellular, acellular, repair-only, 
normal) followed by a least squared differences post-hoc test when the ANOVA showed a 
significant effect.  A paired t-test was also performed on the Ct values of GAPDH to ensure the 
consistency of our housekeeping gene (p > 0.05). Samples from the same animal were treated in 
a paired fashion to account for animal-to-animal variances. The total DNA content was 
compared between cellular, acellular, and uninjured groups using a multi-factor ANOVA. 
Significance for all statistical analyses was set to p <0.05. 
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6.3 Results 
6.3.1 Cells remain viable in the fibrin/nanofiber scaffold in vitro 
The number of cells within the scaffolds remained approximately constant for up to 14 days in 
vitro, with no statistically significant changes over time (Figure 6.3). The percentage of viable 
cells on day 14 compared to day 0 was approximately 81%. Stable cell numbers over time could 
result from maintenance of non-proliferating cells or a balance between proliferating, migrating, 
and apoptotic cells, resulting in a zero-sum outcome. Migration of cells out of the scaffold and 
onto the plastic of the wells was indeed observed. Migration of cells out of the scaffold in the in 
vivo setting may allow the cells to incorporate into the adjacent tendon tissue and produce new 
extracellular matrix. A type II statistical error cannot be ruled out for the non-significant cell 
number outcome; a post hoc power analysis revealed that 14-18 samples would be required to 
detect a statistically significant difference for the effect size seen (i.e., a 15% increase in viability 
at day 1 or 13-26% decreases in viability at days 3 – 14). 
 
 
Figure 6.3:  Cells remain viable within the fibrin/nanofiber scaffold for up to 14 days in vitro. 
Data are presented as a percent change in cell viability compared to day 0. No significant 
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decreases in cell viability were observed at any timepoint (1-14 days) compared to day 0,            
p ≥ 0.05, paired t-tests (N=4). 
 
 
6.3.2 The fibrin/nanofiber scaffolds were well-tolerated in the in vivo flexor tendon repair 
setting 
Based on gross observations at the time of dissection, the fibrin/nanofiber scaffold did not elicit 
any negative responses. The tendons were intact and had minimal adhesions at the repair site 
(Figure 4D). Out of 7 repair-only samples, 5 had no adhesions, 2 had mild adhesions, and 0 had 
severe adhesions. Out of 7 repairs that received scaffolds, 5 had no adhesions, 1 had mild 
adhesions, and 1 had severe adhesions. Histological analysis showed a mild influx of immune 
cells (i.e., PMNs and monocytes) around the implanted scaffolds 9 days post-operatively (Figure 
6.4, Table 6.1). Overall cellularity was increased in the group that received the scaffold, 
including increases in PMNs and monocytes. A small increase in apoptotic cells was also 
observed and was related to the increased presence of PMNs. No significant difference was 
noted for vascular profiles between the two groups.  
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Figure 6.4: No significant immune response was elicited by the fibrin/nanofiber scaffolds when 
implanted in vivo at the site of flexor tendon repair.  (A-C) Representative histologic sections of 
a tendon that was repaired using an acellular fibrin/nanofiber scaffold. The sections were stained 
with either H&E and viewed under brightfield for cell identification (A and C) or stained with 
Picrosirius Red and viewed with polarized light for collagen alignment (B). No obvious 
inflammatory response was observed with the implantation of the scaffold 9 day post-
operatively. Only a small number of immune cells infiltrated the scaffold (black arrows in C). 
The image in C corresponds to the black box in A. (A, B: 4x objective, 1 mm scale bar; C: 40x 
objective, 100 µm scale bar) (D) Gross observations of repaired tendons show no gapping at the 
repair site. A representative sample shown here demonstrates no gap (black arrow) and no 
adhesions between the tendon and the sheath (white arrows) 9 days post-operatively. 
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Table 6.1:  The fibrin/nanofiber scaffolds elicited only a mild immune response in the in vivo 
flexor tendon repair setting. Histological analysis of the immune response to the fibrin/nanofiber 
scaffold was assessed 9 days post-operatively. The number and type of immune cells present in 
tendons after implantation of an acellular scaffold was compared to those present in the repair-
only and the normal/uninjured groups. A standard scoring system was used to determine the 
levels of each outcome (- no prevalence, + mild prevalence, ++ moderate prevalence, +++ 
marked prevalence). FB = foreign body, PMN = polymorphonuclear cells, Mono = monocytes, 
(N=3).   
 
Similarly, there were no statistically significant changes when comparing qRT-PCR results for 
tendons that received acellular scaffolds to those that were repaired without any additional 
treatment (Figure 6.5). For certain genes, a type II statistical error was possible when comparing 
expression in the acellular scaffold group to expression in the naïve repair group. Based on a 
post-study power analysis: N=24 would be required to show that TNFα was significantly higher 
  Normal Repair-Only Scaffold 
Cellularity - ++ + 
Vascularity - -/+ - 
FB - + ++ 
PMN - + ++ 
Mono - ++ ++ 
Apoptosis - - + 
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in the repair-only group, N=28 would be required to show that COX2 was significantly higher in 
the scaffold group, N=39 would be required to show that MMP3 was significantly higher in the 
scaffold group, and N=14 would be required to show that MMP3 was significantly higher in the 
scaffold group.  As expected both repair groups showed a significant up-regulation in gene 
expression relative to uninjured controls (Figure 6.5). Using fluorescent labeling and imaging 
techniques, the scaffold was identifiable at the repair site 9 days post-operatively, indicating a 
slow degradation rate relative to the time-course of tendon healing (Figure 6.1E).  
 
Figure 6.5:  The fibrin/nanofiber scaffolds did not significantly alter the expression of 
inflammation- and matrix degradation-related genes.  Genes related to inflammation (top row) 
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and genes related to matrix remodeling (bottom row) were significantly up-regulated in the 
repair setting (i.e., acellular scaffold and naïve repair groups) relative to uninjured control. There 
were no significant differences in gene expression when comparing the acellular scaffold and 
naïve repair groups. (* p < 0.05 compared to uninjured group). 
 
6.3.3 Successful delivery of ASCs was achieved in vivo using the fibrin/nanofiber scaffolds  
Fluorescent imaging verified the viability of the implanted cells 9 days post-operatively. Co-
localization of the membrane dye (Di-I) and the nuclear stain (Hoescht 33258) were evident in 
the time zero and 9 day cellular groups, but not in the 9 day acellular group (Figure 6.6A-C). In 
support of the qualitative fluorescent imaging, there was a significant increase in total DNA 
content in the cellular group compared to the acellular group and normal/uninjured controls 
(Figure 6.6D). While there is a significant increase in the total DNA of the cellular group, the 
DNA assay does not distinguish between cell types.  We cannot determine, therefore, whether 
that increase was due to the implanted ASCs or infiltration of additional cells (via a chemotactic 
mechanism initiated by the ASCs).  Moreover, the comparison between the uninjured group and 
acellular group indicates that the scaffold alone attracts host cells, however, neither the origin nor 
phenotype of these cells could be determined (e.g., inflammatory vs. fibroblastic).   
 Figure 6.6:  Cells remained viable after 
(A-C) Micrographs showing the 
after implantation. ASCs were labeled with the fluorescent membrane dye Di
seeding and PLGA was labeled 
(blue) to label all cell nuclei. Co
(blue) was apparent at day 0 and 9 days after repair, indicating cell viability. An acellular 
scaffold is shown 9 days post-operatively for comparison. 
and 50 µm for insets. (D) Total DNA content in uninjured tendons, repaired tendons that 
received acellular scaffolds, and repaired tendons that re
p < 0.05, (N=5).  
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in vivo implantation using the fibrin/nanofiber scaffolds.  
fibrin/nanofiber scaffolds at implantation (day 0) and 9 days 
with FITC (green). Sections were stained with Hoescht
-localization of the membrane dye (red) and the nuclear stain 
Scale bars = 200 µm for main images 
ceived cellular scaffolds. 
 
-I (red) prior to 
 33258 
Bars signify     
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6.3.4 ASC delivery did not significantly suppress the early inflammatory response after 
flexor tendon healing  
Preliminary results show minimal effects of ASC delivery on the expression of inflammation- 
and matrix degradation-related genes.  As seen previously, expression of inflammatory genes 
(TNFα, IL-1β, COX2) and matrix degradation genes (MMP1, MMP3, MMP13) were all up-
regulated in the repair setting (i.e., repair only vs. uninjured, acellular scaffold vs. uninjured) 
(Figure 6.7).  The addition of 1 million ASCs to the scaffolds did not significantly suppress the 
expression of these factors.  While the expression of IL-1β 3 days post-operatively was 
decreased (2.1-fold) in the cellular scaffold group compared to the acellular scaffold group, this 
change failed to reach statistical significance (Figure 6.7).  Similarly, MMP1 and MMP3 were 
also down-regulated (2.0- and 1.3- fold, respectively) with ASC treatment (i.e., cellular vs. 
acellular), but statistical significance was not achieved (Figure 6.7).  Moreover, on day 9, there 
was a statistical trend towards down-regulation of MMP1 (1.2-fold) with ASC treatment; 
however, this change did not reach statistical significance (p < 0.10).  The lack of significance in 
this pilot study may have been due to the small sample size (N=3).  A type II statistical error was 
possible when comparing expression in the acellular scaffold group to expression in the cellular 
scaffold group.  Based on a post-study power analysis (80% power, 95% confidence):  N=12 
would be required to show that IL-1β was significantly lower in the cellular group, N=6 would 
be required to show that MMP1 was significantly lower in the cellular group, and N=31 would 
be required to show that MMP3 was significantly lower in the cellular group.  For a sample size 
of N=9, the small increase in MMP13 in the cellular group (compared to the acellular group) 
would become significant.   
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Figure 6.7:  Implanted ASCs had a limited effect on the in vivo expression of inflammation- and 
matrix degradation-related genes.  ASC treatment did not have a statistically significant effect on 
genes related to inflammation (top row) or genes related to matrix remodeling (bottom row) 3 or 
9 days post-operatively.  There were no significant differences in gene expression when 
comparing the acellular and cellular scaffolds.  A significant effect of group (i.e., uninjured, 
repair only, acellular scaffold, cellular scaffold) was observed for all genes.  A significant effect 
of time (i.e., 3d vs. 9d) was observed for all genes except for MMP1 and MMP3.  * p < 0.05, † p 
< 0.10.  Star by the x-axis indicates a significant difference compared to the uninjured group.  
Note: The data from the uninjured, 3 day repair, and 3 day acellular groups were previously 
presented in Figure 6.5, but are presented here again to examine the effect of ASC treatment. 
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6.4 Discussion 
In the current study, we presented an innovative, layered scaffold design that combined the cell 
delivery capabilities of fibrin and the structural integrity of a PLGA nanofiber mat. The layered 
design allows for modularity; the size of the scaffold can be tailored to the specific tendon 
application, and the cell delivery can be controlled. Importantly, in vivo studies in a clinically 
relevant large animal study demonstrated that the delivered ASCs remained viable for at least 9 
days post-operatively. Furthermore, histological and gene expression outcomes from the animal 
model demonstrated that the scaffold was biocompatible up to 9 days in the relevant tendon 
healing setting.  
 
A number of questions must be resolved before the scaffold presented here can be used 
clinically. First, although data in the current study indicate that the scaffold is well tolerated in 
vivo, there is a chance that the PLGA will incite a negative reaction under some conditions. The 
scaffold did attract a small number of PMNs and monocytes, which led to a mild increase in 
apoptosis. Moreover, MMP and COX-2 gene expression in the scaffold group were increased, on 
average, in the current study compared to the naïve repair group. These increases, however, were 
not statistically significant. Second, we tracked implanted ASCs using a membrane dye. 
Although this dye will label cells, it does not indicate whether the cells are alive. The same 
limitation applies to the total DNA assay, which will label DNA regardless of cell viability. Co-
localization of the membrane dye with a nuclear dye (see inset of figure 7B) provides evidence 
that the implanted ASCs were viable at 9 days. However, further analyses (e.g., using a TUNEL 
assay) are needed to conclusively show that implanted cells remain viable throughout the tendon 
healing process.   
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The relatively small sample size and the high variability in our gene expression data may have 
resulted in a type II statistical error (i.e., a false negative). Importantly, in terms of the 
inflammatory response to the scaffold itself, TNFα was decreased and IL-1β was unchanged in 
the scaffold group compared to the naïve repair group. As with the other genes, the differences 
between the repair only and the acellular scaffold groups were not statistically significant. Due to 
ethical and cost consideration associated with a large animal model, we determined that it would 
be inappropriate to increase the sample size such that a power of 80% was achieved; this would 
require N=14-39 for the four genes where a type II error was likeliest. In the case that a negative 
response is seen with the current scaffold materials, alternative polymer formulations can be 
electrospun to form the nanofiber mat layers of the scaffold (e.g., collagen, poly(ε-caprolactone) 
(PCL), poly(L-lactic) acid (PLA)).  
 
While successfully delivery of ASCs was achieved using the fibrin/nanofiber scaffold, 
preliminary results show minimal immunosuppressive effects of ASCs.  With the current sample 
size, no significant suppression of inflammation- or matrix-degradation-related genes was 
observed.  On average, however, the pro-inflammatory factor, IL-1β, and the matrix degradations 
factors, MMP1 and MMP3, were down-regulated in the cellular group compared to the acellular 
group 3 days post-operatively.  On day 9, there was a statistical trend towards down-regulation 
of MMP1 (p < 0.10).  While the current sample size was too low to identify any statistical effects 
of the ASC treatment, a post-study power analysis showed that N=6 and N=12 would be required 
to show that ASCs suppress the expression of IL-1β and MMP1 on day 3, respectively.  N=31 
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would be required to show suppression of MMP3, however.  Thus, future studies may aim to 
increase the sample size of this study to N=6-12.  Immunohistochemistry is also warranted to 
determine whether ASC treatment had an effect on the phenotype of the macrophage population 
present at the repair site.  This study was also limited to gene expression effects.  
Immunohistochemistry would have been useful in determining whether ASC treatment 
suppresses the production of pro-inflammatory cytokines and matrix degradation enzymes.  
Western blotting or zymography may also prove useful for the assessment of protein levels; 
however, this would require additional animals.  
 
In conclusion, a novel scaffold was developed to deliver ASCs in a controlled manner to the site 
of tendon repair. In vitro studies verified that the cells were contained at the repair site and 
remained viable. In vivo studies in a large animal tendon model verified that the approach was 
clinically relevant and that the cells remained viable in the tendon repair environment. 
Specifically, no negative reaction was seen grossly at dissection or at the mRNA level; only a 
mild immune response was detected histologically, viable ASCs were found at the repair site 9 
days post-operatively; and increased total DNA was demonstrated in ASC-treated tendons. The 
novel layered scaffold has the potential for improving tendon healing due to its ability to deliver 
immunomodulatory ASCs in a surgically convenient manner.  
 
Due to the preliminary nature of the study, however, there is not enough data to conclusively 
determine whether delivery of ASCs to the site of flexor tendon repair suppresses the post-
operative inflammatory response.  There was some promising pilot data (i.e., down-regulation of 
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IL-1β and MMP1), but additional animals and assays are required to fully evaluate the effect of 
ASCs in vivo.  Thus, further studies are warranted to determine the long-term effects of this 
scaffold on tendon healing, and the potential for ASCs to suppress the early inflammatory 
response and enhance the biomechanical properties of repaired flexor tendons in vivo.  
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Chapter 7 - Conclusions and Future Directions 
 
7.1 Summary of the Dissertation 
Clinical outcomes for flexor tendon injuries remain poor despite advances in surgical techniques 
over the past three decades1–4.  Flexor tendons are particularly prone to gap formation and 
rupture due to failure of the repair site to accrue strength within the first 3 weeks post-
operatively4,6–11.  Flexor tendon repairs are also susceptible to adhesion formation between the 
tendon and its surrounding sheath, resulting in an inability of the tendon to glide within the 
sheath and loss of motion of the repaired digit5,6,10,12–15.  While passive motion rehabilitation 
protocols have successfully reduced adhesion formation within the digital sheath1–4,22,24,25, 
tendons remain at risk of rupture.  Growth factor therapies have been investigated to accelerate 
the accrual of repair site strength via cell proliferation and matrix deposition, but has had limited 
success7,8,15,27,28,60–66,86.   
 
Previous attempts to improve flexor tendon healing have focused on the later stages of healing 
(i.e., proliferation and matrix synthesis).  The early inflammatory phase of tendon healing, 
however, remains poorly understood and its modulation during healing has not yet been studied.  
Thus, the inflammatory response after flexor tendon injury and repair was characterized for the 
first time to help identify targets for future treatments.  Temporal changes in immune cell 
population and gene expression of inflammation-, matrix degradation-, and extracellular matrix 
(ECM)-related factors were examined 1, 3, and 9 days post-operatively.  We found that 
intrasynovial flexor tendon injuries induce a rapid local inflammatory response characterized by 
early infiltration of inflammatory cells (e.g., monocytes, macrophages, and PMNs) and a 
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significant up-regulation of pro-inflammatory (e.g., IL-1β, TNFα, COX2) and matrix degradation 
genes (e.g., MMP-1, -3, -13) within 1 to 9 days post injury and repair.  Furthermore, a significant 
down-regulation of genes related to flexor tendon extracellular matrix (e.g., COL1, COL3, LUB) 
and tendon fibroblast differentiation (e.g., SCX, TNMD) were observed.  The most striking 
outcome, however, was the greater than 4000-fold up-regulation in the expression of the pro-
inflammatory factor, IL-1β, as early as 1 day post-operatively. 
 
A certain level of inflammation is essential for proper wound healing.  Immune cells (i.e., 
monocytes, macrophages, and PMNs) play a critical role in the clearance of dead cells and 
tissues through phagocytosis and the production of MMPs112,156–160.  Macrophages also play a 
pivotal role in fibroblast chemo-attraction.  Secretion of numerous growth factors by 
macrophages promote cell proliferation and synthesis of extracellular matrix112,156–162.  
Macrophages may also play a role in angiogenesis through the secretion of VEGF112,156–162.  
Several studies have shown that macrophage-depletion is detrimental to proper wound 
healing90,91,162,270  
 
While some inflammation is essential for healing to occur, numerous studies suggest that 
excessive levels of pro-inflammatory cytokines may be detrimental to tendon healing. Thus, we 
sought to determine whether the high levels of IL-1β seen during tendon healing in vivo might be 
harmful to the native TFs.  Using an in vitro model of inflammation via exogenous delivery of 
IL-1β, we found that exposure of TFs to IL-1β caused significant up-regulation of various genes 
related to inflammation and matrix degradation in a dose-dependent manner.  IL-1β also led to 
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significant down-regulation of tendon specific factors (including those related to extracellular 
matrix) and decreased cell viability.  While this model suggested that the IL-1β produced in vivo 
after tendon injury and repair may impair tendon healing (via increased matrix degradation and 
decreased matrix formation), it is unclear whether the dosages examined in this study were 
biologically relevant.  Another limitation of this model was the use of only one exogenous factor 
to simulate inflammation, whereas the in vivo environment includes a milieu of different 
cytokines at the repair site.  
 
Due to the limitations of the IL-1β-induced model of inflammation, a second, more biologically 
relevant in vitro model was established in which inflammation was induced by macrophages.  In 
vivo, monocytes infiltrate the wound within the first few days after injury and differentiate into 
macrophages, which become the dominant immune cell-type at the repair.  Depending on the 
wound environment, monocytes can differentiate into various types of macrophages.  The 
presence of bacterial products (e.g., lipopolysaccharides) and inflammatory cytokines (e.g., 
IFNγ) during the early stages of wound healing promote differentiation of monocytes into pro-
inflammatory M1 macrophages136,138,139,141,156,271, which themselves secrete high levels of pro-
inflammatory factors (including IL-1β).  As seen with the IL-1β-induced inflammation model, 
co-culture of TFs with M1 macrophages also led to up-regulation of inflammation- and matrix 
degradation-related genes and down-regulation of tendon-specific and tendon ECM-related 
genes by TFs.  The effects of other macrophage phenotypes (i.e., non-polarized M0 macrophages 
and anti-inflammatory M2 macrophages) were also assessed.  While M0 and M2 macrophages 
also caused some up-regulation of inflammatory and matrix degradation genes, the effect was 
much less than that of M1 macrophages.  These results, combined with studies by Rodeo et al.92–
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94
, suggest that M1 macrophages may be detrimental to tendon healing due to their secretion of 
pro-inflammatory cytokines. 
 
Based on these results, it is expected that modulation of the inflammatory environment may be 
advantageous to tendon healing.  Studies in the transplant literature suggest that the 
inflammatory environment can be controlled using MSCs136,140,141,173,230,244,254–257,318. Therefore, 
adipose-derived MSCs (i.e., ASCs) were incorporated into the two in vitro models and their 
ability to modulate the inflammatory effects on TFs was investigated.  While ASCs were unable 
to counteract the effects of IL-1β directly, ASC co-culture with M1 macrophages successfully 
suppressed the negative effects of M1 macrophages on tendon fibroblasts.  FACS analysis 
revealed that ASCs induced a phenotypic switch from a pro-inflammatory macrophage 
phenotype (M1) to an anti-inflammatory macrophage phenotype (M2), thus resulting in exposure 
of TFs to fewer pro-inflammatory cytokines.   
 
Lastly, to translate these in vitro findings in vivo, a surgically manageable scaffold capable of 
delivering and retaining ASCs at the repair site was developed.  The scaffold combined a fibrin 
based delivery system (containing 1x106 ASCs) and an electrospun PLGA backbone (to add 
mechanical strength).  A series of in vitro and in vivo studies were performed to 1) verify the 
viability of the ASCs within the scaffold, 2) assess the biocompatibility of the scaffold in vivo, 
and 3) examine the ability of the ASCs to modulate the inflammatory response after flexor 
tendon injury and repair.  The fibrin/nanofiber scaffolds were well tolerated in the in vivo flexor 
tendon repair setting and successful delivery of ASCs was achieved.  There was not enough data, 
144 
 
however, to conclusively determine whether delivery of ASCs to the site of flexor tendon repair 
suppressed the post-operative inflammatory response.  In terms of gene expression, there was 
some promising pilot data (i.e., down-regulation of IL-1β and MMP1), but additional animals 
and assays are required to fully evaluate the effect of ASCs in vivo. 
 
7.1 Limitations and Future Directions 
These studies suggest that the high levels of pro-inflammatory cytokines present during the 
inflammatory phase of flexor tendon healing may cause collateral damage to the native tendon 
fibroblasts, and fine modulation of the inflammatory response may be advantageous for tendon 
healing. However, due to a number of limitations, additional studies are necessary before 
definitive conclusions can be made. 
 
First, the in vivo characterization of the inflammatory response after flexor tendon injury and 
repair (see Chapter 2) did not include immunohistochemical staining to determine which cell 
type was the major source of the pro-inflammatory factor, IL-1β.  According to the literature, 
monocytes/macrophages are the main cellular source of IL-1β161; however, an assessment of 
histological sections showed no monocytes/macrophages at the repair site on day 1, yet IL-1β 
gene expression spiked on day 1.  It is likely that PMNs that infiltrated the wound on day 1 were 
the initial source of IL-1β and as the PMNs began to apoptose and monocytes/macrophages 
infiltrated the repair, the monocytes/macrophages became the primary source.  Future studies 
should include immunohistochemical analysis to help elucidate the source(s) of IL-1β and verify 
the translation of the up-regulated gene into protein.  Moreover, immunohistochemistry would 
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help to determine whether the high IL-1β levels at the repair site induced further up-regulation of 
IL-1β by the local TFs.  However, the appropriate canine antibodies are not yet commercially 
available.   
 
In vitro, gene expression analysis showed IL-1β dose-dependent up-regulation of inflammation- 
and matrix degradation-related genes. However, assessment of resulting protein production was 
not fully analyzed.  Only IL-1β, TNFα, and MMP3 were assessed at the protein level using 
ELISAs.  TNFα was undetected in all groups.  MMP3 was increased in the IL-1β treated 
samples, but the activity level of the MMP enzymes was not verified using zymography.  Lastly, 
due to a technical issue, we were unable to determine whether the increases in IL-1β in the 
treated samples were solely due to the exogenous IL-1β added to the media or whether the TFs 
themselves contributed to those increased levels.  Additional protein assays (e.g., ELISAs, 
Western blots, immunohistochemistry) should be performed to further assess the up-regulation of 
pro-inflammatory cytokines and matrix degradation enzymes induced by IL-1β.   
 
The second in vitro model, in which inflammation was induced by macrophage co-culture, 
suggested that TFs do, in fact, up-regulate their own production of IL-1β and other pro-
inflammatory factors in response to an inflammatory environment.  Co-cultures of M1 
macrophages and TFs produced increased levels of IL-1β and PGE2 compared to M1 
macrophages cultured alone.  This suggests that the additional proteins are secreted by the TFs; 
however, due to the co-culture system, we cannot rule out the possibility that the macrophages 
secreted additional pro-inflammatory proteins in response to co-culture with TFs.  Based on the 
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gene expression data showing that TFs up-regulate their expression of the corresponding genes, 
it is likely that the TFs are producing pro-inflammatory cytokines in response to the 
inflammatory environment.  To further investigate whether or not TFs up-regulate their 
production of pro-inflammatory cytokines in response to inflammation, the inserts of the 
transwells (containing the TFs) could be removed and placed in fresh media for a day or more 
and the supernatant could be tested for inflammatory cytokines.  However, using the current 
experimental setup, the number of TFs obtained was only enough to perform the gene expression 
analysis on day 1.  There were not enough cells to assess protein expression in this way on day 2.  
Future studies, however, should be performed to address this possibility. 
 
An additional limitation of the macrophage-induced inflammation model is the biologic 
relevancy of the macrophage to TF ratio.  The ratio of TFs to macrophages in vivo after flexor 
tendon repair is unknown.  Thus, it is not clear whether the amount of pro-inflammatory 
cytokines that the TFs were exposed to in this in vitro model was biologically relevant.    Future 
studies can address this concern.  First, histologic sections from the in vivo studies can be 
analyzed to determine the ratio of macrophages to fibroblasts during the early inflammatory 
phase of tendon healing.  The ratio of TFs to macrophages in the in vitro model can then be 
adjusted accordingly. 
 
While the macrophage-induced inflammation model improved upon the IL-1β-induced 
inflammation model, further modifications can be made to make the model more biologically 
relevant.  As seen in vivo, PMNs were the primary immune cell type at the repair on day 1.  Gene 
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expression showed peak levels of IL-1β on day 1 before monocytes and macrophages infiltrated 
the wound.  This suggests that the PMNs are an additional early source of IL-1β.  Thus, addition 
of PMNs into the in vitro model may improve the relevancy of this model.  Temporal changes in 
the immune cell population seen in vivo may be mimicked in vitro using multiple transwell 
plates.  TFs can be cultured in the inserts of the wells and co-cultured with PMNs (in the wells) 
for 1-2 days.  The inserts containing the TFs can then be removed and co-cultured with 
macrophages.  The effect of delayed ASC treatment could also be addressed by adding the ASCs 
at different times. 
   
Tri-culture of ASCs with macrophages and TFs suggested that ASCs suppressed the negative 
effects of M1 macrophages on TFs.  However, only gene expression effects were evident on day 
1.  Protein levels of pro-inflammatory cytokines were unaffected by ASC co-culture on day 1.  A 
longer co-culture period (i.e., 5 days) further suppressed the effects of M1 macrophages in terms 
of both TF gene expression and protein expression.  However, the data from the ASC co-cultured 
groups were obtained on day 5, whereas the data from the control groups (M0, M1, M2) was 
obtained on day 1.  Thus, we are unable to say with certainty whether the enhanced effects with 
increased co-culture period were due to increased time for ASCs to induce phenotypic changes in 
the co-cultured macrophages, or whether there were fewer viable macrophages at the 5 day 
timepoint and, thus, fewer inflammatory factors being secreted into the media.  To better control 
for this possibility, the control groups were repeated at longer timepoints.  As with the co-culture 
groups, the macrophages were primed to become M1 or M2 macrophages or left untreated (M0) 
for 1 day. The cells were then cultured in standard medium for an additional 4 days.  However, 
due to decreased macrophage viability at the later timepoints, it is a possibility that the observed 
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changes in TF gene expression may be a result of fewer macrophages present when TFs were 
added to the system.  Increased expression of anti-inflammatory, M2 macrophage specific 
markers (CD206 and CD301) over time strongly supports the idea that longer periods of ASC 
exposure will lead to further down-regulation of inflammation- and matrix remodeling-related 
genes and up-regulation of tendon ECM-related genes towards baseline levels.  Future studies 
can examine the effect of various ASC:Macrophage ratios to determine whether additional ASCs 
would enhance the effect at an earlier timepoint where the experiment can be better controlled. 
 
The molecular mechanism for the ASC-mediated macrophage phenotypic switch remains 
unknown, however.  Studies by other investigators suggest that an intracellular enzyme that 
catalyzes tryptophan into kynurenine (IDO) is responsible for this phenomenon220,249.  The use of 
a pharmacological inhibitor of IDO (1-MT) resulted in a loss of MSC-mediated suppression, 
indicating a possible involvement of IDO in the differentiation of monocytes into anti-
inflammatory M2 macrophages220,261.  Similar studies have not yet been performed in adipose 
derived MSCs.  Assessment of the cytokines secreted by ASCs and inhibition of those factors 
may help to elucidate the mechanism involved in the ASC-mediated macrophage phenotypic 
switch. 
 
A further limitation is that the ability of ASCs to modulate the in vivo inflammatory response 
after flexor tendon injury and repair remains unknown.  A pilot study with a sample size of 3 per 
group showed some promise in terms of suppression of certain inflammation and matrix 
degradation genes. However, additional animals and assays are required in order to form stronger 
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conclusions as to the effectiveness of this approach.     According to a post-study power analysis, 
a sample size of 12 per group would be required to reach statistical significance in terms of 
down-regulation of inflammation- and matrix degradation-related genes.  Furthermore, protein 
levels were not assessed in vivo.  Future studies should examine cytokine levels via 
immunohistochemistry or Western blotting and matrix degradation enzyme activity should be 
assessed using zymography.  Macrophage phenotype should be explored using 
immunohistochemistry to determine whether ASC treatment promotes a phenotypic switch from 
a pro-inflammatory M1 macrophage population to an anti-inflammatory M2 macrophage 
population, as was seen in the in vitro studies.  Due to the limited availability of canine 
antibodies, it may not be possible to address all of these concerns. 
 
Finally, the in vivo model used was an acute injury model in which the injury was created and 
then immediately surgically repaired.  Clinically, a delay of hours to weeks may occur between 
injury and repair; this has important implications for the inflammatory process, which only 
dominates in the first 3 days. While the repair process may induce a second wave of 
inflammation, it is unclear how much damage may have already taken place prior to surgical 
repair and potential ASC treatment.  Future studies can address this concern by inducing a 
tendon injury and leaving it unrepaired for a period of time.  A second surgery hours or weeks 
later can then be performed to repair the injury using ASC-seeded scaffolds.  The outcomes of 
these repairs can be compared to those that are repaired and treated (with ASCs) immediately 
upon injury.  
 
150 
 
7.3 Alternative Approaches 
In addition to resolving some of the limitations mentioned above, alternative approaches can 
further explore the role of inflammation and its modulation during tendon healing.  The ability of 
IL-1Ra, an IL-1 receptor antagonist, to suppress inflammation can be evaluated in vitro and in 
vivo.  IL-1Ra binds to the same receptor as IL-1β (IL-1R) 285,332.  However, bound IL-1Ra does 
not provoke a biological response285,332.  Instead, IL-1Ra acts as an inhibitor by decreasing the 
number of available binding site for IL-1β285,332.  Similar to the in vitro study described in 
Chapter 3, TFs can be exposed to exogenous IL-1β and its effect can be examined using gene 
and protein assays.  IL-1β can then be inhibited in vivo during flexor tendon healing via 
sustained delivery of IL-1Ra.  The delivery system used to deliver ASCs may be useful for 
sustained delivery of IL-1Ra.  Delivery kinetics will depend on the binding affinity of IL-1Ra to 
heparin.  The effect of IL-1β inhibition in vivo after flexor tendon injury and repair can then be 
examined using gene expression and histological assays at early timepoints to observe changes in 
the early inflammatory phase of healing.  Later timepoints can be analyzed for effects on 
biomechanical properties.  Reducing IL-1β levels in vivo may be advantageous for tendon 
healing.  However, some level of inflammation is essential for clearance of dead cells and tissues 
from the wound and for chemotaxis of fibroblasts to the repair site.  Therefore, it is important to 
make sure that the IL-1Ra dosage is not too high so that IL-1β is not completely inhibited.  
 
Genetically modified mouse models can also be used to examine the effect of inflammation on 
tendon healing. Mouse models in which Iκκβ (a regulator of inflammation down-stream of IL-
1β) is constitutively active or deleted in tendon cells can be used to determine the effect of 
inflammation on tendon healing333–335.   Tendon cells can be specifically targeted by crossing 
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these Floxed mice with scleraxis (a tendon-specific transcription factor) Cre mice. An acute 
model of flexor tendon injury and repair (as used in the canine model) is not possible in mice due 
to their small size. Therefore, an overuse or collagenase-induced tendon injury model can be 
induced to incite tendon injury.  These studies will allow for examining the contribution of 
tendon fibroblasts vs. inflammatory cells on the production of inflammatory cytokines. It is 
possible that the majority of inflammatory factors during tendon healing are produced by the 
inflammatory cells (which would be unaffected in these mice).  However, our in vitro studies 
have shown that TFs up-regulate their own expression of inflammatory factors in response to an 
inflammatory environment.  Thus, it is possible that the TFs continue to up-regulate pro-
inflammatory factors after the inflammatory phase is resolved and immune cells are no longer 
producing large amounts of pro-inflammatory factors at the repair site, which could be 
detrimental to tendon healing.  This model may be useful in answering some of these questions. 
 
7.4 Conclusions 
This dissertation elucidates the role of inflammation in flexor tendon healing.  Until now, the 
early inflammatory phase of healing was not well understood and its modulation had not been 
attempted.  Through careful characterization of the early inflammatory phase of flexor tendon 
healing, we found remarkable increases in the expression of pro-inflammatory genes and 
identified potential cellular sources for these cytokines.  The striking increases in genes related to 
inflammation and matrix degradation led us to consider what impact these factors have on the 
native TFs and, ultimately, on tendon healing.  Using two in vitro models of tendon 
inflammation (included a novel macrophage-induced model), we verified that pro-inflammatory 
factors (such as those produced by macrophages) negatively impact tendon fibroblasts and, thus, 
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may impede tendon healing.  In an attempt to suppress those negative effects, ASC-mediated 
modulation of tendon inflammation was attempted for the first time.  In vitro results suggest that 
ASCs are capable of suppressing the negative effects of macrophages on TFs.   Preliminary in 
vivo studies further supported the premise that ASCs can modulate the inflammatory 
environment, but further studies are necessary to demonstrate efficacy.  The potential for ASCs 
to tune the inflammatory environment and enhance tendon healing holds great promise for 
clinical translation.   
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Appendix - Sustained Delivery of Transforming Growth 
Factor Beta Three Enhances Tendon-to-Bone Healing in a 
Rat Model. 
 
A.1 Introduction 
 
Surgically repaired rotator cuff tears are prone to recurrent tears, with a failure rate reaching 94% 
for large tears16,336.  Studies in the clinically relevant rat rotator cuff model show that this high 
rate of failure is due to the fact that the healing process of tendon to bone is reparative (i.e., scar 
mediated) and not regenerative.  The composition and structural organization of the repaired 
tissue does not mimic the original uninjured tissue.  Whereas most uninjured tendon-to-bone 
insertions have a fibrocartilage transition zone between tendon and bone337,338 repaired tendons 
lack a transition zone.  Instead, the interface between repaired tendon and bone is filled with 
disorganized fibrovascular connective tissue whose mechanical properties are inferior to that of 
the uninjured tissue (i.e. the repair is filled with “scar” tissue)320,339–341.  Although the large 
quantity of this fibrovascular tissue leads to a significant increase in the cross-sectional area 
relative to that of the normal insertion, the mechanical properties (i.e., properties normalized to 
cross-sectional area, indicative of the “quality” of the tissue) of the repaired tendon are 
considerably inferior339.   
 
It has been well established in skin that fetal wounds heal in a regenerative manner (i.e., the 
repaired tissue is identical to the original tissue) while adult wounds heal in a reparative manner 
(i.e., via a scar mediated process)152,154,342. Several studies have compared the healing properties 
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of adult tissues to fetal tissues and have identified a pattern of growth factor expression that is 
unique to development152,154,343. For transforming growth factor β (TGF-β) isoforms, fetal wound 
healing is characterized by low expression of TGF-β1 and TGF-β2, high expression of TGF-β3 
and no scar tissue.  Adult wound healing, on the other hand, is characterized by high levels of 
TGF-β1 and TGF-β2, low levels of TGF-β3 and extensive amounts of scar152,154,342,343. Injections 
of exogenous TGF-β3 to the site of a nascent dermal wound reduce scar formation, thus 
implicating TGF-β3 in scar-less fetal and adult wound healing152,154,342. Similar temporal 
expression patterns are seen at the developing and healing tendon-to-bone insertions341,344.  
 
Based on these studies, we hypothesized that sustained delivery of TGF-β3 would promote 
regenerative healing over reparative healing at the healing adult tendon-to-bone insertion site. 
This would be evident as reduced fibrovascular scar tissue formation, improved structural 
organization, and improved mechanical properties in TGF-β3-treated repairs compared to 
controls that received surgical repair alone.  To test this hypothesis, we delivered TGF-β3 using a 
heparin-binding delivery system to the supraspinatus tendon-to-bone repair sites in rat shoulders 
and evaluated repairs using histological and biomechanical outcomes. 
 
A.2 Methods 
 
A.2.1 Growth Factor Delivery System 
Bolus application of growth factors typically leads to clearance of the growth factor from the 
wound site within 48 hours.10  Given that fibroblast cells begin to infiltrate the wound after 2-4 
days, acute delivery of TGF-β3 would have limited effectiveness.  We previously used fibrin 
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matrices containing a heparin-based delivery system (HBDS) to control the release of heparin-
binding growth factors115,345. Release occurs through “passive” dissociation from the delivery 
system and diffusion from the matrix as well as through “active” cell-mediated degradation of 
the fibrin matrix.  Both mechanisms were evaluated in vitro in the studies described below.   
 
A.2.1 In Vitro Growth Factor Release Studies 
TGF-β3 Passive Release Kinetics - Acellular Study: To determine the passive (i.e., acellular) 
release kinetics of TGF-β3 from the delivery system, 400µl fibrin matrices were made in 
quadruplicate (N=4) in 24 well tissue culture plates as described previously345. The matrices 
consisted of 50 ng TGF-β3 (R&D Systems, MN), 20 mg/ml fibrinogen (EMD Biosciences, CA), 
25 mg/ml peptide (0.16 mM – dLNQEQVSPK[βA]FAKLAARLYRKA-NH2, where dL denotes 
dansyl leucine), 45 mg/ml heparin, 50 mM CaCl2, 12.5 units/ml thrombin, and Tris-buffered 
saline (TBS; 33 mM Tris, 137 mM NaCl, 2.7 mM KCl, pH 7.4).  The heparin concentration in 
the fibrin matrices varied from 0 to 4mM to yield the desired growth factor to heparin molar 
ratios (1:0, 1:100, 1:1,000, and 1:10,000).  The heparin to peptide ratio remained constant at 
1:10.  To examine growth factor release into the media, a series of washes with TBS were 
performed over the course of 10 days, as described previously345. An enzyme-linked 
immunosorbent assay (ELISA) for TGF-β3 (R&D Systems, MN) was then performed on all 
wash volumes as well as on the fibrin remaining at the end of 10 days.  To compare the passive 
release kinetics of the matrices with and without the delivery system, the ratio of TGF-β3 
released into the buffer per day from the HBDS group to the amount released from the no HDBS 
group (i.e. HBDS group : no HBDS group) was calculated. 
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TGF-β3 Active Release Kinetics – Cellular Study: To examine cell-mediated release, fibroblasts 
were isolated from the supraspinatus and infraspinatus tendons of Sprague Dawley rats (N=8 cell 
isolations) as described previously345. Fibrin matrices were then seeded with the fibroblasts and 
the active release rate of TGF-β3 was determined.  The procedure was identical to that of the 
acellular study methods described above with the following exceptions: 1) gels were seeded with 
50,000 cells in culture medium (1% FBS DMEM) after the first day of washes, 2) daily washes 
were performed using 1% FBS DMEM to maintain cell viability, and 3) experimental groups 
included matrices containing the delivery system at a factor to heparin molar ratio of 1:1000 
(delivery system group) and matrices lacking the delivery system (i.e. ratio of 1:0) (no delivery 
system group). Matrices were made in triplicate for all experimental groups.  The experiment 
was repeated for 8 cell isolations.  To compare the passive release kinetics of the matrices with 
and without the delivery system, the ratio of TGF-β3 released into the buffer per day from the 
HBDS group to the amount released from the no HDBS group was calculated.   
 
Statistical analysis: A one-way ANOVA with planned polynomial contrasts was used to 
compare the TGF-β3 ratios over time.  Paired t-tests were used to compare the release of TGF- 
β3 from gels with and without the HBDS at each timepoint.  P < 0.05 was considered significant. 
 
A.2.2 In Vivo Studies 
Animal Model: All animal procedures were approved by the institutional Animal Studies 
Committee. Supraspinatus tendons in bilateral shoulders of 76 adult male Sprague-Dawley rats 
(375-400g) were transected and repaired to the humeral head using 5-0 proline suture, as 
 described previously339,341.  In one group of rats, fibrin matrices with the HBDS (+/
(30µl) were incorporated bilaterally at the supraspinatus tendon
the suture through the matrix before completing the repair.  The left shoulders received matrices 
that were loaded with 100ng of TGF
while the right shoulders received matrices lacking the growth factor and
controls (i.e., carrier controls) (Figure 
potential systemic effects of the growth factor as well as to serve as a comparison group to 
conventional treatment (i.e., surgical 
surgically but did not receive any matrices.  The right shoulders received matrices lacking the 
growth factor (i.e., carrier controls).  
(N=11-16 per group) for biomechanical testing.  Animals were sacrificed at 
post-operatively for histological analysis (N=4 per group) (Figure 
uninjured age-matched rats (N=8) was used as normal controls.
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-β3 (100µg/ml, 1:1000 growth factor to heparin molar ratio), 
 served as contralateral 
A.1).     A second group of rats was used to control for 
repair only).  The left shoulders of these rats were repaired 
Animals were sacrificed 28 and 56 days post
14, 28, and 56 days 
A.1). A separate group of 
 
- TGF-β3) 
-operatively 
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Figure A.1:  Study Design.  The left shoulders received matrices loaded with 100ng of TGF-β3 
and the right shoulders received matrices lacking the growth factor.  A second group of control 
rats was used to examine potential systemic effects of the growth factor as well for comparison 
group to surgical repair only.  Animals were sacrificed at 14 days for histology and at 28 and 56 
days for histology and biomechanical testing. 
 
Histology-based assays: Four specimens from each group were examined histologically. 
Specimens were fixed, decalcified, embedded in paraffin, and sectioned at 5 µm in the coronal 
plane. Sections were stained with toluidine blue to examine fibrocartilage, hematoxylin and eosin 
to examine cell morphology, and Masson’s trichrome to examine fibrous tissue.  Proliferating 
cell nuclear antigen (PCNA) immunohistochemistry was done in accordance with the 
manufacturer’s protocol (Zymed Laboratories, San Francisco, CA) as a measure of cell 
proliferation. The antibody was visualized by incubation with diaminobenzidine (DAB). Three 
independent observers (Necat Havlioglu – pathologist, Leesa Galatz – orthopaedic surgeon, and 
Cionne Manning – graduate student), blinded to group and timepoint, evaluated the tissue 
sections for cellularity, cell proliferation, vascularity, inflammation, fibrosis (i.e., scar tissue 
formation), and fibrocartilage formation339,341. A standard scoring system was used to determine 
the levels of each outcome (- no prevalence, + minimal prevalence, ++ mild prevalence, +++ 
moderate prevalence, ++++ high prevalence) Our analysis was focused solely on the tissue 
adjacent to bone (i.e., the healing tendon-to-bone interface). 
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Geometry and biomechanics: Biomechanical testing of the supraspinatus tendon-to-bone 
insertions was performed as previously described339. The thickness of each insertion was 
measured using a laser displacement sensor (Keyence LK-081, NJ) and the width was measured 
using optical methods.  The cross-sectional area was calculated by assuming an elliptical cross-
section. In order to determine the mechanical properties of the healing tendon-to-bone insertion 
without the confounding effect of the suture repair strength, sutures were cut at the entrance of 
humeral head bone tunnel prior to biomechanical testing. To control hydration, temperature, and 
pH during biomechanical testing, tendons were immersed in a physiologic saline bath at 39°C 
(rat body temperature) during testing. A servo-hydraulic materials testing system (Instron Corp., 
Model 8841) was then used to perform the mechanical test (i.e., pre-conditioning, followed by 
stress relaxation, followed by constant ramp at a strain rate of 0.1%/sec until failure).   
Engineering stress was calculated by dividing the tensile force by the initial cross-sectional area 
of the tendon.  Strain was measured optically by tracking two surface stain lines using custom-
written software (Matlab, Natick, MA)339.  Ultimate load, stiffness (i.e., the slope of the linear 
portion of the load-deformation curve), toughness (i.e., the area under the load-deformation 
curve), ultimate stress, and tangent modulus (i.e., the slope of the linear portion of the stress-
strain curve) were determined.   
 
Statistical analysis: For geometric and biomechanical outcomes, groups were compared using a 
two-factor analysis of variance for time and treatment followed by a Fisher least-squares 
differences post-hoc test.  Paired data (i.e. TGF-β3 group vs. experimental group carriers or 
repair-only group vs. control group carriers) were compared using paired t-tests.  P < 0.05 was 
considered significant. 
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A.3 Results 
 
A.3.1 In Vitro Studies 
Sustained growth factor release was achieved in the absence of cells via the HBDS (Figure A.2, 
A).  The percent change of TGF-β3 released from the gels containing the HBDS to those lacking 
the delivery system was initially negative, indicating that more growth factor was being released 
from the no-HBDS gels at the early timepoints.  Over time, however, the percent change was 
positive, indicating that the HBDS gels were releasing more growth factor than the no-HBDS 
gels.  The amount of TGF-β3 released from the two groups (HBDS vs. no-HBDS groups) were 
significantly different at days 0, 1, 2, 5, 7, and 9.  Similarly, the amount of growth factor 
remaining in the HBDS gels at the end of the 10 day experiment was significantly more than the 
amount remaining in the no-HBDS gels.   Moreover, the ratios of TGF-β3 released from the gels 
with and without the HBDS significantly increase over time. Gels without the HBDS (1:0) 
released nearly all (99%) of the growth factor by day 10, whereas the gels with the HBDS at 
ratios of 1:100, 1:1000, and 1:10,000 released 88%, 74%, and 52%, respectively.  The same 
trends were seen in tendon fibroblast seeded gels (Figure A.2, B), although the rate of release 
was accelerated in the presence of cells. The amount of TGF-β3 released from the no-HBDS 
group was greater than the amount released from the HBDS group at the early timepoints.  At the 
later timepoints, however, the opposite trend was observed.  TGF-β3 release from the HBDS was 
significantly increased compared to the no HBDS group at days 7, 8, and 9.  A significant linear 
increase in these ratios (HBDS : no-HBDS) was observed over time.   
 
  
Figure A.2: In vitro Release Kinetics.
environment (B), the ratios significantly increased with time, indicating sustained released of 
TGF-β3 from the gels containing the delivery system. Differences in the amount of TGF
released from the two groups (i.e. HBDS vs. no HBDS) are signified by stars and crosses (* p < 
0.05, † p < 0.1). R: TGF-β3 remaining in the gels at the end of the 10 day ex
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  In both the acellular environment (A) and the cellular 
periment.
 
-β3 
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A.3.2 In Vivo Studies 
 
Histology: There was good agreement among the blinded investigators made by the three 
observers. Large discrepancies in grades were resolved by re-evaluating the slide as a group. 
Blind evaluation revealed increased cellularity and increased cell proliferation (as demonstrated 
by PCNA labeling) at the repair site in the TGF-β3 group at 14 days (Table A.1, Figure A.3).   
 
Group Fibrosis Inflammation Cellularity Proliferation Vascularity 
14 
day 
TGF-β3 +++ +++ +++/++++ +++ +++ 
Exp Carrier + ++ ++/+++ +/++ ++ 
Ctl Carrier ++ + ++/+++ ++ ++ 
Repair Only ++ ++ ++ ++/+++ ++ 
28 
day 
TGF-β3 ++ + ++ -/+ ++ 
Exp Carrier ++ -/+ ++ -/+ + 
Ctl Carrier + -/+ +/++ + + 
Repair Only + + ++ +/++ +/++ 
56 
day 
TGF-β3 ++ -/+ ++ -/+ ++ 
Exp Carrier +/++ -/+ + -/+ + 
Ctl Carrier + -/+ + -/+ + 
Repair Only +/++ -/+ + -/+ + 
 
Table A.1: Histological Assessment.  Grading scheme: - no prevalence, + minimal prevalence, 
++ mild prevalence, +++ moderate prevalence, ++++ high prevalence.  Average grades are 
shown.   
 
 The number of blood vessels (i.e. vascularity) and the amount of 
also substantially increased in TGF
Figure A.3).  An increased immune response (as evidenced by
also apparent in the TGF-β3-treated tendons compared to all other groups a
amount of fibrovascular scar tissue and the number of cells and blood vessels remained high at 
all timepoints in the TGF-β3-treated tendons, whereas differences in lymphocytes and cell 
proliferation were no longer evident at 28 and 56 days.
regeneration was seen in any of the groups at any timepoint (Table 
Figure A.3: Histology. Sections
of the cell cycle stain dark brown) and 
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fibrous tissue (i.e. scar) was 
-β3 group at the earliest timepoint (i.e., day 14) (Table 1, 
 an increase in lymphocytes) was 
 No evidence of fibrocartilage 
A.1). 
 
 stained with PCNA (top panels; cells in the proliferative stage 
hematoxylin and eosin (middle and bottom panels) at 14 
t 14 days.  The 
 days.  The tendons treated with TGF
vascularity compared to controls (i.e., experimental group carriers).
Geometry: At 28 days, the cross
significantly greater than that of any other group (Figure 4
β3-treated tendons had the smallest cross
in the control group (i.e. control group carriers and repair
over time, whereas the tendons in the experimental group (i.e. TGF
group carriers) did not.  Cross-sectional areas o
compared to normal/uninjured tendons at both timepoints.
 
Figure A.4: Geometry. Cross-sectional
compared to control group carriers and repair
TGF-β3-treated tendons was decreased compared to control group carriers and repair
tendons. Cross-sectional areas of repaired insertions were increased compared to 
normal/uninjured insertions (normal = 2.
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-β3 exhibited increases in cell proliferation, cellularity, and 
 [Scale bars = 200µm].
-sectional area of the tendons treated with TGF
.A).  At 56 days, however, the TGF
-sectional area.  The cross sectional area 
-only group) increased significantly 
-β3-treated and experimental 
f all repaired tendons were significantly increased 
 
 
 area of TGF-β3-treated tendons was increased at 28 days 
-only tendons. At 56 days, cross-
6 ±0.4 mm2). * p < 0.05, (N=10). 
 
-β3 was 
-
of the tendons 
 
sectional area of 
-only 
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Biomechanics: At 28 days, the structural property ultimate load of the TGF-β3-treated tendons 
was significantly increased compared to the contralateral control tendons (p = 0.04, 30% 
increase, Figure A.5, A).  There was also a trend towards increased ultimate load in the TGF-β3-
treated group compared to the repair-only group (p = 0.08, 28% increase).  The stiffness and the 
toughness of the TGF-β3-treated tendons were also increased compared to carrier controls 
(stiffness: p = 0.04, 50% increase compared to experimental group carrier; toughness: p = 0.007, 
34% decrease compared to control group carrier, Figure A.5, B & E).  There were no differences 
in the mechanical properties (i.e., ultimate stress and modulus) when comparing the TGF-β3-
treated tendons to all other groups at this early timepoint.  At 56 days, the tendons in the TGF-
β3-treated group had increased ultimate stress compared to tendons in the carrier-only groups, 
but these differences were not statistically significant (p = 0.08, 48% increase compared to 
control group carrier; p = 0.12, 41% increase compared to experimental group carrier, Figure 
A.5, C).  A statistically significant increase was seen for modulus when comparing the TGF-β3-
treated group to the experimental group carriers (p = 0.01, 37% increase, Figure A.5, D). The 
toughness of the TGF-β3-treated group was also significantly increased over the repair-only 
group (p = 0.03, 36% increase, Figure A.5, E). Changes over time were observed in ultimate load 
and toughness.  The ultimate load of tendons increased over time in all groups (p = 0.07, 22% 
increase for TGF-β3 group, p < 0.05, 31% - 46% increases for all other groups).  Similar 
statistically significant trends were seen for toughness over time (p = 0.001). Stiffness, ultimate 
stress, modulus, and toughness were significantly lower in all injury and repair groups at 28 and 
56 days compared to the normal/uninjured group (p < 0.01 for all groups). Ultimate load, 
however, was not significantly different when comparing the normal/uninjured group to most 
injury and repair groups at 56 days (p = 0.68, 4% decrease for TGF-β3 group; p = 0.22, 12% 
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decrease for experimental group carrier; p = 0.37, 9% decrease for control group carrier).  The 
one exception was the repair-only group, in which ultimate load remained significantly lower 
than normal at 56 days (p = 0.05, 20% decrease).   
 
Figure A.5: Biomechanics. At 28 days, the structural properties (ultimate load (A), stiffness (B), 
and toughness (E)) of the TGF-β3-treated insertions were increased compared to carrier controls 
(i.e. experimental group carriers and control group carriers).  Ultimate load increased in all 
groups over time, approaching normal/uninjured values (normal = 28.8 ± 6.0 N).  At 56 days, the 
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mechanical properties (ultimate stress (C) and modulus (D)) of the TGF-β3-treated insertions 
were increased compared to carrier controls. Stiffness, ultimate stress, modulus, and toughness of 
injury and repair groups did not reach normal values by 56 days (normal values: stiffness = 37.8 
± 8.8 N/mm, ultimate stress = 11.1 ±  2.7 MPa, modulus = 128.3 ±  40.6 MPa, toughness = 43.1 
±  12.9 N mm).  * p < 0.05, † p < 0.1.  (N=10). 
 
A.4 Discussion 
Although current rotator cuff repair techniques are successful in alleviating pain, they are prone 
to recurrent ruptures16,336. Failure rates after surgical repair range from 20-94% depending on the 
size of the initial tear16,336.  Studies in the rat rotator cuff model indicate that this high failure rate 
is at least in part due to the fact that the repaired tendons do not mimic the original tendon: the 
healing process is reparative (i.e., scar mediated), not regenerative320,339–341.  The healing tendon-
to-bone insertion is characterized by disorganized fibrovascular tissue formation and a lack of a 
fibrocartilage transition zone at the interface.  Differences in growth factor expression have been 
noted between fetal development and adult healing.  During these two processes, the cytokine 
TGF-β is found in different isoforms.  TGF-β3 expression is elevated during tendon development 
and low during adult tendon healing.  In contrast, TGF-β1 expression is low during development 
but high during adult tendon healing341,344.  Dermal wound healing studies in mice have revealed 
similar trends.  TGF-β3 is abundant during development and is also elevated during fetal wound 
healing, which occurs through a regenerative (i.e., scarless) process.  Furthermore, a shift in 
expression from TGF-β3 to TGF-β1 occurs 16-18 days post-conception, a critical timepoint 
known to coincide with the end of regenerative fetal healing of skin342.  
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Based on these results, we expected that sustained delivery of TGF-β3 would reduce the amount 
of fibrovascular scar tissue formed during adult tendon-to-bone healing, thus leading to an 
improvement in the structural and material properties of the healing tendon-to-bone insertion 
compared to untreated controls.  Contrary to our hypothesis, delivery of TGF-β3 did not lead to a 
reduction in scar tissue formation. Instead of promoting regeneration of a fibrocartilaginous 
transition between tendon and bone, TGF-β3, led to an increase in disorganized fibrovascular 
tissue. The lack of regenerative healing with TGF-β3 may have been due to differences between 
adult and post-natal environments. For example, the cell types present (and their pluripotency) 
are quite different prenatally compared to postnatally. The response of a mesenchymal stem cell 
to TGF-β3 will be much different than the response of a primary fibroblast to TGF-β3. Further 
studies are required in order to determine why TGF-β3 did not have the desired effect in an adult 
tendon-to-bone healing environment.   
 
As seen by the increase in cross sectional area at the early timepoint studied, TGF-β3 promoted 
an increase in extracellular matrix formation during tendon-to-bone healing.  Although TGF-β3 
delivery did not lead to a reduction in scar formation, it did lead to a significant improvement in 
the structural and mechanical properties of the healing tendon-to-bone insertions.  At the early 
timepoint, the structural properties ultimate force and stiffness were increased in the TGF-β3-
treated insertions compared to the untreated control insertions.  At the later timepoint, the 
mechanical properties ultimate stress and modulus were increased in the TGF-β3-treated 
insertions compared to untreated control insertions.  These results indicate that TGF-β3 treatment 
accelerated all phases of the healing process: inflammation was enhanced at early timepoints (as 
seen histologically), cell proliferation and matrix synthesis were increased at early timepoints (as 
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seen histologically, geometrically, and structurally), and extracellular matrix remodeling was 
increased at later timepoints (as seen histologically and in mechanical properties). In summary, 
treatment with TGF-β3 led to increases in cross-sectional area and a resultant increase in 
structural properties at early timepoints.  With time, remodeling of the tissue led to a decrease in 
cross-sectional area and a resultant increase in the mechanical properties (i.e., a better “quality” 
tissue). These results were most apparent for toughness, but improvements were also seen in 
modulus and failure stress. 
 
Implantation of the delivery system alone (i.e. without growth factor) had no significant effect on 
tendon healing.  The biomechanical and histological properties of the insertions that received the 
carrier alone (i.e. experimental group carriers and control group carriers) did not differ 
significantly from the insertions that received surgical repair only.  Thus, differences seen in the 
TGF-β3-treated group can be attributed to TGF-β3 itself and not to any components of the 
delivery system.  Some differences between the two carrier groups (i.e. experimental group 
carriers and control group carriers) were evident in some biomechanical properties, however.  
For example, at 28 days ultimate stress and modulus were significantly higher in the control 
group carriers compared to the experimental group carriers. The only difference between these 
two groups was the treatment in the contralateral shoulders. For the control group carriers, the 
contralateral shoulder received surgical repair only. For the experimental group carriers, the 
contralateral shoulder received TGF-β3 treatment. It is possible that some systemic effects may 
have resulted from the local delivery of TGF-β3. 
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The rat is an appropriate animal model for studying the rotator cuff based on anatomic 
considerations346. Rats have a coraco-acromial arch similar to that of humans, under which the 
supraspinatus tendon passes repeatedly during shoulder motion. This arch in notably missing in 
most non-primate larger animal species. Moreover, the rat rotator cuff is sufficiently large to 
perform a repair that is technically similar to what is used clinically. However, larger animals are 
better suited to reproduce the more complex surgical techniques currently used clinically. A 
limitation of the injury and repair model used in this study is that it approximates an acute rotator 
cuff injury and does not represent the chronic degenerative rotator cuff tears seen in the majority 
of clinical patients.  However, while our results cannot be applied to the scenario of chronically 
degenerated rotator cuff, they are relevant to the human shoulder and to acute tendon injuries 
specifically. A possible limitation in this study is the use of bilateral surgeries. However, our 
experience with bilateral surgeries in past studies has shown no differences in left vs. right 
shoulder activity based on behavioral observations.     
 
Two additional limitations apply to our study.  First, although sustained release of TGF-β3 from 
the HBDS was demonstrated in vitro, the in vivo release kinetics are unknown and likely differ 
from that of the in vitro environment in absolute terms. Second, the mechanism behind the 
improved mechanical properties we observed in the TGF-β3-treated tendons remains unknown.  
Improvements in the biomechanics of the tissue may have resulted from differences in matrix 
production (e.g., collagen III : collagen I ratio), collagen crosslinking, collagen orientation, 
growth factor expression, cell migration, and/or cell recruitment.  
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In this study we demonstrated that TGF-β3 can be delivered at a sustained rate using a fibrin 
matrix containing a heparin-based delivery system and that use of this delivery system in vivo 
enhances tendon-to-bone healing in a rat model.  Although TGF-β3 treatment led to improved 
toughness relative to repairs that received the conventional treatment (i.e. surgical repair only), 
the biomechanical properties of TGF-β3-treated tendons were still significantly inferior to those 
of normal (i.e., uninjured) tendon-to-bone insertions.  Thus, while delivery of TGF-β3 for 
enhanced tendon-to-bone healing holds promise, further studies are necessary to optimize the 
delivery methods and the choice of biological factors for improved tendon-to-bone healing.  
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